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4.18 Vismodegiband residues within 8 Å of it in ECL1, 3 and 4 and TM6 . . . . . 123
4.19 Selected minimised binding pocket residues comparing crystal structure and
after minimisation with CHARMM and MOE . . . . . . . . . . . . . . . . . . 124
4.20 Residues that were tarted below H470 . . . . . . . . . . . . . . . . . . . . . . 126
4.21 Predicted binding mode of compound K2.10 against SMO . . . . . . . . . . 128
4.22 Predicted binding mode of compound K2.19 against SMO . . . . . . . . . . 129
4.23 Normalised Gli mRNA levels for K2.1 - K2.20 at 10µM and 100µM . . . . . 131
4.24 Other work involving oxysterol inhibitors to SMO . . . . . . . . . . . . . . . . 133
4.25 Predicted binding modes of K5 and K6 . . . . . . . . . . . . . . . . . . . . . 135
4.26 Predicted binding pose of K2.7, K2.11 and K2.12 . . . . . . . . . . . . . . 136
4.27 Interaction matrix of all compounds tested in Rounds 1 and 2 . . . . . . . . . 137
7.1 Prepared Pim-1 docking binding site - SEED . . . . . . . . . . . . . . . . . . 171
7.2 Prepared Pim-1 docking binding site - FRED . . . . . . . . . . . . . . . . . . 172
7.3 Prepared Pim-1 docking binding site - DOCK . . . . . . . . . . . . . . . . . . 172
7.4 Pim-1 Thermal Shift Assay (TSA) results . . . . . . . . . . . . . . . . . . . . 173
7.5 IC50 curves for compounds 57 and 58 - Eurofins . . . . . . . . . . . . . . . . 186
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CHAPTER 1. INTRODUCTION 13
1.1 Abstract
Investigation of the cause of disease is no easy business. This is particularly so when one
reflects upon the lessons taught us in antiquity. Prior to the beginning of the last century,
diagnosis and treatment of diseases such as cancers was so bereft of hope that there was little
physicians could offer in the way of comfort, let alone treatment. One of the major insights
from investigations into cancers this century has been that those involved in research leading
to treatments are not dealing with a singular malady but multiple families of diseases with
different mechanisms and modes of action. Therefore, despite the end game being similar in
cancers, that of uncontrolled growth and replication leading to cellular dysfunction, different
diseases require different approaches in targeting them.
This leads us to a particular broad treatment approach, that of drug design. A drug is, in
the classical sense, a small molecule that, upon introduction into the body, interacts with
biochemical targets to induce a wider biological effect, ideally with both an intended target
and intended effect. The conceptual basis underpinning this ‘lock-and-key’ paradigm was
elucidated over a century ago and the primary occupation of those involved in biochemical
research has been to determine as much information as possible about both of these protein
locks and drug keys. And, as inferred from the paradigm, molecular shape is all-important
in determining and controlling action against the most important locks with the most potent
and specific keys.
The two most important target classes in drug discovery for some time have been protein
kinases and G Protein-Coupled Receptors (GPCRs). Both classes of proteins are large
families that perform very different tasks within the body. Kinases activate and inactive
many cellular processes by catalysing the transfer of a phosphate group from Adenosine
Tri-Phosphate (ATP) to other targets. GPCRs perform the job of interacting with chemical
signals and communicating them into a biological response. Dysfunction in both types of
proteins in certain cells can lead to a loss of biological control and, ultimately, a cancer.
Both of kinases and GPCRs have entirely different chemical structures so structural knowl-
edge therefore becomes crucial in any approach targeting cells where dysfunction has oc-
curred. Thus, for this thesis, a member from each class was investigated using a combina-
tion of structural approaches. From the kinase class, the kinase Proviral Integration site for
MuLV (Pim-1) and from the GPCR class, the cell membrane-bound Smoothened receptor
(SMO).
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The kinase Pim-1 was the target of various approaches in chapter 3. Although a heavily
studied target from the mid-2000’s, there is a paucity of inhibitors targeting residues more
remote from structural characteristics that define kinases. Further limiting extension possi-
bilities is that Pim-1 is constitutively active so no inhibitors targeting an inactive state are
possible.
An initial project (Project 1) used the known binding properties of small molecules, or,
‘fragments’ to elucidate structural and dynamic information useful for targeting Pim-1. This
was followed by three projects, all with the goal of inhibitor discovery, all with different foci.
In Project 2, fragment binding modes from Project 1 provided the basis for the extension
and development of drug-like inhibitors with a focus on synthetic feasibility. In contrast,
inhibitors were found in Project 3 via a large-scale public dataset of purchasable molecules
that possess drug-like properties. Finally, Project 4 took the truncated form of a particularly
attractive fragment from Project 1 that was crystallised with Pim-1, verified its binding mode
and then generated extensions with, again, a focus on synthetic feasibility.
The GPCR SMO has fewer molecular studies and much about its structural behaviour re-
mains unknown. As the most ‘druggable’ protein in the Hedgehog pathway, structural studies
have primarily focussed on stabilising its inactive state to prevent signal transduction. Allied
to this is that there are generally few inhibitors for SMO and the drugs for cancers related
to its dysfunction are vulnerable to mutations that significantly reduce their effectiveness or
abrogate it entirely. The elucidation of structural information in therefore of high priority.
An initial study attempting to identify an unknown molecule from prior experiments led to
insights regarding binding characteristics of specific moieties. This was particularly impor-
tant to understand not just where favourable moieties bind but also sections of the SMO
binding pocket with unfavourable binding. In both subsequent virtual screens performed in
Chapter 4, the primary aim was to find new drug-like inhibitors of SMO using large public
datasets of commercially-available molecules. The initial screen retrieved relatively few in-
hibitors so the binding pocket was modified to find a structural state more amenable to small
molecule binding. These modifications led to a significant number of new, chemically novel
inhibitors for SMO, some structural information useful for future inhibitors and the elucida-
tion of structure-activity relationships useful for inhibitor design. This underpins the idea
that structural information is of critical importance in the discovery and design of molecular
inhibitors.
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1.2 Zusammenfassung
Die Untersuchung der Ursache einer Krankheit ist keine leichte Aufgabe. Dies gilt ins-
besondere, wenn man über die Lehren nachdenkt, die wir aus der Antike gelernt haben.
Vor Beginn des letzten Jahrhunderts war die Diagnose und Behandlung von Krankheiten
wie Krebserkrankungen so hoffnungslos, dass Ärzte kaum Trost, geschweige denn eine Be-
handlung anbieten konnten. Eine der wichtigsten Erkenntnisse aus der Erforschung von
Krebserkrankungen in diesem Jahrhundert ist, dass es sich dabei nicht um eine einzelne
Krankheit, sondern um mehrere Familien von Krankheiten mit unterschiedlichen Mechanis-
men und Wirkungsweisen handelt. Trotz der Tatsache, dass der finale Verlauf von Kreb-
serkrankungen ähnlich ist, d.h. unkontrolliertes Wachstum und Replikation, die zu zellulärer
Dysfunktion führen, erfordern die verschiedenen Krankheiten daher unterschiedliche Ansätze
in der Behandlung.
Dies führt uns zu einem besonders breiten Behandlungsansatz, dem des Wirkstoffdesigns. Die
beiden wichtigsten Zielklassen in der Wirkstoffforschung sind seit längerem Proteinkinasen
und G-Protein gekoppelte Rezeptoren (GPCRs). Beide Kategorien von Proteinen umfassen
große Familien, die sehr unterschiedliche Aufgaben im Körper erfüllen. Dysfunktionen bei-
der Arten von Proteinen in bestimmten Zellen können zu einem Verlust der biologischen
Kontrolle und letztlich zu Krebs führen. Sowohl Kinasen als auch GPCRs besitzen völlig
unterschiedliche chemische Strukturen, sodass bei der Adressierung dysfunktionaler Zellen
strukturelles Wissen von entscheidender Bedeutung ist. Daher wurde in dieser Arbeit je ein
Mitglied aus beiden Klassen mit einer Kombination verschiedener strukturbasierter Ansätze
untersucht. Aus der Familie der Kinasen die Kinase Proviral Integration Site for MuLV
(Pim-1) und aus der Familie der GPCRs der zellmembrangebundene Smoothened Rezeptor
(SMO).
Die Kinase Pim-1 war das Ziel verschiedener Ansätze in Kapitel 3. Obwohl es sich um ein
stark untersuchtes Target aus der Mitte der 2000er Jahre handelt, gibt es nur wenige In-
hibitoren, die Aminosäuren adressieren, welche weiter von strukturellen Merkmalen entfernt
sind, welche Kinasen ausmachen. Weitere Einschränkungen sind dadurch gegeben, dass Pim-
1 konstitutiv aktiv ist, sodass bei der Entwicklung von Inhibitoren nicht auf eine inaktive
Proteinkonformation abgezielt werden kann.
Ein erstes Projekt (Projekt 1) nutzte bekannte Bindungseigenschaften kleiner Moleküle, um
strukturelle und dynamische Informationen zu gewinnen, die bei der Adressierung von Pim-1
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nützlich sind. Es folgten drei Projekte mit dem Ziel, Inhibitoren unter Berücksichtigung un-
terschiedlicher Gesichtspunkte zu entwickeln. In Projekt 2 bildeten Fragmentbindungsmodi
aus Projekt 1 die Grundlage für die Erweiterung und Entwicklung von medikamentähnlichen
Inhibitoren mit einem Schwerpunkt auf synthetischer Darstellbarkeit. In Projekt 3 wurden
Inhibitoren aus einem großen, öffentlich zugänglichen Datensatz von kaufbaren Molekülen
mit medikamentenähnlichen Eigenschaften herausgesucht. Schließlich wurde in Projekt 4 die
verkürzte Form eines besonders attraktiven Fragments, das mit Pim-1 kristallisiert wurde,
aus Projekt 1 aufgenommen der Bindungsmodus verifiziert und dann Erweiterungen gener-
iert, wiederum mit dem Fokus auf der synthetischen Darstellbarkeit.
Über den GPCR SMO gibt es weniger molekulare Studien und vieles über sein strukturelles
Verhalten ist weiterhin unbekannt. Als das am besten adressierbare Protein im Hedgehog
Signalweg haben sich bisherige strukturbasierte Studien in erster Linie darauf konzentriert,
den inaktiven Zustand zu stabilisieren, um so eine Signaltransduktion zu verhindern. Daher
gibt es generell nur wenige Inhibitoren für SMO und die Medikamente für Krebserkrankungen
im Zusammenhang mit der Dysfunktion von SMO sind anfällig für Mutationen, was ihre
Wirksamkeit signifikant verringern oder ganz aufheben kann.
Eine erste Studie, in der versucht wurde, ein unbekanntes Molekül aus früheren Experi-
menten zu identifizieren, resultierte in Erkenntnissen über die Bindungseigenschaften bes-
timmter Struktureinheiten. Dies war besonders wichtig, um nicht nur Bereiche günstiger
Interaktionen, sondern auch Bereiche ungünstiger Interaktionen in der SMO-Bindungstasche
zu verstehen. In den beiden nachfolgenden virtuellen Screens, die in Kapitel 4 beschreiben
werden, bestand das Hauptziel darin, in großen, öffentlich zugänglichen Datensätzen kom-
merziell verfügbarer Moleküle neue medikamentenähnliche Inhibitoren für SMO zu finden.
Der erste Screen sowie die nachfolgenden Modifikationen resultierten in einer signifikanten
Anzahl chemisch neuartiger Inhibitoren für SMO, sowie strukturellen, für die Entwicklung
zukünftiger Inhibitoren nützlichen Erkenntnissen und der für das Inhibitor-Design nützlichen
Aufklärung von Struktur-Aktivitäts-Beziehungen. Dies untermauert die Idee, dass Struktur-
informationen für die Entdeckung und das Design molekularer Inhibitoren von entscheidender
Bedeutung sind.
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2.1 Structure-based virtual screening
Early-stage drug discovery efforts most commonly begin with the identification of chemical
compounds displaying pharmacological activity against a target protein. This is broadly
achieved via two approaches: High-Throughput Screening (HTS), where large libraries of
molecules (105 to 106/day) are physically tested against a protein, and Structure-Based Vir-
tual Screening or Structure-Based Drug Design (SBVS/SBDD), where molecules are evalu-
ated computationally prior to synthesis and physical testing.
The processes involved in HTS have been optimised over many years with attendant minia-
turisation of assay plates and automation amongst the first wave of innovation [1]. There
were other innovations such as in combinatorial synthesis, where structurally diverse arrays
of small molecules, or, ‘building blocks’, are combined to generate huge chemical libraries [2]
and in assay methods [3] but HTS campaigns are generally characterised by a low ratio of
signal-to-noise. The efficiencies gained by SBVS are intended to solve the inefficiencies of
HTS, namely, high cost in terms of both time and money but, primarily, the often indiscrim-
inate or imprecise investigation of a molecular target.
SBVS takes as its basis a foundational concept within molecular biology that from molecular
form flows biological function. Operationalised, this infers knowing the molecular structure of
a biological macromolecule, such as a protein receptor, means understanding and predicting
its function. Experimental methods (e.g. X-ray and NMR crystallography) have proven
wildly successful at cataloguing receptor structures to the atomic level, have provided a
basis for the beginnings of computational methods, that is, a 3-dimensional model of receptor
structures and for establishing activity against receptors.
However these are often prohibitively expensive methods in terms of time and labour so do
not lend themselves to large-scale testing of molecular libraries. Instead, they are often used
in an incremental manner to establish the binding mode of molecules known to bind and then
with derivatives. Cheaper methods such as molecular binding assays [4] (e.g. fluorescence
anisotropy) and signal transduction assays enable larger-scale testing of compounds against
biological targets.
Compounds tested in these assays can be broadly categorised according to purpose. Small
molecules, or, ‘fragments’, are low molecular weight (≤250 Da) compounds that are biologi-
cally active. These can be as small as a ring system (e.g. indole) and are often also termed
‘scaffolds’ as they tend to be a generic molecular entity that can be built-upon. Molecular
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frameworks apparently capable of serving as ligands for multiple targets led to the develop-
ment of ‘privileged scaffolds’. These are molecular entities, such as a quinoline, that tend to
feature in many drug molecules (e.g. Amodiaquin, Camptothecin) where libraries including
these entities are synthesised to target broad classes of targets [5].
‘Lead-like’ molecules are larger (∼300-400Da) molecules demonstrated or believed to be ther-
apeutically useful but with scope for further optimisation to improve potency. Although
classes of approved drugs do exist that are no bigger than lead-like molecules [6], generally
‘drug-like’ compounds are larger (≤500Da), more potent and possess properties (e.g. logP,
polar surface area, bioavailability) that improve the drug’s ability to reach targeted parts of
the body and reduce undesirable reactions such as toxicity and carcinogenicity [7] [8].
That these molecules are already known to be drug or lead-like molecules and have already
been synthesised potentially ensures a lack of novelty is built into the process. Thus, the
emergence of computer-based methods to more efficiently develop inhibitors with new chem-
istry. In one such approach, Virtual Screening (VS), databases of commercially-available
molecules firstly have 3D representations elucidated from a source such as X-ray crystal-
lography and are tested via computational methods against a known protein target, also
typically sourced from X-ray crystallography. Predictions of a given molecule’s binding pose
and affinity are made and then tested experimentally.
The size and characteristics of molecular databases are concerns [9]. The size of chemical
space is vast but large portions of it are biologically uninteresting. So, whilst screening larger
databases would be both slow and inefficient, strategies targeting biological relevancy are not
without risk or compromise. Many biologically-relevant small-molecule databases have been
made available online with library sizes in the thousands (e.g. WOMBAT [10], KEGG [11])
millions (e.g. CHEMBL [12], PubChem [13]) and hundreds of millions (ZINC [14]).
Issues remain in handling even mid-sized databases in the range of hundreds of Gb/Tb
within a reasonable timeframe without requiring specialised computing facilities, such as a
High-Performance Computing Cluster (HPCC). Reducing the computing effort often requires
decisions prior to calculations being performed (e.g. only target molecules of lead/fragment
size, logP cut-offs) or in finding ‘representative’ molecules afterward (e.g. clustering methods)
that are target-specific and require expert knowledge of the target itself.
The de novo molecule design approach allows the computational chemist to instead design
much smaller databases of molecular structures based upon the 3D structure of the recep-
tor’s binding pocket. This essentially guides a progressive optimisation of a given molecular
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representation mapped to ΔGbinding whilst allowing for the role of water in the binding pro-
cess and taking into consideration protein flexibility [15]. This, however, can and does often
result in the loss of information regarding Absorption, Distribution, Metabolism, Excretion
and Toxicity (ADMET) that is internalised by curated databases of molecules known to be
biologically active. Prioritising the optimisation of binding properties and in vitro efficacy,
more often than it should, leads to molecules that fail in clinical trials (‘late-stage attrition’)
with failure on grounds such as toxicity or adverse effects reported in up to 50% of drug
candidates [16]. This has led to a conclusion that profiling of ADMET properties and omis-
sion of molecules from further consideration should occur at earlier stages, namely, at the
screening stage.
Secondly, both ligands and receptors are flexible molecules and the degree of flexibility
increases dramatically with the number of rotatable bonds in any given molecule so ensuring
adequate conformational sampling of both is challenging. There is often difficulty in ensuring
a reasonable starting structure from X-ray crystallographic studies, often stemming from high
motions in the proteins under study. These motions often cause large flexible loops to be
unresolved or make it difficult to unambiguously distinguish oxygen atoms and NH2 groups.
Additionally, identifying a target’s binding site(s) is often made challenging by the flexibility
of the receptor, whether it is amino acids in the binding pocket or entire loops occluding
it. Furthermore, water molecules are crucial for ligand binding to a particular receptor but
often not resolved by crystallography.
Techniques exist to address these problems in static and dynamic ways and all have implica-
tions for the accuracy of predictions regarding binding-site and receptor behaviour. Chemical
probes can be used to identify binding ‘hot spots’ on a static 3D structure from X-ray crys-
tallography (e.g. SiteMap [17], Fpocket [18]), multiple chemical probes applied to protein
dynamics (e.g. MDMix [19]) normal mode analysis to determine a receptor’s ensemble of
most likely conformations (‘micro states’) as well as the dynamics between them [20] and,
finally, using the coordinates of water in simulations transformed to distribution functions
and discretized into a 3D grid from which thermodynamic quantities can be calculated, the
thermodynamic profile of a binding pocket and implications for ligand binding characterised
(e.g. Grid Inhomogenous Solvation Theory [21])
Finally, accurately quantifying binding energies in an aqueous environment is largely out of
reach even for the most accurate computational methods (e.g. Thermodynamic Integration).
Protein-ligand binding affinity can be determined from the experimentally measured binding
constant KB
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∆G = −RTlnKB = ∆H − T∆S (2.1)
Experimentally determined binding constants, KB, are typically in the range of 10
−2 -
10−12mol·L−1 and correspond to a Gibbs free energy of binding, ΔG, of between -10 and
-70kJ·mol−1 in aqueous solution [22]. Two broad components addressed by the above rela-
tion are the ‘enthalpic’ and ‘entropic’ contributions to ligand binding, the former a function
of making and breaking of electrostatic interactions between all three of protein, ligand and
water with enthalpic contributions a function of the release of water to solvent and loss of
conformational mobility of receptor and ligand.
Both enthalpic and entropic contributions often compensate between each other. Features
that have been found to lead to more energetically favourable protein-ligand complexes in-
clude steric complementarity between protein and ligand, complementarity of surface prop-
erties (e.g. lipophilic parts of the ligand interact with lipophilic parts of the protein) and
that the ligand adopts an energetically favourable conformation. However, as stated, bind-
ing involves a complex equilibrium between ensembles of solvated species varying in their
conformation. In contrast, scoring functions that can be calculated quickly and efficiently
use often crude approximations, use only one receptor-ligand geometry, neglect the unbound
state of binding partners and often neglect cooperative effects of different interactions, usu-
ally assuming more of an additive relationship [23].
That said, at the high-throughput level SBVS inhabits, one can still use estimated energies for
relative ranking of potential ligands as, although an accurate estimate is not possible, some
correlations with experimentally-determined affinity are. Dozens of methods for estimating
binding affinity of a protein-ligand complex have been developed since the early 90’s and a
consequent taxonomy broadly groups them into five classes: (1) force field-based methods,
(2) empirical scoring functions, (3) knowledge-based methods, (4) Quantum Mechanics (QM)
scoring functions and (5) machine learning methods.
Force-field or ‘physics-based’ methods estimate affinity by complementing modelled estimates
of gas-phase electrostatic interactions between protein and ligand and a pre-calculated cubic
grid with solvation terms as estimated by continuum solvation models e.g. Generalised
Born solvation model (GBSA). These methods fall under the general term of ‘molecular
docking’ methods and have been implemented in UCSF’s DOCK [24], Autodock VINA [25]
and OpenEye’s FRED [26]. Both receptor and ligand are rigid in these methods so they rely
on input of multi-conformer ligands for fitting into the receptor’s binding pocket. Flexible
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docking solutions exist, where an initial rigid fit is complemented with bond rotation and
energy cut-offs [27] or incorporates both ligand and binding pocket flexibility via Genetic
Algorithms [28]. However, these are often an order of magnitude slower than rigid methods
and do not guarantee a significantly better result in all cases, such as with more diverse sets
of molecules [29].
Empirical scoring functions estimate the binding free energy of a ligand by the summing of all
individual free energies for interactions in a complex, where each function (fi) of ligand (rl)






Empirical scoring functions contain chemically-intuitive terms describing typical interactions
(e.g. H-bonding, hydrophobic interactions, binding entropy) but also contain penalty func-
tions for complexes that deviate from ideal values (e.g. atomic clashes, angle criteria).
Attempts have been made to improve scoring functions by weighting modalities of H-bonding
[30] [31], ionic [32] and hydrophobic [33] interactions differently. This is as opposed to treating
them as if they are identical or not significant in the overall binding, such as is the case with
London or cation-Π interactions. However, most methods tend to suffer from the same
problem, that difficulty remains in predicting binding affinities of ligands that materially
differ from those used in their training sets [34].
Knowledge-based scoring functions essentially sum all pairwise protein-ligand interactions
where the potential between atom pairs i and j with distance r between them, ωij(r), is
evaluated from the inverse Boltzmann law, the atomic densities are evaluated in pairwise
fashion between the system state (ρij) and a reference state and where interactions are
assumed to be zero (ρ∗ij).






Using the assumption that a larger number of contacts between ligand and protein is indica-
tive of attractive interactions, distributions of these contacts can be converted to atom-pair
potentials, or, Potentials of Mean Force (PMF). Thus, in contrast to empirical scoring func-
tions, that are derived from a training dataset generally obtained from the Protein Data
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Bank (PDB), knowledge-based scoring functions make use of statistical analysis of struc-
tural information without the need for experimental binding data. Improvements have been
observed by augmenting potentials with geometric [35] and solvent [36] data. Although fast,
relatively straightforward to compute, and useful for re-ranking of docking results, no sin-
gle scoring function consistently outperforms others when applied to diverse test sets with
performance likely target-specific [37].
QM methods allow polarisation and charge-transfer effects of a region around the ligand
to be modelled and incorporated into the energy terms of the scoring function [38]. More
correctly under the QM/MM (Quantum Mechanics/Molecular Mechanics) approach, the
ligand was treated with a relatively expensive linear-scaling semi-empirical Hamiltonian and
the surrounding system with a cheaper classical Hamiltonian and the AMBER ff99SB force
field. The effective Hamiltonian of the system was therefore a sum of the MM, QM and
QM/MM Hamiltonians.
Ĥeff = ĤMM + ĤQM + ĤQM/MM (2.4)
Following energy minimisation steps, binding free energies were then calculated from the
gas-phase binding free energy coupled with the solvation free energy.
Other approaches [39] integrating linear-scaling semi-empirical methods with the Linear
Interaction Energy with Continuum Electrostatics (LIECE) model showed good agreement
with experimentally-determined binding free energies of inhibitors against classes of proteins
as diverse as an aspartic protease and a kinase.
The primary limitation for such methods is, however, throughput. Although certain optimi-
sations drastically increased the speed of calculation (e.g. using energy minimisation instead
of molecular dynamics), each molecule’s calculation took approximately an hour in 2008.
Although computational speed has dramatically increased in this time, one could imagine
that computations would remain of the order of tens of minutes per molecule, significantly
slower than other scoring function approaches.
Finally, machine learning based scoring functions do not assume a functional form regarding
binding affinity and structural features of the protein-ligand complex. Instead, they generate
features directly from a training set of molecular data. Features generated from interatomic
pairs of ligand and protein atoms are then selected via machine-learning algorithms (e.g.
Random Forest, Support-Vector Machine), to build and validate a model to compute an
outcome of interest, most commonly, binding affinity.
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Machine learning scoring functions have been reported to outperform other classes of scoring
function in predicting binding affinity of known protein-ligand complexes [40] even with less
chemically discriminative models [41]. However caution must also be exercised as it has been
reported that whilst producing excellent agreement with known complexes, machine learning
methods have proven less suited to predict affinity for novel molecules to novel targets [42].
2.2 Fragment-based drug-discovery
One difficulty within the SBVS approach can lie within the molecular size of ligands. Screen-
ing with larger and more complex compounds can lead to a sort of molecular ‘over-fitting’
problem, where molecules are prioritised and selected for further development primarily be-
cause they are larger. This increases the probability of both false positives in computational
studies and interactions with unintended targets in trials [43] [44].
In using one approach to solve this problem of larger false-positives, Fragment-Based Drug
Design (FBDD), one starts small. Molecules of low molecular weight are screened against
molecular targets. Although these molecules display lower overall affinity, the logic of FBDD
follows that specific interactions from the fragment will result in a stable and predictable
binding mode and that molecular extensions from this fragment will retain this binding
mode in addition to the interactions provided by the extension. The approach also offers
the proposition of an increase in the number of viable starting points in the binding pocket
that should result in a greater diversity of molecules discovered and optimised to bind to
a particular target. This potentially gives practitioners the opportunity to build desirable
properties into a molecule from the beginning. Flowing from the FBDD philosophy, molecules
should prioritise novelty, possess molecular properties useful in biological systems and, more
recently, extensions should be relatively easy to synthesise.
A campaign to ensure chemical novelty for crystallographic fragment screens was conducted
on molecules of less than 20 heavy atoms sourced from numerous commercial manufacturers
[45]. This was born from the idea, later confirmed, that as fragments tend to be low-
affinity binders, biophysical screening methods often miss molecules that are found to be
hits via crystallography [46]. An initial library of > 200 000 fragments was reduced via
several filtering steps, including the removal of reactive functional groups, toxic molecules
and to ensure adherence to Lipinski’s ‘rule of 5’ [47]. From there, clustering steps to ensure
chemical novelty pared the library down to 361 molecules. The library demonstrated a high
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crystallographic hit-rate (19.7%) against an aspartic protease target and elucidated molecules
with novel binding modes and chemotypes against this target [48].
Lower hit-rates but higher-affinity ligands were found in larger campaigns against multiple
targets [49] but the trend is clear, that more libraries are being designed with chemical
novelty in mind [50]. It does behove those looking for hits to be mindful of the biophysical
screening methods used as it has been demonstrated that, whilst faster, assay methods
(e.g. fluorescence assay, ElectroSpray Ionization-Mass Spectometry) often result in vastly
different hit rates with little overlap between them in identifying hits, in addition to not
directly providing information about binding modes [51].
After finding fragments that bind, ligands can be extended, or, ‘elaborated’ in a number
of ways. Successful examples of fragment linking or ‘target-guided synthesis’ have been
reported, such as where multiple fragments binding to different areas of a receptor’s binding
pocket are linked synthetically and then tested [52]. There are few successful campaigns in
the literature, however, as designing a useful linker with appropriate flexibility has proven
to be problematic. Too rigid and the original binding poses of each fragment are unlikely to
be stable in the elaborated molecule. Too flexible and there will be an entropic penalty to
pay that may abolish binding entirely.
Other approaches used, such as ‘tethering’, progress by synthesising disulfide-containing
molecules that covalently bind to cysteines adjacent to the binding pocket. Tethering has
been shown to effectively ‘probe’ a pocket and assist in finding an allosteric pocket, identify
fragments suitable to interfere with Protein-Protein Interface (PPI) formation or to stabilise
a complex that wouldn’t otherwise occur or form with much less stability [53]. The ap-
proach does demand specialised libraries of disulfide fragments [54] as well as the design and
expression of multiple cysteine mutants for screening, limiting its utility.
In addition to structural information, one can be more concerned with synthetic feasibility
of molecules from fragments known to bind to a target, as we were in chapter 3. The net
effect is to increase the probability of hits, a philosophy under the broad methodology of de
novo drug design. A library [55] of ‘synthetically tractable’ but drug-like molecules was also
reported that resulted in a freely-available dataset of molecules derived from Chembridge [56]
building blocks.
Beginning with relatively strict criteria for fragments (MW ≤ 250 Da, nrotatable bonds ≤
2, nchiral centres ≤ 1) and reactions, a collection of 58 ‘robust’ reactions [57] was used to
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exhaustively react ∼8000 building blocks in silico. This generated ∼21 million molecules with
a focus on both chemical novelty and being drug-like but small enough to allow for further
optimisation. Other approaches allow for customised libraries to be built or the reverse
process, retro-synthetic deconstruction of a molecule or series of interest. This method also
has, at its core, a focus on synthetic feasibility and from a small set of fragments, use of the
approach suggested diverse extensions with up to a 40-fold improvement in affinity against
the β2 Adrenergic Receptor [58].
2.3 Molecular docking
The broad philosophy and techniques underpinning in silico ligand discovery efforts in chap-
ter 3 and chapter 4 require intricate methods to estimate binding affinities and make full
and proper use of structural information gained via experiment and developed molecular
libraries. A common approach to facilitate the combination of both ligand and target struc-
tural information is molecular docking.
The principle inherent within molecular docking is to use the structure of a target protein
to detect molecules active against it. In doing so, molecular docking takes advantage of
the large and growing (>153 403 as at Jan 2019) amount of 3D protein structures made
available via the Protein Data Bank (PDB) [59]. Broadly, this is achieved via the placement
and scoring of molecular poses and then the evaluation of their fit in the binding pocket.
Aside from marked differences in scoring functions, molecular docking programs are often
characterised by two important facets; the degrees of freedom allowed within their algorithms,
whether that be in the orientation or flexibility of the ligand, protein or both, and methods
in how those degrees of freedom are searched. How solvation is handled and, for example,
detection of atomic clashes also affects the accuracy of calculations. A meaningful taxonomy
of docking software is beyond the scope of this thesis but two broad types used in chapter 3
and chapter 4 will be discussed.
2.3.1 Physics-based methods
The Solvation Energy for Exhaustive Docking (SEED) method used in chapter 3 places
poses of fragment-sized molecules (≤ 250 Da) in a receptor binding pocket exhaustively in
order to estimate the binding energy of each pose [60]. Pre-defined rules (e.g. dielectric
value of solvent/solute, maximum angular deviation from ideal H-bond geometry) govern
the generation and placement on binding pocket residues of vectors of uniform length on all
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H-bonding groups in a direction of ideal H-bonding geometry.
A similar procedure occurs with polar groups on all pre-generated conformers of ligand
molecules before matching of H-bond vectors is completed. Additional rotations around
vector matches are performed to enhance sampling of conformational space in the binding
pocket. Bad contacts are detected via the measurement of atomic van der Waals (vdW)
distances and evaluation of binding energies to a pre-generated grid over the whole receptor.
After placement of a fragment pose, an evaluation of the total interaction energy is com-
pleted. Electrostatic energies in solution are calculated as the sum of all receptor and ligand
desolvation energies and fragment-receptor interaction energies, evaluated atomically via







Where τ = (1/εp) - (1/εw) and where;
RGBij =










j are the effective Born
radii of each atom [61].
Receptor desolvation is calculated via continuum electrostatics assumptions (e.g. uniform
dielectric constant in solvent and solute regions). This negates the need for explicit treatment
of solvent effects. Desolvation of the receptor is therefore the calculated energy difference
between an uncharged fragment and a charged receptor in solution upon binding, or, the







Fragment desolvation is defined as the calculated energy difference between a charged frag-
ment and uncharged receptor in solution upon binding, or atoms of partial charges qi and qj















Where Eselfi is the interaction between the charge itself and solvent, non-zero for intra-









The difference in fragment energy is then evaluated simply as the energies of bound and
unbound fragment in solution.
∆E = Edocked − Efree (2.10)
An alternative approach by UCSF’s DOCK suite (chapter 3 and chapter 4) places ligands
uses a bipartite graph-matching algorithm to map subsets of atomic distances within a ligand
to subsets of receptor-sphere internal distances [62]. Spheres are generated and placed into
the binding pocket, reflecting groove and ridge complementarity of a pre-generated molecular
surface [63] [64]. Complementary ligand orientations are then matched to the positions of
these spheres (Figure 2.1). Separate electrostatic and vdW grids are calculated from the
molecular surface and distance-dependent potentials between ligand and the nearest surface
of the grids are calculated.
Figure 2.1: Depicted here is an example of the receptor:ligand sphere matching algorithm in UCSF DOCK. (A) A
receptor with four spheres (empty circles) and ligand with three (coloured stars) is depicted prior to docking. (B) Four
possible orientational matches of ligand spheres (coloured stars) at a given distance tolerance (in Å). Increasing the
distance tolerance results in more orientations (i.e. with sphere 4) (from Coleman et al, 2013)
After ligand placement, a scoring function is applied to each atom in the pose comprising pre-
computed partial charges interacting with the nearest grid points in pairwise fashion [65]. A
vdW term is calculated from the AMBER united atom force field [66], an electrostatics term
is calculated from a Poisson-Boltzmann calculation using electrostatics grids (QNIFFT [67])
and desolvation handled via Generalised Born approximation of the fractional desolvation
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of all atoms in the pose [68]. The final score is then simply an additive relation combining
each of these components.
Escore = EvdW + Eelectrostatics + Eligand,desolenergy) (2.11)
Desolvation can also be estimated by applying the full transfer free energy, ∆Gtransi , to each





The fractional desolvation, Di, over all atomic radii, ai is then evaluated where dV is the









In contrast to SEED, DOCK assumes a lower dielectric constant inside the pocket than
outside the pocket.
2.3.2 Shape-based methods
An approach from OpenEye is within the family of ‘exhaustive docking’. Given the hypoth-
esis that the shape of the receptor is the most important factor in virtual screening, firstly,
a negative image of the receptor’s binding pocket is generated by docking a set of drug-like
molecular probes with only one conformer. The top-scoring poses of each probe are then
‘averaged’ to form a potential field that is converted to a density field by assuming a spher-
ical Gaussian density distribution. The field created has higher potentials both at positions
where ligand atoms make useful contacts with the receptor (e.g. polar H-bonds) and where
ligand atoms are likely to occupy when molecules are large enough to stretch across multiple
sub-pockets.
Unless pre-computed conformers are supplied, FRED [69] generates conformers then system-
atically enumerates all likely rotations and translations of each conformer within the binding
pocket of the receptor. After generating an initial ensemble of poses and filtering all clear
clashes using a negative image of the binding pocket, all remaining (tens-of-thousands to
tens-of-millions) poses are scored and the top-100 are retained for the next step, a solid-
body optimisation with 36 degrees of freedom. The top scoring pose is then kept as the final
pose (Figure 2.2).
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Figure 2.2: FRED docking process depicting the ligand scoring, optimisation and placement process. Conformers are
exhaustively generated and progressive filtering steps applied as thousands of poses are scored and rejected based upon
distances from the protein surface. Poses are then scored and a solid-body optimisation follows prior to presentation
of the finalised pose position (from McGann, 2011).
FRED’s empirical scoring function, Chemgauss, models and smooths distance-based poten-
tials for multiple types of interactions (e.g. H-bond, metal chelation) with additional facets
modelled such as penalties for H-bonds with solvent broken by the docking process. A sep-
arate scoring function, Chemical Gaussian Overlay (CGO), models how well a pose overlays
upon the structure of a known ligand, ensuring bias towards known binders in the docking
process. This additional step is implemented in OpenEye’s HYBRID program and has been
validated against a test set of 40 protein targets and multiple conformations of each protein
accounts for binding site flexibility [26].
2.4 Molecular dynamics simulations
Whilst a valuable perspective, molecular docking where ligand and protein conformations are
held rigid does not address dynamic protein and ligand behaviour at all. Similarly, flexible
docking is limited to finding an energetic minimum for ligands and residues within range
of them. The starting protein structures for these techniques are very often those obtained
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from X-ray crystallography. The result is therefore more of an ‘averaged’ view of the system
under study.
From the dynamics of a molecular system, making/breaking of hydrogen bonds, free energies,
water interaction patterns, configurational changes (e.g. ring flips, puckering) and many
other quantities can be estimated. The view of the energy landscape of protein folding has
traditionally been that of the ‘funnel hypothesis’, that its native state corresponds to its free
energy minimum in cellular solution conditions. However, at a larger scale, seminal papers
[70] [71] have elucidated an understanding of protein systems dynamically sampling multiple
conformational states, not necessarily all related to function. As the funnel hypothesis has
given way to a more realistic description of the temporally-resolved motions of a system,
more realistic treatments of chemically relevant quantities as they relate to time-resolved
conformational movements of biomolecular assemblies has been the result [72].
Many techniques exist to alter the course of simulations and explore more conformational
micro states, whether it be via biasing forces or guiding restraints. For example, in the gen-
eration of pathways through known endpoints of a system to gain information about allowed
or disallowed states such as Targeted or Adaptive Steered Molecular Dynamics (T/SMD).
Or, enhanced sampling of conformational states using techniques such as Umbrella Sam-
pling, conformational flooding and Ensemble-Biased Metadynamics. For now, only unbiased
(equilibrium) simulation methods as used in chapter 3 will be discussed.
2.4.1 Equilibrium simulation
The ingredients for a successful simulation are many and rooted in statistical mechanics,
used to transpose information collected at the microscopic (atomic) level into macroscopic
observables (e.g. potential energies, pressure, temperature). These can be used to study
both thermodynamic properties of a system (∆G) or kinetic (time-dependent) events.
By linking the macroscopic thermodynamic state of a system (Number of Particles N, Tem-
perature T, Pressure P) to its microscopic state (atomic positions q and momenta p), an
ensemble, or a collection of micro states that all have the same constrained properties as
the macroscopic system in multidimensional space (phase space) can be constructed. As a
molecular dynamics simulation generates a sequence of points in phase space as a function of
time, these points conform to different conformations of the system and belong to the same
ensemble.
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Depending upon the system under study, common ensembles include:
Ensemble Constraints Variables Thermodynamic system
Microcanonical (NVE) Number of atoms N
Volume V
Internal energy E
Energy of each particle εi Isolated
Canonical (NVT) Number of atoms N
Volume V
Temperature T
Internal energy Ej Closed
Grand canonical (µVT) Chemical potential µ
Volume V
Temperature T
Number of particles Ni
Internal energy Ej
Open






Table 2.1: Comparison of various classical thermodynamic ensemble types, their properties and constraints in addition
to the macroscopic thermodynamic system with which they may be compared (adapted from [73])
Broadly, if one allows a system to to run indefinitely, then that system will eventually pass
through all possible micro states. Thus, one aim of MD simulation is to generate enough
representative conformations of a system such that a sufficient amount of phase space is
sampled. This ensures that the link between macroscopic variables and microscopic states
is established. An ensemble average is the mean of a quantity (e.g. temperature, pressure)
that is a function of the micro state of a system. Ensemble averages, justified via agreement
with experiment, are therefore calculated over a large number of replicas of the system.
The ensemble average where the observable quantity of interest, A(pN , rN ), is expressed as




dpNdrNA(pN , rN )ρ(pN , rN ) (2.14)
The probability density of the ensemble with Hamiltonian H, Temperature T , Boltzmann
Constant kB and partition function Q is then:
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] (2.15)
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kBT
] (2.16)
This integral relies upon the availability of all possible micro states and a MD simulation
passing through all of these states. Instead, MD simulations can be used to calculate a time-
related ensemble average. So, a simulation of time t, number of steps M and instantaneous














A(pN , rN ) (2.17)
This leads to the insight of the Ergodic Hypothesis that the time-average of A equals the
ensemble average:
〈A〉ensemble = 〈A〉time (2.18)
With the assumption that the time average of a sufficiently long simulation is equal to the
ensemble average of thermodynamic quantities, we now have a basis for conducting MD
simulation to obtain said quantities.
In practice, the act of conducting a MD simulation is based upon Newton’s Second Law of
Motion where the total force acting upon atoms are related to their mass m and acceleration
a.
Fi = miai (2.19)
Integration of the equations of motion then allow us to determine positions, accelerations
and velocities of atoms as they vary over time (trajectory). So for atoms of velocity v and
position x at constant acceleration a:
F = m · a = m · dv
dt




After integration, expressions for time-dependent atomic velocities and positions from initial
velocities v0 and positions x0 can be stated as:
v = at+ v0 (2.21)
And:
x = v · t+ x0 (2.22)
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Combined, an expression is yielded to track changes in positions of atoms over time from




· a · t2 + v0 · t · x0 (2.23)







Initial positions are usually chosen from experimentally determined structures (e.g. X-ray
or NMR spectroscopy). Initial velocities vi are usually selected randomly from a Maxwell-
Boltzmann or Gaussian distribution of temperature T that yields the probability that an


























As the potential energy, a function of atomic positions (3N), must be calculated analytically,
several popular algorithms exist. The algorithm used most commonly by the Ambertools
simulation software is the Leap-frog algorithm. Velocities are first calculated at time t+ 12δt



















From the integration of the equations of motion, an estimate of the energy of a system may
be obtained via a potential energy function, or, force field. There are many force fields that
introduce approximations and impose limitations on their use with certain systems.
For example, specific force fields govern the motion and boundary conditions of everything
from small molecules to large protein systems [74,75] where secondary structure inherent in
protein systems means dihedral corrections and rotation barriers for certain residues under
certain circumstances must be applied. The parametrisation of these more complex force
fields coupled with the number of variants are beyond general description here.
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For now, as a general example of a well-developed general purpose force field, the General
Amber Force Field (GAFF [76]) shall be introduced. A simple harmonic function form
calculates the bond and non-bonded energy of a given atom pair (i, j) in media of dielectric
constant ε. Partial charges (qi, qj), bond angles θ separated by distance R are augmented by




























All of the above are implemented in CPU-bound and GPU-accelerated codes in the Amber-
tools [77] suite of programs used in chapter 3 and from here, the first stages of a simulation
can begin.
First, an energy-minimised starting structure is solvated via the overlay of water molecules
to completely surround the solute.
A heating stage follows where initial velocities are assigned to atoms in the system and water
molecules allowed to move. The system is heated from low temperature and the movements
of the solute restrained to minimise large forces that may lead to instability. As the system
is heated and the system stabilises, restraints on the solute are loosened and ultimately lifted
entirely as the system reaches the target temperature.
The purpose of the next stage, equilibration, is to allow the system to stabilise with respect
to quantities such as temperature, pressure and energy over time. It is run for as long as it
takes for this to occur, typically a few nanoseconds.
The final stage, production, is run for as long as is desired to observe the chemical phenom-
ena in question. In this phase, thermodynamic parameters are calculated so the length of
the simulation is dependent upon the ensemble as identified earlier and whether adequate
sampling of conformations have occurred to ensure the accuracy of these quantities.
2.5 Energy minimisation
Primarily, the goal of energy minimisation in chemistry is to determine a set of coordinates
representing a molecular conformation such that the potential energy of the system is at a
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minimum on the potential energy surface describing the molecule. Several algorithms are
implemented in chemistry software packages, generally working in Cartesian space, with
varying convergence criteria, complexity and tolerances for how far a molecule really is from
a local minimum, or, stationary point. Differences in in a given system govern which method
is most appropriate.
For now, only two first-order minimisation methods, Steepest Descent and Conjugate Gradi-
ent, both implemented in the Chemistry at HARvard Macromolecular Mechanics (CHARMM
[78]) software package, will be discussed. Also discussed will be an approach combining a
rapid method of estimating ligand conformational entropy with a second-order optimisation,
implemented in the OpenEye software SZYBKI. All of these approaches were used to find
energetic minima of proteins and protein-ligand interactions in chapter 3 and chapter 4.
2.5.1 Steepest descent minimisation
First introduced by Cauchy [79], the aim of the steepest descent, or, gradient descent method
is to find the minimum of a function f(x), x ∈ RN and that f : RN → R of gradient
gk = g(xk) = ∇f(xk) [80]. The minimum of a given quadratic function is found by computing
steps along a given search direction dk.
xk+1 = xk + αkdk, k = 0, 1, ..., n (2.29)
Where the step length αk is given such that:
αk = argminf(xk) + αdk) (2.30)
For the steepest descent method, the search direction is given as where the slope is negative,
or, dk = −∇f(xk). The algorithm therefore proceeds until a given convergence tolerance is
reached or variations fall below a given tolerance.
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Algorithm 1 Steepest descent algorithm
Input: Given an initial x0, d0 = −g0 and convergence tolerance tol
1: for k = 0 to maxiter do
2: Set αk = argminφ(α) = f(xk − αgk
3: xk+1 = xk − αkgk
4: Compute gk+1 = ∇f(xk+1




The CHARMM implementation of steepest descent adjusts the step size as the calculation
approaches convergence. For example, if a step results in a lower energy, the step size is
increased by 20% whereas if the energy rises, the step size is halved until convergence is
reached.
2.5.2 Conjugate gradient minimisation
From a similar starting point to the steepest descent, the conjugate gradient method [81] uses
the property of vector conjugacy of a set of nonzero vectors {p0, p0, ..., pn−1} to a Symmetric
Positive Definite (SPD) matrix A (A-conjugacy).
pTi Apj (2.31)
This set of A-conjugate vectors acts as a basis for the whole of real number space IRN and
can be used to express the difference between the exact solution x∗ and the first guess x0 as
a linear combination of these conjugate vectors.
x∗ − x0 = σ0p0 + σ1p1 + ...+ σn−1pn−1 (2.32)
By using this property of conjugacy, the coefficients σk are equivalent to the step size αk
needed to minimise a quadratic function along xk + αkpk so the exact solution becomes a
linear combination of the initial guess coupled with step size and the conjugate vectors.
x∗ = x0 + α0p0 + α1p1 + ...+ αn−1pn−1 (2.33)
This only demonstrates that, in theory, a set of A-conjugate vectors exists. To each successive
step, each new direction pk is chosen as a linear combination of the negative residual −rk
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(equal to the steepest descent, or, negative gradient direction) and only the previous search
vector pk−1.
pk = −rk + βkpk (2.34)
Where βk is found by imposing a conjugacy condition, p
T









The algorithm therefore becomes an exercise in using the previous step as a guide toward
the nearest minimum. The step length is calculated (step 2) then the solution is updated
with that step (step 3). The residual is updated (step 4) and then, finally, the new search
direction is obtained in the final two steps (5 and 6).
Algorithm 2 Conjugate gradient algorithm
Input: r0 = Ax0 − b, p0 = −r0




3: xk+1 = xk + αkpk




6: pk+1 = −rk+1 + βkpk
7: end for
As the step size is determined by the algorithm itself, in CHARMM it is implemented as
an automatic step. In terms of minimising the number of steps taken to reach convergence,
the conjugate gradient method will significantly outperform steepest descent. However, with
poor conformations, it will generate more integer overflows. Hence, it is common practice
to apply both algorithms to a given structure, beginning with steepest descent minimisation
followed by conjugate gradient minimisation as it nears the energetic minimum.
2.5.3 Minimisation and ligand entropy
Estimation of ligand entropy is essential to accurate estimation of the binding free energy
in a protein-ligand environment. However, accurate condensed-phase calculations of the
conformational entropy are computationally expensive, usually determined by MD simulation
assuming a trajectory is run for long enough. As accurate prediction of molecular entropy
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relies upon a given molecule being at its energetic minimum, a fast but relatively accurate
treatment of ligand entropy in a protein-ligand environment [82] is necessary in drug-design
research where the number of ligands being evaluated is often large.
Ligand entropy is estimated as the sum of configurational entropy Sc and solvation entropy
∆Ss
S = Sc + ∆Ss (2.36)
Configurational entropy
Configurational entropy is estimated as a relation to a partition function q with Boltzmann














The conformationally-dependent partition function q of conformer i with internal energy εi,
translational, rotational and vibrational partition functions (qt, qir and qiv respectively) and







Introduction of a simplifying assumption, that a ligand in a protein-ligand complex has three
translational and three rotational degrees of freedom, mean q can be evaluated as either qv








Vibrational frequencies underpinning the evaluation of qiv are evaluated from normal-mode
analysis of the relation between mass-weighted second-derivative Hessian matrices Hm, the






Where eigenvalues λi of H







The second-order Broyden-Fletcher-Goldfarb-Shanno (BFGS [83]) minimiser is used to con-
struct a diagonalised matrix H−1i+1 after each step i from atomic position vector xi to predict
the positions of atoms in the next step xi+1, where f(xi) is a function governing where the
desired minimum is.
xi+1 = xi +H
−1
i+1∇f(xi) (2.42)
In words, BFGS optimisation, especially limited-memory (L-BFGS) as implemented in Szy-
bki, is a way of finding a (local) minimum of an objective function, in this case f(xi), making
use of the objective function values and its gradient ∇ from a starting point of an initial di-
agonalised Hessian. So, with every iteration, the approximate Hessian approaches the exact
Hessian. Upon reaching a good quality Hessian, the optimisation is complete and a minimum
established by calculation of normal frequencies.
Primarily, there are two advantages to second-order minimisation methods using the Hessian
and gradient over first-order methods using the gradient. Firstly, speed of convergence.
Algorithms such as Steepest Descent tend to exhibit linear convergence [84] whereas L-
BFGS has superlinear, and therefore much faster, convergence [85]. Secondly, L-BFGS tends
to outperform both Steepest Descent and Conjugate Gradient on low-dimensional problems
(< 10 000 parameters), especially if the starting point of the optimisation is far away from
a local minimum [86].
Solvation entropy
Solvation entropy ∆Ss is estimated from an additive relation between electrostatic (∆Ss,elec)
and hydrophobic (∆Ss,hyd) components.
∆Ss = ∆Ss,elec + ∆Ss,hyd (2.43)
The electrostatics component is further broken down into bulk effects and polar solute-











The second term is evaluated at a constant of 28 J.molK−1 based upon various gas-phase
calculations of molecules with proton donors or acceptors interacting with water molecules.
46
Accurate treatment of specific hydrophilic solute-solvent clusters was determined to be be-
yond the scope of the method, making Szybki computationally too expensive for the purposes
of drug design research.
Finally, the hydrophobic term is evaluated in approximate fashion from the hydrophobic







Where ∆Gs,hyd is an additive relation of the free energies of cavitation ∆Gcav, solute-solvent
vdW ∆GvdW and induction (permanent dipole-induced dipole) ∆Gind.
∆Gs,hyd = ∆Gcav + ∆GvdW + ∆Gind (2.46)
All three free energies are estimated from approximate methods to allow for the packing den-
sity solvent around the ligand (e.g. Scaled Particle Theory, or, SPT) as well as analytically-
determined relations that calculate solvent and ligand polarisabilities and dipole moments.
2.6 Ligand-based techniques
The use of ligand-based techniques in drug design has previously been a very fertile area
of research [87]. The broad philosophy is used to develop drug candidates in the absence
of structural information describing the target and is predicated on the assumption that
structurally similar molecules will have similar biological activity [88]. An outgrowth of this
has been statistical and analytical tools to elucidate the structural parameters and descriptors
that link a given molecule or molecular class to biological activity.
A popular family of techniques to address this are Quantitative Structure-Activity Relation-
ships (QSAR [89] [90]). The broad method involves in silico modelling of candidate ligands
that are energy minimised. Molecular descriptors for ligands are generated and are often
structural, physicochemical and/or based on calculations from knowledge-based, molecular
mechanics or quantum mechanical tools. A mathematical relation is developed to explain
variation in a dependent variable, that being biological activity against the target. The model
is then tested, refined and validated via an array of techniques more usually associated with
linear regression analysis.
Other approaches, such as the 3D Pharmacophore model [91], focus primarily on the lig-
and structure but integrate some structural information. To that end, a 3D pharmacophore
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model is an essential set of interactions aligned in three-dimensional space of small-molecule
ligands with a protein structure. These interactions encompass intuitive chemical descriptors
such as hydrogen-bond donors and acceptors but also integrate harder to elucidate interac-
tions such as charge-transfer interactions and electrostatic interactions with e.g Fluorine
atoms in a ligand. Variants on this, such as the Conformationally-Sampled Phamacophore
approach (CSP [92]) integrate molecular dynamics simulation as an initial step to increase
the probability of finding the receptor-bound form of the ligand.
2.6.1 Similarity and fingerprinting
Another outgrowth of ligand-based methods is in molecular 2D similarity, or, ‘fingerprints’.
The development of a fingerprint generally involves the encoding of 2D chemical structure
information (e.g. number of rotatable bonds, number of atoms) in a bit-string. This is
then compared to others via Tanimoto coefficient as a measure to determine the similarity
between comparison molecules [93].
The Tanimoto coefficient τ is evaluated where NA, NA and NA&B is the number of fea-






An attempt to integrate more molecular features into molecular fingerprints resulted in the
Extended-Connectivity Finger Print (ECFP [94]) method, a variant of the Morgan algorithm
[95] and explicitly designed to capture features relevant to activity.
The ECFP algorithm firstly assigns integers to the atoms in the query molecule prior to an
iterative updating stage where an atom’s identifier is updated to reflect the identifiers of their
neighbours. This includes basic chemical information (e.g. attached bond types, whether
part of a ring, atomic mass) followed by a duplicate removal stage (Figure 2.3). The final
stage is ‘folding’, a method to increase the information density stored in a fingerprint. With
fixed-length comparisons, strings that could contain most concievable chemical moieties,
fingerprints for small molecules will contain many 0’s and therefore be ‘sparse’ whereas for
very large molecules, the bit string will contain many 1’s and therefore be ‘rich’. This was
not considered an efficient way to store molecular representations.
The folding process begins with a fixed fingerprint size that is very large to accurately
represent any molecule expected to be endcoded. The fingerprint is then ‘folded’ be dividing
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it into two equal halves then combining the two halves using a logical OR. The result is
shorter fingerprints for molecules in our library but with a higher bit density. We can then
repeatedly fold the fingerprint until a pre-determined information density (the ‘minimum
density’) is reached or exceeded (Figure 2.4).
Figure 2.3: The ECFP and unique identifier generation process displaying initial assignment of atom identifiers,
updating of those identifiers and removal of duplicate strings (multiple identifier representations of equivalent atom
neighborhoods) prior to generation of the final list of identifiers for the encoded moiety (from ChemAxon.com)
Figure 2.4: Generation of the the fixed-length bit-string from unique identifiers during the ECFP generation process,
otherwise know as ‘folding’ (from ChemAxon.com)




Novel ligands for the kinase
Proviral Integration site for MuLV
(Pim-1)
In conjunction with my supervisor, Prof. Dr. Peter Kolb, I was responsible for the overall
research planning, strategy and execution of all projects. This is with the exception of
Project 4 where Prof. Dr. Diederich noted the significance of the X-ray crystal structure
that began the project. I was responsible for completing all computational work with the
exception of the docking of aniline-triazoles in Project 2 and library collation for Project
4, both completed by Dr. Florent Chevillard. Chemical synthesis of all compounds was
carried out by Mr. Lukas Heyder from our collaborators, AG Diederich. I was responsible
for assay testing of compounds with help from Mr. Matthias Oebbeke with exception of those
purchased for Project 3 that were also tested by Eurofins Inc. All Thermal Shift Assays and




3.1.1 The kinase Pim-1
The Proviral Integration site for MuLV (PIM) kinases are a family of serine/threonine kinases
in the CalModulin-Dependent Kinase (CAMK) family.
PIM genes were first identified in the 1980s as potent oncogenes associated with murine
leukaemia virus (MuLV)-induced lymphomas in mice [97] and comprise a family of three
genes: Pim-1, Pim-2 and Pim-3. These genes have differing tissue expression profiles [98]
and a sequence homology of >60%. This leads to compensatory activation [99] in the absence
of one or more of the proteins expressed by PIM genes but particularly Pim-1 [100].
Pim-1 interacts with and phosphorylates a variety of cellular targets and performs a variety
of roles involved in cell cycle progression and death. Pim-1 inhibits apoptosis via interactions
with regulator proteins bcl-2 and Gfi-1 [101] but has arguably a more significant role in a
pathway involving the Janus Kinases and Signal Transducer and Activator of Transcription
proteins (JAK-STAT pathway [102]).
The JAK-STAT pathway (Figure 3.1) is involved in cellular processes leading to DNA tran-
scription such as cell survival, proliferation and differentiation [103]. Pim-1 has cell cycle
substrates necessary for mitosis (NuMA [104]), cyclin-dependent kinase inhibition to regulate
DNA synthesis (p21Cip1) [105], inhibitors (p27Kip1 [106]) and activators (Cdc25A [107] and
Cdc25c [108]) of cell division. Pim-1 also has a role inhibiting the formation of a heterodimer
between Bcl-2 and Bcl-2-associated death promoter (BAD) via phosphorylation of S112 and
S136 in the latter, leading to inhibition of Bak/Bak-triggered apoptosis [109].
Likely the most potent collaboration, however, is between Pim-1 and a transcription factor,
c-Myc [110]. c-Myc regulates many important genes and processes (e.g. telomerase activity,
differentiation) and its disregulation, most commonly via amplification, is associated with
most cancers [111]. c-Myc typically has a very short half-life of 10 to 20 minutes prior to its
dephosphorylation and ubiquitination as part of one or more Raf pathways [112]. However, in
one of the most compelling collaborations described between any combination of oncogenes,
it has been established that even mild Pim-1 over-expression and increased levels of c-Myc
are associated with highly malignant monoclonal tumours [113], despite being relatively weak
oncogenes individually. Pim-1 inhibits c-Myc degradation via increased phosphorylation at
two key sites in c-Myc (S62 and S329), found via protein stability assays to dramatically
increase the half-life of c-Myc to >90 minutes [114].
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Figure 3.1: Pim-1 in the JAK/STAT pathway. Upon activation by cytokine binding to cellular receptors (green
cylinder), JAK2 (pink ovoid sphere) autophosphorylates its cytoplasmic receptor domain, creating recruitment sites
for STATS (yellow ovoid spheres). STATS 3 and 5 directly bind to the Pim-1 promoter regions and up-regulate its
gene expression. Expression of all three PIM proteins are also induced by activation of transcription factor complexes
such as NF-kB. Additionally, Pim-1 is also able to negatively regulate the JAK/STAT pathway via binding to SOCs,
a group of negative regulators. PIM in the JAK2 pathway subsequently phosphorylates, and consequently activates
or inactivates, a number of enzymes and transcription factors (light blue ovoid spheres) and kinase inhibitors (aqua
spheres) in many cellular pathways (adapted from [102]).
Consequently, Pim-1 kinases are overexpressed, not just in a variety of haematopoietic ma-
lignancies but also solid tumours. This often leads to cancers in the prostate [115], lungs,
gastric system, pancreas and squamous cell carcinomas of the upper-body [116].
As levels of Pim-1 are effectively rate-limiting for tumour progression in certain lymphomas,
this makes it an attractive target for drug therapies against these diseases. Some unique
structural factors that make Pim-1 even more apposite a drug target are that it is con-
stitutively active, requiring no further post-translational modification once properly folded.
Pim-1’s cellular activity is also regulated by its own synthesis and degradation, hence, ex-
pression and activity are predictable [117].
53
Structurally, Pim-1 posesses the usual kinase features such as a characteristic bi-lobular fold
comprising the N-terminus and C-terminus is augmented by a catalytic domain comprised
of an activation loop (DFG loop), a ‘hinge’ region generally occupied by Adenosine Tri-
Phosphate (ATP) and a flexible two-stranded β-sheet (Glycine-rich or P-Loop). Within the
binding pocket are two residues key for kinase inhibitor binding. The adenine moiety of
ATP interacts with E121 in the Hinge so inhibitors targeting this residue are known as
‘ATP-mimetic’ whereas the opposite side of the pocket contains a catalytic [118] Lysine
(K67) that interacts with inhibitors in ‘ATP-competitive’ fashion (Figure 3.2).
Figure 3.2: The basic structure of the kinase Pim-1. Depicted here are the N-terminus and C-terminus (grey cartoon)
signifying the respective beginning and end of the protein sequence, a flexible Glycine-rich P-Loop (pink cartoon), the
DFG loop (straw cartoon) that adopts alternative conformations delineating activation or inactivation, a conserved
Lysine (K67, stick representation) that plays a catalytic role in phosphate transfer from bound ATP to Pim-1’s co-
substrate, a hinge region (green cartoon) that directly binds the adenine moiety of ATP via E121 (stick representation)
and a bound ligand (PDB:3BGP, green carbons, stick representation) displaying a binding mode usually associated
with ‘ATP-mimetic’ inhibition.
As with other kinases, Pim-1 has several regions where non-conserved residues are found.
This arises because ATP does not occupy the entire volume of the binding pocket so regions
around the segments of a bound ATP molecule have been named accordingly. Two of the
more important areas are the Hydrophobic Pocket, situated behind the adenine moiety of
ATP and the Specificity Surface, situated at the opening of the binding pocket [119]. Both
areas are believed to be important for kinase selectivity (Figure 3.3).
PIM inhibition has been intensely studied for over a decade and highly diverse classes of
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Figure 3.3: The Pim-1 binding pocket showing the protein in complex with AMPPNP (PDB:1YXT) and non-
conserved regions categorised by ATP binding mode, green areas where apolar binding occurs and red where polar
interactions occur. Key residues (e.g. E121, D128) are depicted by light-grey stick representations.
inhibitors have been published [120] displaying a few important structural features. Gener-
ally, ligands have possessed a rigid core to fill the ATP binding site, interacting with apolar
residues (e.g I104, F49). Polar interactions have generally been formed with residues in a
hydrogen-bonding network comprised of a catalytic lysine (K67) and residues in the DFG
loop (D186).
So-called ‘hinge binders’ have been situated in the adenine pocket. However, Pim-1 is
uniquely apolar when compared to other kinases. Hence, where there are at least two polar
bonds available in the hinge in other kinases, the position and geometry of a Proline (P123)
in Pim-1 negates the possibility of ligands interacting with residues other than the canonical
hinge-ATP interaction, a hydrogen-bond acceptor interaction with the backbone carbonyl of
E121. This dramatically reduces the potential affinity of hinge binders and is reflected in the
higher Km for ATP in PIM proteins, in the three-digit μM-range for Pim-1 vs single-digit
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to double-digit μM for other Ser-Thr kinases [121]. Those developing Pim-1 ligands have
consequently focussed on ATP-competitive rather than ATP-mimetic inhibition.
Far less common is the targeting of residues at the Specificity Surface (D128-D131). Stau-
rosporine has been shown to bind in a ATP-mimetic fashion to the hinge and D128 via its
methylamino group [122]. A High-Throughput Screen (HTS) and structure-guided optimi-
sation campaign also resulted in very potent inhibitors that targeted the hinge, K67 and
D128 via short but rigid chain linkers between ring groups [123,124] (Figure 3.4). But these
are the only examples in the literature. This is perhaps surprising as these residues are
conserved in all three PIM kinases and a focus of these campaigns was on the development
of pan-PIM inhibitors.
Figure 3.4: Example Pim-1 X-ray structures depicting rigid short-chain linkers between aromatic moieties interacting
with polar residues in the binding pocket. (A) A ligand (pink carbons, ball-and-stick representation) is depicted
forming polar interactions with residues (green, stick representation) such Pim-1’s catalytic Lysine (K67) and D128
(from Burger, et al 2013). (B) A ligand (orange carbons, stick representation) is depicted forming polar interactions with
residues (light blue, stick representation) K67, the conserved backbone and a salt-bridge with D128 (from Ishchenko,
et al 2015)
3.1.2 Structure-based Virtual Screening
In light of the structural information obtained from previous campaigns, Structure-Based
Virtual Screening (SBVS) offers the possibility of large-scale structure-based ligand discovery
for Pim-1. Large-scale docking campaigns have well-known limitations [9] and the size of
drug-like chemical space is very large, estimated to be in excess of 1060 molecules [125].
Nonetheless, by fitting libraries of small molecules into a binding pocket and scoring them
with a function containing well-developed physics-based terms and parameters, a relatively
large amount of chemical space can be quickly sampled.
Fragment-based Drug Design (FBDD) offers the possibility of sampling a greater amount
of this space than any HTS campaign [126]. This is considered a function of the greater
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efficiency of exploring the chemical space of smaller molecules up to 30 heavy atoms (∼1020
[127]). Fragments hits, despite lower potency overall, form high-quality, enthalpy-driven
interactions with a target protein due a net loss of rigid-body entropy caused by the ligand
binding event [44]. The small size of these molecules does, however, impact on detection
of fragments. The use of X-ray crystallography has proven to be the most reliable method
for finding ligands as many well-developed biophysical methods miss fragment-sized hits at
their detection limits [46].
Target characteristics are also important in the design of a suitable library for FBDD. With
respect to kinases, as they have evolved to bind ATP, molecules targeting the region where the
adenine portion of ATP binds, known as ‘ATP-mimetic’, have proven successful at finding
novel and selective ligands [128]. In contrast, some of the more unusual kinase hits have
been developed to nM affinities from initial hits some distance away from the ATP binding
site [129], or in an ‘ATP-competitive’ fashion, or ‘allosteric regulators’.
The synthetic feasibility of molecules from fragment hits has also been demonstrated to lead
to ligands [130]. The pursuit of hits using methods to react chemical building blocks or
fragments exhaustively in silico can, in principle, lead to easily-synthesisable molecules [57].
Ligands can be biased toward novelty, generated and applied to computational methods
quickly [58]. Conversely, finding novel chemotypes is also possible with large and diverse
libraries when compared to rational design campaigns from initial HTS hits. Rapid testing
of molecules can also be facilitated by using libraries comprised of commercially-available
molecules as ZINC Is Not Commercial (ZINC [131]).
The aims of this work are broadly within the scope of novel ligand discovery via SBVS and
FBDD. In Project 1, fragments from an internal fragment library [45] were docked with
Pim-1 and PKA and compared to X-ray crystallographic structures solved in-house. In an
attempt to answer questions concerning which starting structure to use and how to develop
reliable predictions, docking to multiple structures both simulated and derived from X-ray
studies was conducted with multiple docking codes and results compared.
For Project 2, a library of extended fragments determined to produce reliable fragment
binding modes was constructed via exhaustive in silico reactions, docked and tested against
Pim-1 and a selectivity target, PKA. In Project 3, the same targets were screened against a
lead-like subset of ZINC, tested in-house and by third-party vendor, protein-ligand complexes
crystallised and their structures solved.
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Finally, Project 4 addresses an X-ray hit from the internal fragment library, Fragment num-
ber 200 (f200), that was not the complete molecule in the library but found a quality inter-
action with Pim-1 ’s catalytic lysine and a nearby water network. The binding mode and
protonation state of the fragment was confirmed by simulation, the fragment then extended
in silico and docked, inhibitors then synthesised and tested.
3.2 Materials and methods
3.2.1 Protein preparation
Three-dimensional crystal structures of Pim-1 were prepared from in-house datasets or down-
loaded from the Protein Data Bank [59] (PDB: 3BGP). Missing atoms or residues were
repaired and minimised with Wit!P [132], hydrogens added and their positions minimised
with CHARMM v31b2 [78]. Protonation states of histidine residues in all structures were
determined via visual inspection. Each histidine was allocated a status of HID, HIE and HIP
for docking dependent upon whether the ε, δ or both nitrogens in the imidazole side-chain
were considered likely to be protonated.
Each protein structure was prepared for docking with three program suites: Solvation Energy
for Exhausive Docking (SEED) version 3.3.5 [60], OpenEye’s OEDocking suite (v3.2.0.2) [69],
DOCK 3.6 [68]/3.7 [24].
For SEED, defaults regarding departures from ideal hydrogen bonding geometry, clashes,
and other chemical parameters were used and residues comprising the binding site of the
protein were determined via manual inspection. Pre-defined rules regarding bond-length,
angle and direction of H-bond donors and acceptors allow the construction and distribution
of vectors of unitary length on all hydrogen bonding groups of ideal geometry. To reduce
computations of unlikely polar-bond geometries, coordinates of a known ligand were used to
restrict the number of force vectors evaluated to those not exceeding a set geometry criterion
(10-70◦).
The structure was prepared for docking with FRED using the pdb2receptor module in the
OEDocking suite. Parameters regarding box shape, size and contours were calculated au-
tomatically and it was determined after preparation that the binding site was adequately
covered.
Finally, the receptor was prepared for DOCK via the generation of a set of spheres repre-
senting the invagination of the receptor binding pocket. This was generated using a program
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included in the DOCK distribution, sphgen [133]. The number and positions of spheres gen-
erated automatically was deemed adequate for coverage of the Pim-1 receptor. The oxygen
atoms in E121 were ‘tarted’ by increasing their respective atomic partial charges by 0.4 with
a consequent increase in the overall electrostatic potential surrounding this residue.
Images of the binding pocket for the SEED, FRED and DOCK binding pockets can be found
in Appendix Figures 7.1, 7.2 and 7.3 respectively.
3.2.2 Ligand preparation
Molecules for all projects were drawn from an internal fragment library [45] as well as ZINC12
[131] and ZINC15 [14].
The internal fragment library was developed from databases of commercially available com-
pounds with the focus on chemical novelty of ‘drug-like’ fragments amenable to development
strategies such as growing and merging. This process resulted in a fragment library of 361
molecules that was validated against an aspartic protease receptor, Endothiapepsin [48].
For docking with SEED and FRED, the fragment library was prepared from Simplified
Molecular Input Line Entry System (SMILES [134–136]) using OpenEye’s QUACPAC [137]
suite for appropriate protomer and tautomer generation. Multiple 3D conformers for each
protomer were generated with OMEGA [138]. To reduce the number of similar conformers
and lower the computational effort required, values of the -rmsrange parameter were in-
creased sequentially from 0.5 - 1.2 with number of rotatable bonds (1-7) in a given molecule.
The -erange parameter was set to 5.0 kcal·mol−1. This reduced the number of conformers
from hundreds to < 20 in most cases without substantially compromising the amount of
conformational space explored. AM1-BCC [139] partial atomic charges were calculated for
each conformer.
Generation of the fragment library for use with DOCK was completed using the internal
ligand generation pipeline implemented with the DOCK 3.7 suite to generate the .db2 files
required. The pipeline takes SMILES as input and uses ChemAxon [140] programs for
protomer generation, CORINA 4.1 [141] for initial 3D conformer generation, AMSOL 7.1
[142] to compute atomic partial charges and ligand desolvation terms and finally OMEGA
to generate conformers.
Both ZINC12 and ZINC15 are freely-available databases of, in principle, biologically-relevant
and purchasable compounds. Additional web-based resources are available such as similarity
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searches and activity prediction. The database focusses on chemical novelty and offers several
‘tranches’ for download such as ‘fragment’, ‘lead-like’, ‘drug-like’, etc. For this work, only
lead-like databases were downloaded directly from the ZINC12 and ZINC15 websites.
Finally, after initial fragment docking, extensions to the internal fragment library were gen-
erated using the Python IN silico de novo Growing UtIlities (PINGUI [58]). This method
takes a given molecule, identifies sites, or, ‘reactive handles’ on the molecule amenable to
extension and reacts them exhaustively in silico with building-block libraries using 58 robust
reactions [57] to ensure synthetic feasibility.
Molecules in another series of aniline triazoles were reacted in silico with a fragment derived
from an in-house developed database, SCUBIDOO [55]. The scaffold (4012414) and all
synthesised derivatives were predicted to interact with both K67 and the hinge (E121). A
coupling reaction, Buchwald-Hartwig cross-coupling, was chosen to extend the molecules at
the meta position of the aniline in order to target D128. In total, 6 molecules were selected
from this series for docking and testing (Figure 3.5).
Figure 3.5: Depicted here is the Pim-1 binding pocket in complex with an aniline triazole scaffold (dark grey, stick
representation) and key residues (light grey, stick representation) labelled. Predicted polar interactions are represented
by yellow dashed lines. The scaffold’s triazole was predicted to interact with the catalytic lysine (K67) and its aniline
nitrogen predicted to interact with a hinge residue (E121). A halogen in meta position of the aniline is highlighted
(green circle) to show the proposed in silico reaction site
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For Project 4, extensions to a ligand found for Pim-1 from the internal fragment library
(f200 ) were generated at position 5 on the aryl component of its quinoxaline core (Figure
3.6). Extensions from this position therefore made amenable the targeting of charged residues
near the Specificity Surface (D128 and D131). One coupling reaction was used (Suzuki [143])
and this was reacted in silico with building blocks from the MolPort [144] library.
Figure 3.6: Depicted here is the Pim-1 binding pocket in complex with a substituted quinoxaline (green carbons, stick
representation) and key residues (light grey, stick representation) labelled. Position 5 of the quinoxaline is highlighted
(green square) to show the proposed in silico Suzuki reaction site
3.2.3 Molecular dynamics simulations
All molecular dynamics simulations were completed with the Amber and AmberTools suite
of programs (versions 14 [145] and 16 [146]). Simulations post-processed with MDMix [19]
were completed with Amber 16.
Ligands were prepared from files containing atomic coordinates (.mol2 ) and fixed partial
charges calculated using the Restrained ElectroStatic Potential (RESP) model [147]. This
was completed via geometric optimisation and electrostatic potential calculations on con-
verged wave functions using Gaussian 09 rev C.01 [148] at the HF/6-31G* level of theory.
Software in AmberTools (Antechamber [149]) was used for file conversion between Gaussian
logs and .mol2 files.
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Protein structures were initially prepared using MOE [150] to add hydrogens, fix chain breaks
and missing atoms. The positions of all crystallographic water molecules were retained.
Amber Tool’s LEaP module was used to generate topologies and coordinates for both ligands
and proteins. The force fields chosen for all simulation steps (heating, equilibration and
production) were The General Amber Force Field (GAFF [76]) for ligands and ff99SB [151]
for the protein, respectively. The protein-ligand complex then had charges neutralised with
Na+ and Cl- ions and was solvated with a truncated-octahedral TIP3 [152] water box of
10 Å in size repeated in all three spatial dimensions such that the closest distance between
any atom present in the protein and the edge of the periodic box was also 10 Å to ensure
total coverage of the complex.
Prior to production MD, each complex first underwent two energy minimisation stages, then
a heating stage from 100K to 300K and six subsequent equilibration stages at constant
volume and temperature for a total of 5 ns (2 fs time steps). All heating and equilibration
stages had protein heavy atoms restrained with restraint weights progressively reduced to
zero as the complex progressed from one stage to the next.
Upon confirmation of a complex’s thermodynamic stability in terms of temperature, pressure
potential energy and other variables, a constant volume and temperature (NVT) simulation
was conducted with periodic boundary conditions. All bonds with hydrogen were constrained
using the SHAKE algorithm [153] and Langevin thermostat [154] for temperature regulation.
After checks for stability of the system (e.g. temperature, pressure, RMSD), each produc-
tion simulation was run for 100ns with three repeats per simulation for a total of 400ns of
simulation time.
For Project 1, the Hierarchical Agglomerative Clustering algorithm in AmberTools’ CPP-
TRAJ was used to output the most frequent conformation of the protein binding pocket.
Five clusters were calculated and the average distance between members of clusters was used
to determine membership of each cluster.
For the purposes of trajectory analysis, a hydrogen bond between two atoms is defined as
between 2.4-3.4 Å heavy atom distance and angle of 120-240◦.
MDMix simulations in Project 4 were conducted on the Pim-1 apo structure. These simula-
tions used an additional protein forcefield, ff99SB-ILDN [155], that cites improved side-chain
potentials for the ff99SB force field.
62
Each simulation had a single minimisation stage and five equilibration stages where the
temperature was progressively increased to 300K at constant pressure and restraints were
only applied to non-hydrogen atoms. Simulations also used a 20% mixture of three solvents
in a truncated octahedral box; water, acetamide and ethanol (Figure 3.7). Each production
simulation was run for 50 ns at constant pressure (NPT) with four replicates making a total
of 15 simulations (3 solvents x 5 simulations per solvent), or, 250 ns of simulation time per
solvent.
Figure 3.7: Example Pim-1 apo structure with 20% ethanol/water solvent mixture and binding pocket residues
labelled. Red spheres are water molecules whereas ethanol molecules are depicted as stick representations
From these simulations, binding ‘hot spots’ were calculated from solvent counts per 5 Å3 grid
element. The observed vs expected population was used to calculate the binding free energy
using the inverse Boltzmann relation.




Solvent densities were visualised as isomeshes of ∆G ≤ -1.0 kcal·mol−1.
63
3.2.4 Docking and minimisation
For FRED and HYBRID, program defaults were used with the exception of dock resolution
(=HIGH). Only the highest scoring pose for each molecule was retrieved.
For SEED, both polar and apolar docking algorithms were selected and all poses to an
evaluated energy of +5.0 kcal·mol−1 were retrieved. Otherwise, program defaults regarding
protein clashes, charge cut-offs and so on were used. Poses were assessed in terms of both
fragment and receptor desolvation energies and total interaction energies.
For DOCK, parameters governing van der Waals clashes were increased from defaults (20
kcal·mol−1 → 500 kcal·mol−1) i.e. poses where the vdW score exceeded this value were
discarded. The matchgoal parameter was also set higher (1000→ 5000) to increase sampling
of molecular orientations. Simplex minimisation was used. Sphere colouring was not used.
Only the highest scored pose was retrieved. Regarding all other parameters, program defaults
were used.
Protein structures from simulations often results in residues where side chain rings and
backbone amides were bent significantly out-of-plane. To alleviate this, atomic positions
were energy minimised using CHARMM with different harmonic force constants applied at
different levels of the protein. Force constants were applied by atomic mass resulting in a
force on a given atom in kcal·mol−1/Å−1 · 2.
Prior to docking, simulated structures were energy-minimised with CHARMM, progressively
weaker harmonic restraints applied at different levels of the protein. Protein backbone atoms
were the most restrained with a force constant of 2.0, side chain atoms at 0.4 with hydrogens
the most unrestrained at 0.08.
The positions of all pose structures within the Pim-1 active site were optimised using SZYBKI
[156]. Optimisation parameters were set to minimise torsional strain of molecular poses using
the Merck Molecular Force Field (MMFF94 [157]) with the Poisson-Boltzmann solvation
model [158]. All residues within 3 Å of a given pose were also minimised. Program defaults
regarding the optimisation method (e.g. BFGS [159] algorithm) were used.
To measure the quality of a docking prediction with respect to crystallographically-determined
atomic positions, the Root Mean Square Deviation (RMSD) of atomic positions was used. It









Molecular poses retrieved less than 1 Å RMSD from the ligand’s crystal position were con-
sidered a near-perfect fit with poses less than 2 Å considered very good and less than 3 Å to
be good.
Clustering of poses for Project 2 was completed with ChemMine [160], an online service for
small molecule data analysis. A Tanimoto similarity (Tc) of cut-off of 0.4 or lower using the
Extended-Connectivity Finger Print version 4 fingerprint (ECFP4 [94]) was used with their
hierarchical clustering functionality to sort molecules into ‘bins’. The first compound from
each bin was retained.
All similarity checks of molecules were conducted against the CHEMBL [12] database at
https://www.ebi.ac.uk/chembl/.
Assays
In Project 2 potential inhibitors were tested against Pim-1 and a selectivity target, Protein
Kinase A (PKA) using a Z′-LYTETM Kinase Assay Kit (Invitrogen/Thermo-Fisher) with
substrate peptides appropriate for the protein used.
The peptide substrate is labelled with two fluorophores (coumarin and fluorescein) that make
up a Fluorescence Resonance Energy Transfer (FRET) pair and in the primary reaction,
the γ-phosphate of ATP is transferred to a serine or threonine residue on the peptide. In
subsequent reactions, a site-specific protease cleaves unphosphorylated peptides, disrupting
FRET between donor (coumarin) and acceptor (fluorescein) fluorophores (Figure 3.8). From
here, an emission ratio of donor vs acceptor emissions after excitation at 400 nm is calculated.
Both cleaved and uncleaved FRET-peptides contribute to the fluorescence signals. The
emission ratio will therefore remain low if the peptide is phosphorylated (i.e. low kinase
inhibition) and will be high for unphosphorylated peptide, reflecting inhibitory activity.
For both enzymes used in the assay, an initial optimisation step was performed to determine
the appropriate enzyme concentration for screening. The assay protocol recommends near-
Km, ATP concentrations and kinase concentration that phophorylates 20-40% of the assay
substrate peptide.
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Figure 3.8: Z’LYTE biochemical assay schematic depicting the (1) Kinase Reaction, where a synthetic peptide is
phosphorylated by the kinase; (2) the Development Reaction, where unphosphorylated peptides are cleaved by the
Development Reagent and; (3) measurement of emission ratios of cleaved vs uncleaved peptide reflecting the presence
(or absence) of fluorophores in FRET and, therefore, inhibitory activity (from Z′-LYTE KINASE ASSAY KIT –
SER/THR 7 PEPTIDE PROTOCOL, https://www.thermofisher.com/order/catalog/product/PV3180)
For both Pim-1 and PKA, the kinase concentration meeting these requirements was deter-
mined to be 80μg/mL (20μg/mL final concentration in each well based on a 10μL assay).
The ATP concentration used was 16 μM (4 μM final concentration) with Km determined to
be in the range of ∼4.2μM with each assay. Inhibitors were initially solved in 4% DMSO and
serially diluted to one-digit nM concentration and a final DMSO concentration in each well
of 1%. Staurosporine was tested for comparison purposes in each assay performed.
All compounds were tested with two mechanical and three biological replicates in black, flat-
bottom 384-well plates (Greiner MODEL; 7849000) and FRET of both coumarin (445nm)
and fluorescein (520nm) fluorophores was measured at each well and the emission ratio
calculated.
Per cent phosphorylation was calculated as a function of the emission ratio of compounds
tested and controls thusly:
% Phosphorylation = 1− (EmissionRatio× F100%)− C100%
(C0% − C100% + [EmissionRatio× (F100% − F0%)]
(3.3)
All IC50 plots were created in Qtiplot [161]. Dose-dependent inhibition was then quantified
by plotting fitting a sigmoidal curve via a 4-parameter logistic equation [162]. The IC50
of a given compound was calculated at the mid-point of the curve, indicating half-maximal
inhibition of the protein by a given inhibitor.
The binding affinity Ki of an inhibitor in a binding assay of fixed substrate concentration







The Hill slope (d) of the plot was used as an indicator of possible ligand aggregation [164].
y = min+
max−min
1 + ( xIC50 )
d
(3.5)
For Project 3, compounds were tested both in-house and by a third-party vendor (Eurofins
Inc.). Compounds were tested against Pim-1 and their residual activities at a concentration
of 10 μM calculated via single-point inhibition assay [97] against a panel of human kinases.
Compounds displaying activity were then re-tested at concentrations close to their likely
IC50.
Inhibition constants Ki were determined of molecules with measured IC50s using the Cheng-
Prusoff relation [165]. We assume Michaelis–Menten kinetics of all enzymes tested, interact-






3.3.1 Project 1: Docking software comparisons vs structures from MD
simulation
Three X-ray structures were chosen for comparison, one from the PDB (3BGP) and two re-
sulting from equilibrium simulations of the apo structure (apo MD) and 3BGP (3BGP MD).
The 3BGP structure was chosen as it most broadly represented structural characteristics
thought important for ligands binding to Pim-1. It did not differ markedly from 97 other
Pim-1 structures on the PDB (RMSD x̄ = 0.37 Å, σx̄ = 0.05) and was therefore chosen for
further docking.
Trajectories from simulations of the apo MD structure were combined for cluster analysis.
The first frame in the trajectory was chosen as the reference frame and, after alignment,
RMSDs calculated for binding pocket residues, K67, the P-Loop and the DFG loop. It was
determined that the overall RMSD of the protein did not vary markedly during the course
of the simulation and quickly achieved an equilibrium (<1 ns).
67
The first cluster for each of the 3BGP MD and apo MD binding pockets contained 64%
and ∼ 86% of the total frames from trajectories respectively. There was overall a greater
variation in RMSDs between each frame and the centroid of each cluster for the 3BGP MD
binding pocket (RMSD x̄ = 2.10 Å) when compared to the apo MD pocket (RMSD x̄ =
1.83 Å). This variation was also reflected in average RMSDs from cluster centroids when the
P-Loop alone was considered (RMSD x̄ = 2.44 Å for 3BGP MD vs 1.38 Å for apo MD). This
variation in-turn reflects greater flexibility of the P-Loop in the presence of a bound ligand
as, presumably, the absence of a ligand allows flexible residues to return to a more relaxed
state.
However, with respect to the 3BGP MD trajectory, the first cluster was closest in terms of
RMSD (0.861 Å) to its crystal structure when compared to the other four clusters (RMSD x̄
= 1.30 Å), reflecting a more ’averaged’ bound ligand state and was thus chosen for fragment
docking.
Descriptive statistics regarding simulations of this structure can be found in the Appendix
Table 7.1.
A Thermal Shift Assay (TSA) was performed as a crystallographic pre-screening step on all
361 compounds in the internal fragment library and from these, 31 molecules displayed a
‘significant’ (> 4 ◦C) positive temperature shift, indicative of stability in the protein-ligand
complex (Appendix, Figure 7.4). The crystal structures of 12 of these molecules in complex
with Pim-1 were subsequently fully resolved and used as references for assessing docking
performance.
All 12 fragments were docked to the the 3BGP X-ray structure as well as the apo MD and
3BGP MD structures. When docking to the X-ray structure of 3BGP, SEED recreated polar
contacts in most (92%) cases and retrieved at least one pose per fragment close to the crystal
binding mode (Table 3.1). FRED and HYBRID performed similarly when compared to each
other, in over half of cases retrieving poses close to the crystal binding mode of each fragment.
DOCK was unable to retrieve poses near the crystal binding mode.
Broadly improved pose retrieval was achieved when docking to the apo MD structure. SEED
and HYBRID were able to retrieve more poses that recreated the crystal binding mode but
SEED, FRED and HYBRID all performed worse in terms of RMSD. Improved performance
in terms of the number of crystal poses retrieved and RMSD was noted with DOCK.
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Docking fragments to the 3BGP MD structure improved the RMSD of fragments from the
crystal binding mode for both HYBRID and SEED with respect to apo MD structure whilst
also achieving similar performance to the 3BGP crystal structure. Unlike, the 3BGP crystal
structure, poses were retrieved for DOCK when using the 3BGP MD structure for docking.
Program PDB:3BGP apo MD 3BGP MD
RMSD x̄ (σx̄) % poses RMSD x̄ (σx̄) % poses RMSD x̄ (σx̄) % poses
FRED 2.58 (1.33) 75% 3.07 (1.15) 50% 3.45 (1.06) 58%
HYBRID 2.61 (1.17) 67% 3.37 (0.97) 75% 2.69 (1.38) 58%
SEED 1.68 (0.50) 92% 2.62 (0.95) 100% 2.15 (1.15) 100%
DOCK - (-) - 3.98 (1.09) 50% 3.90 (0.64) 42%
Table 3.1: Comparison of mean and standard deviations of RMSDs (Å) from fragment X-ray structures for poses
docked to PDB:3BGP, apo MD and 3BGP MD. Per-cent poses is defined as the proportion of docked poses within 5 Å
of the position of the bound X-ray ligand
Complete data regarding fragment RMSDs from X-ray crystal structures against both 3BGP
and apo MD targets can be found in Appendix Tables 7.2 and 7.3 respectively.
3.3.2 Project 2: synthetically-feasible extensions of an internal fragment
library
The initial fragment project found 54 fragments with a stable binding mode in Pim-1 of
which 34 possessed so-called ‘reactive handles’ amenable to extension. A thermal-shift assay
was conducted and 20 (59%) displayed a positive temperature shift, indicative of a net
increase in stability of these protein-ligand complexes. From these fragments, 37 reactions
in silico with 7805 building blocks from the ChemBridge [56] dataset generated a docking
library of 171 919 (313 299 protomers).
As there were large disparities in the number of molecules generated by each in silico reaction,
the full library was divided into separate docking instances by reaction to avoid ‘drowning
out’ of potentially good but similarly scored molecules from each reaction. Where there were
500 or more poses retrieved, the top-500 from each dock was retained for analysis. Otherwise,
each pose in a given dock was analysed.
A complete list of each dock and the size of each library can be found in the Appendix Table
7.5.
Visual inspection of poses retrieved resulted in library of 1156 molecules that was reduced
to 517 after minimisation and eliminating those with unsatisfactory binding modes (e.g.
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stranded H-bond donors, shape complementarity). They were divided into groups depending
on whether they retained the binding mode of the fragment from which they were derived
(394 ) or not (123 ). Each of these groups was further divided into separate groups depending
on whether they interacted with residues near the Specificity Surface or not.
In the case of molecules that retained their fragment binding mode, 146 poses displaying an
interaction with D128 were retrieved whilst 248 poses were not predicted to be interacting
with this residue. Of molecules displaying a different pose to their original fragment binding
mode, 20 molecules interacting with D128 were retrieved whereas 103 were not predicted to
be interacting with this residue.
There were many more molecules retaining their predicted fragment binding modes as com-
pared to those where the extended molecules displayed a different binding mode from the
original fragment. ECFP4 Tanimoto similarity was used to cluster this group into ‘bins’ and
the first molecule from each bin retained. After clustering and visual inspection, common
in high-throughput and virtual screening [166,167], a final list of 47 molecules was collated.
This list comprised of 27 molecules displaying a binding mode extended from their originally
predicted fragment position (‘BM’) and 20 where the extended molecule displayed a different
binding mode to the initial fragment prediction (‘novel’). These molecules were subjected
to assessment and grading by lab members experienced in docking, the grades collected and
analysed with 21 chosen for synthesis. Derivatisation and optimisation of some compounds
resulted in a final list of 37 compounds (Figure 3.9).
Whilst there was a great diversity in which moieties were positioned within the Pim-1 pocket,
the binding mode for all predictions was similar. All poses retrieved were interacting with
K67 and most were also predicted to be interacting with residues near the Specificity Sur-
face, particularly D128. In most cases, interactions with K67 were via a salt-bridge with
a carboxylate whereas D128 was generally predicted to interact with a charged endocyclic
amine group such as a protonated piperidine (Figure 3.10). Due to the bi-partite nature of
molecules created by PINGUI, most molecules were comprised of two or more ring systems
with flexible linkers rather than the bulky π-systems of known ligands for Pim-1 that interact
with D128 e.g. Staurosporine, Bisindolyl Maleimides.
A complete list of molecules 13 to 49 can be found in the Appendix Table 7.6.
It was decided from the above predictions to synthesise 10 compounds. Of these, 9 were
actually synthesised with one failing (Table 3.2). All were racemic mixtures. Of these, 3
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Figure 3.9: Schematic of Project 2 preparation, docking and post-processing. Docked molecules were first created by
reacting internal library fragments in silico with ChemBridge building blocks. They were then divided into separate
docking instances by reaction type, docked and the results aggregated and clustered by Tanimoto similarity (ECFP4
fingerprint). After detailed visual inspection, groups were formed based upon whether molecules retained the original
fragment binding mode or not (frag BM and ‘novel’ BM respectively). A preliminary list in each of these categories
was subjected to visual inspection and grading by lab members prior to the formation of a final list for analysis by
collaborators for synthesis. Minor alterations and synthetically-feasible derivatives were suggested by collaborators
prior to the final synthesis of 9 molecules that were then tested for inhibitory activity via FRET-based assays.
molecules (27, 29 and 47) were the original molecules predicted to interact with Pim-1 and 6
were synthesised with small alterations (e.g. pyridine → benzene) to ensure synthetic feasi-
bility. After minimisation, all 9 molecules were predicted to have net favourable interaction
energies (Appendix Tables 7.7, 7.8 and 7.9)
All molecules were tested via FRET assay with 5 showing at least mild activity against
Pim-1. The most potent was 26, measured to be inhibiting at an Ki=24.99 μM. This is as
compared to Staurosporine, measured to be inhibiting at a calculated Ki=4.7 μM (Figure
3.11).
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Figure 3.10: Predicted binding mode of 29 (black carbons, stick representation) in the Pim-1 binding pocket, key
residues (light grey, stick representation) labelled and 2D structure (inset) of the pose displayed. Predicted polar
interactions are represented by yellow dashed lines. Depicted here are salt-bridge interactions formed between 29’s
carboxylate and K67 as well its diazepane nitrogen and D128
Figure 3.11: Dose-response curves of FRET-based assays from extensions via in silico reactions with our internal
library. Depicted here is the per-cent phosphorylation against the LOG10 ligand concentration of tested compounds
displaying activity against Pim-1 with error bars (standard-error of measurement) and curves fitted to the data (multi-
coloured lines). The IC50 of a given compound was calculated at the mid-point of the curve, indicating half-maximal
inhibition of the protein. The most potent ligand, 26, is represented by the lime green line with Staurosporine (black






























































































































































































































































































Compound 26 was predicted to interact with the side chains of K67 and D128 and the
backbone of D186 (Figure 3.12).
Figure 3.12: Predicted binding mode of the (E)-isomer of 26 (black carbons, stick representation) in the Pim-1
binding pocket, key residues (light grey, stick representation) labelled and 2D structure (inset) of the pose displayed.
Predicted polar interactions are represented by yellow dashed lines. Depicted here is a salt-bridge interaction between
the carboxylate of 26 and K67 with the hydroxy group of its substituted benzofuran interacting with D128. This
ligand was the most potent of all tested with a calculated Ki of 24.98 μM.
All molecules from the aniline triazole series were tested via FRET assay with 52 the only
ligand to result in a measurable Ki of 137.0 μM (Figure 3.13). However, although a curve
could be fit, the values of per-cent inhibition suggest very little inhibition by this compound
was actually occurring.
Molecule 52 was the only ligand in the series predicted to directly target D128 (Figure 3.14).
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Figure 3.13: Dose-response curves of FRET-based assays from extensions via in silico reactions with our internal
library. Depicted here is the per-cent phosphorylation against the LOG10 ligand concentration of tested compounds
displaying activity against Pim-1 with error bars (standard-error of measurement) and curves fitted to the data (multi-
coloured lines). The IC50 of a given compound was calculated at the mid-point of the curve, indicating half-maximal
inhibition of the protein. In this case, 52 (red line) is displaying very mild inhibition. Staurosporine (black line) is
again depicted for comparison. Each experiment was repeated with two mechanical replicates and three biological
replicates.
Figure 3.14: Predicted binding mode of the most potent ligand from the aniline triazole series, 52 (black carbons, stick
representation), the predicted binding mode of the aniline triazole scaffold (dark grey carbons, stick representation)
in the Pim-1 binding pocket, key residues (light grey, stick representation) labelled and 2D structure (inset) of the
pose displayed. Predicted polar interactions are represented by yellow dashed lines. The aniline triazole scaffold
(SCUBIDOO fragment 4012414) is overlayed to exemplify the fragment-based growing approach used.
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None of the compounds tested from either series showed activity against PKA.
A complete list of molecules 50 to 55 can be found in the Appendix Table 7.10.
3.3.3 Project 3: novel inhibitors from the ZINC dataset
Several constraints were applied to the ZINC datasets downloaded for docking; molecules had
to be purchasable, their molecular weight between 250 and 350Da, logP ≤ 3.5 and contain
protomers within a pH range of 6-8. Applying these restrictions led to a database size of 4
601 296.
The entire dataset was docked and after checks for availability, torsional strain and likely
protonation states, 28 were submitted for group evaluation. Of these, 6 were selected for
purchase after checking for similarity with known actives. Molecules chosen for purchase
were found to be generally dissimilar to 8834 known actives against Pim-1 (Tc: x̄ = 0.40,
σx̄ = 0.09).
As Pim-1 has a more apolar hinge, the canonical Pim-1 backbone hinge interaction tends
to be large apolar moieties and this series were no exception with many molecules retrieved
and 4/6 purchased having an indole predicted to be in this position (Figure 3.15). Most
compounds were also predicted to interact with the catalytic lysine (K67) with some (3/6)
predicted to interact with both the hinge and K67. A diverse array of chemotypes were
predicted to interact with K67 but generally they were rigid, fused-ring systems (e.g. iso-
quinoline, triazolo-thiadiazolyl/pyrimidine).
A complete list and 2D structures of molecules 56 to 61 can be found in the Appendix Table
3.3.
A TSA was conducted on the all purchased compounds and from these, 5 molecules displayed
a positive temperature shift of at least 4◦C, again indicative of stabilisation of the formed
protein-ligand complex. Summary TSA data can be found in Appendix Table 3.3.
Despite one compound displaying a negative shift on the TSA, all compounds were selected
for crystallography. All compounds were co-crystallised [168] with the aid of a consensus
peptide, Pimtide [169]. Datasets were subsequently obtained for all compounds but only
crystal structures of 2 of these molecules in complex with Pim-1 could be fully refined.
Protein-ligand X-ray structures were determined of molecules 57 and 61 to a resolution of
1.97 Å and 2.21 Å respectively.
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Figure 3.15: Predicted binding mode of 59 (black carbons, stick representation) in the Pim-1 binding pocket, key
residues (light grey, stick representation) labelled and 2D structure (inset) of the pose displayed. Predicted polar
interactions are represented by yellow dashed lines. Depicted here are interactions between the secondary amide of 59
and K67, an indole nitrogen with hinge residue E121 and its primary amide and D128.
Unexpectedly, 61 displayed quite a different binding mode in its crystal structure when
compared to the docking prediction (Figure 3.16). Its isoquinoline motif was not found to
be interacting with K67 as predicted. Instead it was positioned on the hinge side of the
binding pocket. The secondary amide of 61 formed a bridging interaction with W278, R6
of Pimtide and D131 at the Specificity Surface and its pyrrolidine was positioned to form an
interaction with D186 rather than D128 and D131 at the Specificity Surface of Pim-1.
The exact binding mode of 57 was not clear as the ligand was only partially visible in the
X-ray structure. However the position of the ligand was redolent of a different binding mode
than that predicted during the initial screen (Figure 3.17).
As with 61, it appeared likely that 57 was involved in a water-bridged interaction with
Pimtide. It is possible that the the crystallised ligand was the hydrolysis product of the
ester linking 57’s indole and pyrrole moieties. It was, however, subsequently determined
that by including Pimtide and crystallographic waters in receptor preparation, the binding
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Figure 3.16: X-ray structure of 61 (left, green carbons, stick representation) in complex with Pim-1 and Pimtide (ma-
genta carbons, stick representation) as compared to the docking prediction (right, black carbons, stick representation)
with no Pimtide. Key residues (light grey, stick representation) are labelled and the 2D structure (inset) of the pose
displayed. Predicted polar interactions are represented by yellow dashed lines. This depicts the very different binding
mode with respect to the docking prediction when the secondary amide of 61 formed a water-mediated interaction with
R6 of Pimtide and a salt-bridge between its pyrrolidine and D186. This is as compared to the predicted interactions
between its isoquinoline with K67 and salt-bridge between its pyrolidine and D128. Despite the sequence similarity of
Pimtide to the known Pim-1 co-substrate, this molecule was not found to be active on orthogonal assays where Pimtide
was not present and is thus unlikely to reflect a inhibatory binding mode with the Pim-1 co-substrate.
mode of the complete structures of both 57 and 61 could be replicated by re-docking to
their X-ray structures (Figure 3.18).
All 6 compounds were tested against a panel of 10 kinases by a third-party vendor and their
residual activities calculated. Compounds 57, 58 and 59 showed inhibitory activity against
Pim-1 specifically with 58 also reducing the activity of Pim-2 and mTOR.
Molecules were tested via FRET-based assay and Ki’s of 57, 58 and 61 subsequently eluci-
dated. Compound 58 was found to found to be a mild ligand against Pim-1 (Ki=15.09 μM
with 57 showing signs of inhibition at higher concentrations (Figure 3.19). All others showed
little or no activity.
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Figure 3.17: X-ray structure of 57 (left, green carbons, stick representation) in complex with Pim-1 and Pimtide
(magenta carbons, stick representation) as compared to the docking prediction (right, black carbons, stick represen-
tation) with no Pimtide. Key residues (light grey, stick representation) are labelled and the 2D structure (inset) of
the pose displayed. Predicted polar interactions are represented by yellow dashed lines. Although only part of the
ligand was placed in the binding pocket, the difference in the binding mode can be seen as the interactions predicted
by docking, substituted indole with hinge residue E121 and pyrrolidine with D186, likely did not form in the X-ray
structure.
Compound 58 was predicted by FRED to interact with the hinge with an indole positioned
there (Figure 3.20). An additional polar interaction was predicted, a triazolo-thiadiazole
moiety predicted to interact with the catalytic lysine (K67). It also displayed the highest
positive temperature shift on the TSA (5.16 ◦C± 0.23), indicative of higher protein-ligand
complex stability.
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Figure 3.18: Depicted are the X-ray structure binding modes of ligands 57 (left, green carbons, stick representa-
tion) and 61 (right, green carbons, stick representation) in complex with Pim-1 and Pimtide (magenta carbons, stick
representation) as compared to the docking prediction (black carbons, stick representation). Key residues (light grey,
stick representation) are labelled and the 2D structure (inset) of the pose displayed. Predicted polar interactions are
represented by yellow dashed lines. In both cases, only by including in the docking calculation both Pimtide and
cystallographic water molecules (red oxygens, light grey hydrogens, stick representation) that were interacting with
Pimtide in the X-ray structure was the X-ray binding mode of the ligand able to be recreated.
Figure 3.19: Dose-response curves of FRET-based assays of compounds 57, 58 and 61. Depicted here is the per-cent
phosphorylation against the LOG10 ligand concentration of tested compounds displaying activity against Pim-1 with
error bars (standard-error of measurement) and curves fitted to the data (multi-coloured lines). The IC50 of a given
compound was calculated at the mid-point of the curve, indicating half-maximal inhibition of the protein. In this
case, 57 (green line) is displaying mild inhbitory activity whereas 61 (red line) shows almost no activity and some
indication of fluorescence at higher ligand concentrations. Staurosporine (black line) is again depicted for comparison.
































































































































































































































































































































































































































































































































































Figure 3.20: Predicted binding mode of 58 (black carbons, stick representation) in the Pim-1 binding pocket, key
residues (light grey, stick representation) labelled and 2D structure (inset) of the pose displayed. Predicted polar
interactions are represented by yellow dashed lines. Depicted here are interactions between the triazolo-thiadiazole
core of 58 with K67 and its indole with hinge residue E121. After also being tested against a panel of other kinases,
58 was found to be active against Pim-2. As both Pim-1 and Pim-2 share significant sequence homology with Pim-3,
58 is thus a candidate selective pan-PIM inhibitor.
Activities against all kinases tested and calculated Ki’s against Pim-1 can be found in the
Appendix Tables 7.11 and 7.12.
3.3.4 Project 4: extensions of truncated fragment f200
Prior to commencing any fragment elaboration it was necessary to establish the binding
mode of the fragment in the binding pocket as this had implications for its stability and that
of extensions to it. As hydrogen atoms are not well resolved by X-ray diffraction studies,
the crystallographic structure of f200 does not provide explicit information regarding the
protonation state of the ligand.
In the X-ray structure, three water molecules (W63, W62 and W29) were resolved and
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arranged in a network within the binding pocket, bridging interactions with I104 and K67.
One of the crystallographic waters, W62, is closest (∼ 3.8 Å) to the amide of the ligand’s
quinoxaline core, albeit slightly beyond hydrogen-bonding distance and with apparently sub-
optimal geometry for an interaction. Nonetheless, prior work [170] has suggested that W62
is the only buried water in Pim-1’s binding pocket.
Calculated water hot spots from MDMix simulations of Pim-1’s apo structure depict areas
of elevated solvent density surrounding the positions of all three waters and much of the
area of elevated solvent density adjacent to a position similar to W62 was within hydrogen-
bonding range of the position of the quinoxaline core (Figure 3.21). There was significantly
less solvent density surrounding a similar position of W63 suggesting waters positioned here
may be displacable to allow room for a buried water to form a polar bond with the ligand.
Figure 3.21: Output from MDMix showing areas of solvent density below -1.0 kcal·mol−1 (blue mesh) overlayed
with the f200 crystollagraphic ligand (green carbons, stick representation) and crystallographic water molecules (red
spheres) to illustrate the proximity of these water molecules to calculated solvent density from MD simulations.
Further simulations of the ligand confirmed that the water in a similar position to W63 (W3)
is less stable in the binding pocket, leaving it ∼2 ns into the production simulation. This
allowed an inward rearrangement of I104’s side chain into the binding pocket and a water
(W2) to move into hydrogen-bonding range of the quinoxaline amide nitrogen. Although the
water network was disturbed by this event, the interaction between the quinoxaline amide
and W2 (x̄DISTANCE = 3.00 Å, x̄ANGLE = 148.46
◦) and another between the amide carbonyl
and K67 (x̄DISTANCE = 2.94 Å, x̄ANGLE = 154.33
◦) meant the ligand’s binding mode was
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stable for > 10 ns. After this point, polar interactions were broken and the ligand began to
leave the binding pocket.
By contrast, simulation of a negative control, the imino tautomer of the quinoxiline’s amide
group, showed a close contact between the hydroxy group of the iminol and K67 after heating
and equilibration when positioned similarly to the X-ray ligand (Figure 3.22). Soon after
commencing production, W3 again left the binding pocket (∼2 ns) and the water network
was again disturbed. The ligand was ejected from the binding pocket soon after (∼3 ns).
Figure 3.22: Positions and distances (Å) from an MD snapshot between ligand (turqoise carbons, ball-and-stick
representation), water molecules in the Pim-1 binding pocket W1, W2 and W3 (red oxygen, white hydrogens, vdW
representation) and K67 for f200 amide (left) and iminol (right) tautomers. In the former case, interactions are predicted
to form between the quinoxaline’s amide carbonyl and K67 as well as the amide nitrogen and a buried water molecule
(W2). In contrast, the proximity of the iminol hydroxy to the hydrogens of K67 leads to repulsion and lower stability in
the binding pocket as demonstrated by its shorter simulation time before interactions are broken (∼2 ns) as compared
to > 10 ns for the amide tautomer.
Plots of all distances and RMSDs measured during simulations can be found in Appendix
Figures 7.6 and 7.7.
Reacting the ligand in silico resulted in a docking library of 841 molecules. The binding
modes of all docked poses were again assessed by an initial visual inspection and analysis.
From these an initial list of 38 molecules was selected. They were again submitted for
evaluation and grading by lab members, grades were collated and analysed and 8 molecules
were subsequently selected for synthesis.
As with Project 2, all molecules chosen displayed predicted interactions with residues at
the Specificity Surface, specifically D128. However, two molecules displayed an alternative
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predicted binding mode for the initial fragment. For 62 and 68, the interaction between
the carbonyl group of the quinoxaline’s amide nitrogen is preserved but the amine is instead
predicted to interact with D186 whilst retaining the interaction with D128 (Figure 3.23).
Figure 3.23: Example alternative predicted binding modes in the Pim-1 binding pocket of 62 (left, black carbons,
stick representation) and 68 (right, black carbons, stick representation) in the Pim-1 binding pocket. Key residues (light
grey, stick representation) are labelled and 2D structure (inset) of the pose displayed. Predicted polar interactions are
represented by yellow dashed lines. In the case of 62, the molecule was predicted to retain the X-ray crystallographic
binding mode of the f200 quinoxaline and an additional polar interaction between its indole moiety and D128. An
alternative predicted binding mode of 68 depicts interactions between the quinoxaline, K67 and D186 as well as a
salt-bridge between its piperidine D128.
A complete list and 2D structures of molecules 56 to 63 can be found in Appendix Table
7.13.
Molecules 63, 66, 67 and 69 were tested and did not show activity against Pim-1.
3.4 Discussion and conclusions
That any given docking program is able to find molecular poses close to their determined
crystal position has been established as an important performance criterion by prior work
[171] in so-called ‘cognate’ docking. It was demonstrated that the molecular pose closest in
terms of RMSD to the crystal structure is not necessarily the highest scoring pose. As we
often do not know the crystal pose a priori, the more ‘real world’ test is to dock multiple
low-energy conformations of a given molecule to the target.
As demonstrated, generation of multi-conformer molecules for docking is crucial to ensure
adequate sampling of conformational space and accurate placement of the molecular pose
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prior to scoring. However, the number of conformations needed to ensure adequate sampling
is not straightforward. What we see from this study is that from only a few conformers per
molecule (x̄ = 4.5, min = 1, max = 24), reliable fragment binding modes from docking were
the result.
The two conformer generation and docking pipelines used in this work further support the
influence of molecular shape in docking. Docking with the programs FRED, HYBRID and
SEED all used the same database. Although SEED was overall superior in terms of RMSD
with respect to the crystal structure as reference, FRED’s performance in retrieving a given
pose close to the crystal structure was acceptable considering only the top scored pose was
retained. Despite generally being within the top 5% of docked poses, at no stage was the
top scored SEED pose also the closest in terms of RMSD.
DOCK generally failed to recreate crystal binding modes when retaining only the top scored
pose, despite manipulation of matching spheres into positions ideal for polar contacts. This
is suggestive that for physics-based methods such as SEED and DOCK, one would generally
need to analyse the placement of multiple poses rather than relying on the scoring function
as sole arbiter of pose quality.
More influential is the conformational shape of the protein. The structure used for most
docking here, 3BGP, broadly represents the most frequent conformations of ligand-bound
Pim-1 structures uploaded to the PDB. This is particularly the case with respect to important
flexible residues such as the catalytic lysine (K67) and residues in the P-Loop. It clearly
outperformed the apo MD structure when a given ligand had a carboxylate anion forming
a salt bridge with K67. In this case, the 3BGP structure often retrieved poses <2 Å from
the X-ray position whereas the apo MD structure failed to recreate the binding position of
these molecules in all cases.
The reason becomes more clear when one compares the positions of K67 and P-Loop residues
of the 3BGP and apo MD structures. Although the average RMSDs of residues themselves
did not deviate much during the course of the apo MD simulation, the positions of both are
very different with respect to the two residues in the X-ray structure (Figure 3.24). Thus, the
shape complementarity of the binding pocket was disturbed. The next effect was that the
apo MD structure did not retrieve poses close to that of the fragment in the X-ray structure,
even when using software (HYBRID) where information regarding the likely binding site was
supplied by the position of the ligand from the geometry in 3BGP.
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Figure 3.24: Depicted are differences between the positions of K67 and F49 (P-Loop) in 3BGP (green carbons, stick
representation) and apo MD (pink carbons, stick representation) structures. This is indicative that in the absence of a
bound ligand, both F49 and K67 retract into the binding pocket, negatively affecting docking codes’ ability to recreate
X-ray binding modes as shape complementarity is disturbed.
RMSDs and number of poses retrieved by HYBRID, SEED and DOCK were improved or
remained similar when docking to a snapshot from MD trajectory taken from the simulation
based on the 3BGP X-ray structure. This is suggestive that simulating with a bound ligand
will result in a conformation that reflects the ligand’s binding mode but one that is also
suitable for the retrieval of new ligands. However, results were significantly better with
HYBRID as opposed to FRED so some binding site information is still required.
Alternatively, this also suggests that with knowledge of the binding pocket, preferring HY-
BRID over FRED with a simulated structure reduces the probability of prioritising an un-
likely fragment binding mode for further development. This lends further support to protein
conformation being the most important criterion when deciding upon a starting structure
for rigid docking.
From this, a workflow can be expected (Figure 3.25). Where binding site information is
augmented by a bound ligand, superior docking results were obtained by simulation of a
bound ligand structure followed by minimisation and then docking with software that inte-
grates binding pocket information e.g. HYBRID. This approach is benefited by reducing the
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reliance upon the researcher’s choice of starting structure.
Although HYBRID outperformed both FRED and DOCK generally, DOCK outperformed
HYBRID in some cases, such as when an interaction with the catalytic Lysine (K67) was
predicted to interact with a moiety on the ligand weaker than a salt-bridge. Salt-bridges
are generally over-estimated by force-field methods [172] but it may be that HYBRID, with
its focus on shape, underestimates the importance of ligands possessing weaker interactions.
Whether this occurs in HYBRIDs scoring step, where interaction potentials are smoothed, or
in its Chemical Gaussian Overlay (CGO) step, where the docked pose is directly compared
to the bound ligand, is unclear.
In the absence of binding pocket information, it remains that the choice of starting protein
structure generally requires expert intervention or analysis of multiple protein structures.
Following this, good results can be obtained via a more traditional work flow of unbiased
fragment docking to establish the most likely binding mode by analysis of multiple poses
followed by a second round of docking with programs optimised for larger molecules e.g.
FRED.
Fluorescence assay results from fragment extensions in Project 2 were somewhat mixed but
go some way to confirming that compounds targeting residues at the Specificity Surface of
Pim-1 require a more rigid structure. Previous ligands had either large rigid rings or rigid
amide linkers and 26, the most potent ligand, was the only compound tested that had an
unsaturated linker between a benzoic acid moiety and a substituted benzotetrahydrofuran
predicted to directly interact with D128. Similarly, 52, although possessing a saturated
linker between its aniline triazole moiety and its piperidine, the molecule was likely made
more rigid by an internal hydrogen-bond between its triazole and a secondary amine in the
chain.
The specific moiety interacting with Specificity Surface residues is also likely affected by
their proximity to the bulk water boundary, an area where relatively low-permittivity of
a protein’s binding pocket meets the relatively high permittivity of bulk water. D128 is
quite close to where the boundary likely is and prior work [173] has elucidated that solvent
polarisation effects at the protein-solvent interface have a ‘dampening’ effect on energies
and forces acting upon pair-wise electrostatic interactions. More specifically, interactions
between charged atoms are particularly decreased by this effect (solvent screening) [174].
Although the estimation of overall interaction energy for all tested molecules was predicted
to be favourable by docking and after minimisation, in every case where a charged moiety
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Figure 3.25: Suggested workflow for various docking software when coupled with molecular dynamics simulation.
Recommended tasks are modelled by rounded rectangles, decision points by diamonds, recommended software by
squared rectangles and databases by ovoid cylinders.
was predicted to interact with D128, solvent screening effects were predicted to be high.
Thus, molecules with moieties such as a piperidine or charged primary amine in this position
displayed either poor or negligible affinity in the assay. Other compounds, such as 52, had
a piperidine predicted to interact with D128. But the piperidine nitrogen also has an ethyl
substituent, possibly negating solvent polarisation effects. However, despite possessing a
measurable affinity for Pim-1, it was a relatively poor ligand inhibiting in the three-digit μM
range.
In any case, charged molecules forming salt bridges in a protein binding pocket are tradition-
ally prioritised highly in docking. Where residues are within the binding pocket, these are
likely to be very strong interactions. This is borne out by the number of ATP-competitive
inhibitors for Pim-1 where a salt bridge is formed with the charged side-chain of K67, in-
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cluding many of the inhibitors in this work. However, although not a definitive indicator of
the likelihood of an interaction, the results of this study make clear that a reduction in the
relative strength of interactions with solvent-exposed charged residues should be considered
when analysing a given molecule’s overall binding characteristics.
The trend with regard to inhibitors with predicted charged interactions was confirmed in
Project 3. Any inhibitors in possession of charged moieties predicted to interact with D128
(60 and 61) showed little to no activity against Pim-1. The most potent compound from
this series, a triazolo-thiadiazole (58), was predicted to bind in ATP-competitive fashion and
did not address D128 at all. Although an X-ray structure was not obtained of this ligand,
it achieved the highest measured positive temperature shift on the TSA. It inhibited at the
two-digit μM range or better on orthogonal assays and appeared to be a selectively pan-PIM
inhibitor. Its potency and position within the binding pocket therefore offer a reasonable
starting point for a molecular optimisation campaign.
Two inhibitors were crystallised and their X-ray structures solved, 57 and 61, the latter
the first X-ray structure on the PDB to display a direct interaction with Pim-1’s consensus
peptide (Pimtide). The binding modes of both compounds were only able to be recreated by
re-docking them to their crystal structures with Pimtide and its crystallographic waters in
place in the prepared structure. Compound 61’s pyrrolidine was found to be interacting with
D186 in the DFG loop, the only X-ray structure found to be interacting with this residue
without also interacting with the charged side chain of K67.
Additionally, whilst 61 showed little activity in the absence of Pimtide in our FRET assay,
57 was mildly active in this assay, an orthogonal inhibition assay and showed a positive
temperature shift in the TSA performed in addition to being crystallised with Pimtide.
Structurally, 57 possesses a substituted indole and pyrrole acceptor. These are frequently
reported amongst known Pim-1 inhibitors and their typical placement is predicted by the
docking binding mode i.e. the indole placed at the hinge interacting with E121 and the
pyrrole predicted to interact with K67. This is suggestive of multiple binding modes for this
ligand but this was not confirmed.
Simulations of the quinoxaline fragment and a negative control in Project 4 tentatively
confirmed the stability of its binding mode within the binding pocket of Pim-1. A network of
three waters between I104 and K67 is found in many Pim-1 X-ray structures but simulations
here have demonstrated that, in line with previous work, only one of them (W29), bridging
with K67, is likely to be conserved in Pim-1 generally. Simulations have also demonstrated
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that upon the ejection of the least stable water, closest to I104, there is a rearrangement of
the remaining waters. One of them, W62, formed a direct interaction with the protonated
amide nitrogen of the ligand’s quinoxaline core. A new network of interactions was thus
formed involving direct interactions with the quinoxaline’s carbonyl and K67 in addition to
the those already described (Figure 3.22).
The X-ray binding mode of the quinoxaline fragment was somewhat corroborated by simu-
lations but, unfortunately, activity of the fragment itself was not detected in FRET-based
assays. This is presumably due to the low affinity of fragment sized-molecules, a common
phenomena in FBDD campaigns [43]. Four synthesised extensions were also tested and found
to be inactive against Pim-1.
The exact reason for lack of activity by these compounds in the FRET assay is unclear. How-
ever, all of the predicted inhibitors were extended in silico from position 6 of the quinoxaline
core. Whilst this allowed for extensions that were predicted to interact with D128, none of
the apolar sections of extensions tested were particularly close to the hinge.
By way of contrast, in addition to possessing greater rigidity and a predicted interaction
between D128 and an uncharged moiety (a hydroxyl), the apolar benzofuran sidechain of 26
was also predicted to be more proximal to the more apolar Pim-1 hinge. It therefore seems
reasonable to suppose that inhibitors extended in silico at position 6, rather than 5, may
more effectively address the Pim-1 hinge in docking studies and possess the added benefit of
greater shape complementarity in the Pim-1 binding pocket (Figure 3.26).
Figure 3.26: Predicted binding modes of 26 (black carbons, stick representation) vs 62 (left, straw coloured carbons,
stick representation) and an example docked pose (right, straw coloured carbons, stick representation). Depicted here
is a prediction of decreased distance and enhanced shape complementarity to the more apolar Pim-1 hinge region (green
region) after Suzuki Coupling in silico at position 6 to the quinoxaline core from Project 4 as opposed to extending
from position 5.
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It bears asking the question whether completing analysis, synthesis and testing in-house, as
per Project 2 and Project 4, is a more efficient approach than purchasing ligands and using
3rd-party vendors for testing as per Project 3. Broadly comparing the two approaches, using
a large dataset such as ZINC, curated to be lead-like, is the more reliable method purely for
finding new ligands. PINGUI is pitched as an ideas generator and on that front it succeeds as
it certainly did generate many possibilities for synthesis and testing in Project 2 and Project
4.
However, its utility is dependent upon the presentation of a reliable fragment binding mode.
This is, as demonstrated, difficult to achieve without expert knowledge in choosing the target
protein structure. Related, upon determining a reliable fragment binding mode, it was found
that only few molecules actually retained it upon extensions being added.
Assuming the docking program gets the binding mode right, more molecular possibilities
are always useful. But the claim of synthetic feasibility is also questionable as, in almost all
cases, the molecule tested was either synthesised using a different method due to the risk of
low yields or synthetic complexity or for similar reasons, a derivative with a minor change
(e.g. pyridine → aryl ring) was proposed. This necessitated additional work to confirm the
binding mode of the derivative prior to any attempts at synthesis as less than half of the
molecules were synthesised with the reaction as proposed.
There was also a vast difference in both the computational and personnel effort to develop a
similar number of inhibitors at a similar range of potency against Pim-1. This appears to be
the case even when the focus was on synthesising specialist inhibitors to address specific areas
in the Pim-1 binding pocket. Using the PINGUI-developed library in Project 2 necessitated
compiling and parametrising an initial library for docking and separate docking runs on a
HPC cluster to avoid results being dominated by in silico reactions that naturally tend to
generate a lot more products than others. This was followed by further filtering steps prior
to analysis. All of this was followed by synthesis effort that was not straightforward and
subsequent affinity testing. Compare and contrast this to merely downloading and docking
a ZINC subset as in Project 3, an order of magnitude larger than the dataset in Project 2,
followed by affinity testing and structural information gained from X-ray crystallography.
However, the costs of completing all steps in-house must be balanced against the gains. From
Project 1, structural information about the Pim-1 binding pocket was gained as decisions
regarding starting X-ray structures and which software to use in subsequent virtual screening
campaigns were simplified.
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In Project 2, more was learned regarding the likelihood of successful novel ligand synthesis
and how minor changes to ensure synthetic feasibility can also ensure subsequent ligands.
A chemotypically broader array of molecules synthesised and tested elucidated structural
information about Pim-1 itself as we now know several moieties that are both less likely to
interact with charged residues near the bulk-water interface but also how to ameliorate these
solvent polarisation effects.
Finally, more was learned regarding the stability of Pim-1’s structural waters from Project
4 and how this leads to a stable binding mode for a novel scaffold for Pim-1. From a stable
fragment binding mode, synthetically feasible products were the result from using only one
reaction at one site on the quinoxaline’s core structure. More sites are available to be used
to explore the Pim-1 binding pocket.
What constitutes a ‘hit’ is also an important question posed by this work. A hit, of course,
requires experimental confirmation. However, there are degrees to this. Through a significant
amount of work, a few inhibitors in the μM range or worse were the result. So perhaps one
may not consider these relatively weak ligands real hits. These compounds are, however, not
optimised for binding to Pim-1 and the two clear hits from synthesis projects, 26 and 52,
are chemically diverse and provide excellent starting points for optimisation campaigns.
There were essentially three hits from Project 3. Compound 61 may not be considered a
real hit as it only crystallised via an interaction with Pimtide and therefore showed no assay
activity. This is despite the likely similarity between Pimtide and the substrate in cellular
conditions. Its activity in the absence of Pimtide could not be assessed as Pimtide’s sequence
(ARKRRRHPSGPPTA) fits within the peptide sequence in the assay kit used. However, 57
and 58 were both active in orthogonal assays. Despite not progressing to full refinement in
crystallographic studies, 58 in particular appears to be a selective pan-PIM inhibitor, albeit
at the μM level.
Additionally, the binding properties of Pimtide with respect to ligands demands further in-
vestigation. The water-mediated interaction of 61 with Pimtide involved a charged moiety
and occurred near the bulk-solvent boundary (Figure 3.27). Using Pimtide potentially ob-
viates the need for a direct interaction between a charged ligand and charged residues that
are difficult to target for similar reasons to those near the Specificity Surface (D128-D131).
These residues in addition to those near the Ribose pocket (E171) and the Phosphate Groove
(K169, D167) offer the possibility of novel and selective inhibitors for Pim-1 as there are few
published inhibitors targeting them and they are less conserved in kinases.
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Figure 3.27: Crystal structure of 61 (green carbons, stick representation) in complex with Pim-1 a water-mediated
interaction (red, cross representation) and Pimtide (magenta carbons, stick representation). Key residues (yellow, stick
representation) are labelled and predicted polar interactions are represented by yellow dashed lines. Depicted here are
charged residues near the Ribose pocket and Phosphate Groove (see Figure 3.3) that could potentially be targeted in
the Pim-1 binding pocket for the development of peptide inhibitors.
Pimtide’s binding position and proximity to the binding pocket also offer the possibilities for
the design of peptide inhibitors. It was reported in a review of computational and lab-based
studies that peptide inhibitors can be viable strategy for the development of substrate-
competitive inhibitors, particularly for Ser-Thr kinases [175]. Computational approaches are
complicated by the conformational flexibility of peptides and in vivo work is made more
difficult by their poor stability and bioavailability. However, Pimtide’s rigidity and the
predictability of its binding mode with Pim-1 suggests a role as a Protein-Protein Inhibitor,
of which there has been recent success using structure-guided methods with more flexible
peptides against a Tyrosine kinase, ABL [176]. This is, however, quite separate from the
ATP-competitive inhibitors discussed in this study.
So what makes a good ligand for Pim-1? As intimated by the results presented here, rigidity
is important for high-affinity binding to Pim-1, particularly on the hinge side of the pocket.
With respect to the more apolar Pim-1 hinge, a very recent optimisation campaign [177]
confirmed that rigid, often large ring systems where vdW interactions dominate, are impor-
tant for positioning the ligand in the absence of the second conserved hydrogen-bond donor
usually found in the hinge of kinases. The ligands from that study, a series of tetrahydropy-
rrolo quinazolinones, were made more rigid and planar by the presence of an intramolecular
hydrogen-bond between the pyrrole-NH to the quinazolinone-N and made large potency
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gains on this basis (Figure 3.28, A). Indeed, the necessity of planarity was made clear by
an study [178] of activity cliffs with respect to a series of benzofuranones, where a series of
hinge-binding pyrrolo pyridines were synthesised where the only difference was the position
of the pyridine Nitrogen. Even a slight disturbance of planarity resulted in large decreases
in affinity.
The search for novelty may therefore be more fruitful from the side of the Pim-1 binding
pocket occupied by its catalytic Lysine, K67. Another very recent optimisation campaign
of diamino pyrazoles [179] reported pM inhibition whilst targeting residues near the Speci-
ficity Surface (e.g. D128, E171) (Figure 3.28, B). Their results suggest that the necessity
for rigidity on the hinge sided of the binding pocket is perhaps less important on the Lysine
side, offering some flexibility in terms of shape-complementarity and, consequently, in what
moieties can target less conserved or solvent-exposed residues in this region. The binding
position of ligands such as Staurosporine, ostensibly a hinge binder, does prima facie contra-
dict this. Its very large fused aromatic ring system, however, does also satisfy the need for
rigidity. Nevertheless, for future campaigns targeting more novel residues, strategies involv-
ing chemotypes extending from the catalytic Lysine side of the Pim-1 pocket would appear
to be more effective at finding more affine and potentially selective ligands.
Figure 3.28: Example ligands suggesting future targeting strategies for Pim-1. (A) Depicted is a ligand (green
carbons, stick representation) with multiple rigid endocyclic systems in the Pim-1 binding pocket with crystallographic
water molecules (red, spheres). Key residues (tan carbons, stick representation) are labelled and likely polar bonds are
represented by dashed black lines. The ligand also forms an intramolecular hydrogen-bond between its pyrrole-NH and
the quinazolinone-N that preserves the planarity of the ligand (adapted from Wang, H-L, et al 2019) (B) In this case,
a ligand (pink carbons, stick representation) in complex with Pim-1 (orange, cartoon representation) targets solvent-
exposed residues (e.g. D128) by extending from the catalytic Lysine side of the Pim-1 binding pocket, a strategy that
resulted in ligands with improved shape complementarity (adapted from Wang, X, et al 2019)
To summarise, whilst Project 3 was a more rapid method to find novel ligands based in
existing knowledge of Pim-1 and kinases generally, more was learned from the other projects
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that will guide subsequent ligand optimisation campaigns and generate productive streams
of research in and of themselves. On balance, the net gain in terms of chemical novelty and
structural understanding of Pim-1 and kinases is therefore larger with the latter. Promis-
ing results from structural studies should also inform the development of Pim-1 peptide
inhibitors, further adding to structural information about Pim-1 generally. The data gained
from all of these projects should guide structure-based optimisation of Pim-1 inhibitors to-
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Members of the Hedgehog (Hh) signal pathway, first identified in studies on Drosophila
embryonic development, play a foundational role in the cellular communication and develop-
ment of vertebrate organisms. Of the large families of secreted peptide factors, for example,
Wingless-related integration site (Wnt), fibroblast growth factor and TGF-β, Hh provides
one of the more arresting examples of conservation of function between developmental reg-
ulation of a quite diverse array of organisms [180].
In vertebrate systems, three main genes have been identified as conserved; Desert Hedge-
hog (Dhh), Indian Hedgehog (Ihh) and Sonic Hedgehog (Shh). Expression of these genes
regulate the specification of cell fate, proliferation and survival depending on the tissue be-
ing addressed. The pathway is therefore implicated in the vast majority of vertebrate tissue
formation and, aside from tissue maintenance and repair, is dormant in adult cells [181] [182].
Given these important regulatory mechanisms, misregulation of the Hh pathway via various
activating, inactivating and loss-of-function mutations unsurprisingly leads to an array of
medical issues. Primarily, these are various cancers including medullablastomas, glioblas-
tomas, breast cancers and one of the most common human forms, Basal Cell Carcinomas
(BCCs) [183].
Within the Hh pathway, a membrane receptor that has been identified as amenable for inhi-
bition is the Smoothened receptor (SMO). SMO is a G Protein-Coupled Receptor (GPCR)
with a traditional 7-Transmembrane (7TM) bundle, four Extra-Cellular Loops (ECLs) and
an extra-cellular Cysteine-Rich Domain (CRD), believed to play a crucial role in regulation
of its activity [184] (Figure 4.1). Despite sharing little sequence identity with other human
GPCRs [185], the designation of SMO as a GPCR has been controversial [186]. However, it
has been determined that SMO exhibits the characteristics of a GPCR, demonstrating that
coupling to Gα is required for Hh signalling in vivo [187].
SMO’s activity in the Hh pathway is largely dependent upon its trafficking with other pro-
teins in and out of the primary cilium (Figure 4.2). Upon binding of one of the three Hh
signals to a 12-Transmembrane receptor, Patched (PTC1), SMO is phosphorylated by the
kinase GRK2 and free to accumulate in the primary cilium via coupling to heterotrimeric
G proteins and β-Arrestin. Kinesin-like proteins such as Kif7 facilitate the formation of a
special compartment at the tips of the primary cilium [188] that allow for complexation of
SMO-mediated downstream signal transduction mechanisms, such as phosphorylation and
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Figure 4.1: The complete SMO assembly, inactive comformation (PDB:5L7I). Depicted here are SMO’s extracellular
loops (CRD, grey cartoon representation), its heptahelical transmembrane domain (7TM, multi-coloured cartoon) and
intracellular C-terminal domain (ICD, grey cartoon). Allosteric binding in the CRD results in conformational changes
in the other domains that impel SMO toward an active conformation.
therefore activation of transcriptional effectors (e.g. Zinc finger protein Gli1). Full length
Gli proteins dissociate from the unphosphorylated Kif7 and the Gli-repressor SuFu [189],
bypass proteolytic processing, enter the nucleus and activate cellular transcription.
Absent a Hh signal, SMO remains bound to PTC1 and Gli proteins are instead isolated by
Kif7 and SuFu to be differentially phosphorylated by PKA, GSK3β and CK1. Gli proteins are
further processed into transcriptional repressors. These truncated Gli proteins pass through
the cytoplasm and into the cell nucleus to repress transcription.
The activities of SMO and PTC1 are, thus, crucial determinants of disease. At least 85% of
inactivating PTC1 and 10% of activating SMO mutations drive uncontrolled replication in
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Figure 4.2: The Hedgehog (Hh) pathways in cells, activated and inactivated. Depicted here are known pathway pro-
teins (ovoid spheres, multiple colours), signal molecules (yellow, spheres), proteosomes (red, rectangles), the endosome
(light brown, rectangle), cilial microtubule assembly (large cylinder assembly) and lipid membrane with membrane
proteins CAM-related/down-regulated by oncogenes (CDO), Brother Of CDO (BOC) and Hedghog Interacting Pro-
tein (HHIP) that bind Hh signal molecules. Depicted here, in the absence of a Hh signal, SMO is held in complex with
Patched (PTC1) at the base of the primary cilia and is therefore unable to prevent Gli proteins from being cleaved into
transcriptional repressors, hence, gene transcription is inactive. In the presence of a Hh signal, PTC1 is complexed
with HHIP and the Hh signal and SMO is able to translocate to the tip of primary cilium where it accumulates and
prevents Gli cleavage. Gli proteins are subsequently phosphorylated and activated by Kif7 and SuFu where they can
pass into the nucleus and activate transcription (adapted from Teglund, et al. 2010)
Hh tumours [190]. Despite this and suggestions of other targets downstream of SMO [191],
particularly in avoiding drug resistance [192], SMO is thus considered the most ’druggable’
protein in the Hh pathway [193].
The first crystal structure [194] of SMO provided structural information regarding antag-
onism via a known small molecule inhibitor to SMO. Of other small molecule inhibitors
against SMO, a particular success was the clinical drug Vismodegib (Erivedge) [195], a more
polar molecule than earlier inhibitors such as Cyclopamine. However, a missense mutation in
TM6 (D473) common to many BCCs has been reported to disrupt Vismodegib binding [196].
Attempts to circumvent resistance with ligands that avoid D473 has led to ligand binding
unaffected by the mutation to D473 by Taladegib [197], used in trials for solid tumours
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and other cancers (DrugBank Accession Number: DB12550) (Figure 4.3). Other work has
prioritised novelty via an inhibitor binding deep within the 7TM bundle (SANT-1) as well
as alteration of the binding pocket by an agonist, SAG1.5 [198], inhibitors that assiduously
avoid D473. Although D473 is the most common mutation in BCCs, others have been re-
ported [199]. A tool compound containing a large pthalazine core, TC114, was also used to
elucidate specific structural roles played by ECL3 and TM6 for crystallographic study [200].
Figure 4.3: Some published drugs and inhibitors against SMO. Taladegib has previously been subject to adenocar-
cinoma and solid tumour Phase I and II clinical trials treating at Stages I - IIIB that have completed or it has been
withdrawn from the trial. Vismodegib is currently in clinical trials for patients suffering from Basal Cell Carcinomas,
pancreatic and prostate cancers at various stages and has been subject to numerous other clinical trials. TC114 and
SANT-1 are not clinical candidates.
There is a sizeable gap in the literature regarding SMO inhibitors and chemical diversity.
This is in terms of chemotypes, ligand binding modes and susceptibility to mutations as
many SMO ligands rely on only one or two polar interactions, primarily binding via apolar
interactions. Experience thus far with Vismodegib suggests it would be prudent to explore
alternative binding modes, multiple positions within the TM7 bundle and more interactions
to stabilise a ligand within the binding pocket.
In light of the structural information obtained from previous campaigns, Structure-Based
Virtual Screening (SBVS) offers the possibility of large-scale structure-based ligand discovery
for SMO. Large-scale docking campaigns have well-known limitations [9]. Nonetheless, by
fitting libraries of small molecules into a binding pocket and scoring them with a function
containing well-developed physics-based terms and parameters, a relatively large amount of
chemical space can be quickly sampled.
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Finding novel chemotypes is also more likely with large and diverse libraries when compared
to a rational design campaign as in previous studies. Rapid testing of molecules can also be
facilitated by using libraries comprised of commercially-available molecules as ZINC Is Not
Commercial (ZINC [131]).
More recent work has elucidated structural information regarding the role of cholesterol
as an agonist in the extra-cellular CRD [201] and rearrangement of various loops that al-
low communication across the cell membrane. Although SMO’s endogenous ligand remains
unknown [202], it has been found that cholesterol is both necessary and sufficient to ac-
tivate SMO [203]. Binding of antagonists (e.g. Vismodegib) in SMO’s Trans-Membrane
Domain (TMD) induce conformational changes in ECL3 that propagate to the extra-cellular
Cysteine-Rich Domain (CRD) and occlude the cholesterol binding site. This intrusion of
ECL3 leads to side chain rotations of W109 and R161 and the formation of a cation-π inter-
action between them where cholesterol would ordinarily bind. This interaction suggests that
a ligand binding in the TM7 domain should therefore prevent binding of cholesterol but the
reverse is not necessarily the case.
Until recently, no ligand was crystallised in complex with SMO where cholesterol has bound
to the CRD. However, an unpublished X-ray structure of active-state SMO with bound
cholesterol was recently solved where a large region of difference (Fo-Fc) electron density
was noted in the TM7 region, indicative of a bound ligand. A diverse array of compounds
such as assay kit ingredients, PEG, protein expression compounds, or hydrolysed cholesterol
were ruled out by collaborators (see Table 7.14 for a complete list).
This work therefore has several aims. Firstly, attempts to identify the unknown molecule(s)
in the area of electron density (referred to as the Completely Unknown Region of Electron
Density, or, ‘CURED’ for the rest of this work) were made with a mixture of datasets.
Second, the use of small molecule probes to analyse the allosteric binding pocket of SMO
and to suggest which moieties would be favourable or unfavourable in different regions.
Finally, the discovery, testing and further development of novel inhibitors for SMO.
4.2 Material and methods
4.2.1 Receptor preparation
Three-dimensional crystal structures of SMO were prepared from an unpublished X-ray
structure and two downloaded from the Protein Data Bank [59] (PDB: 5L7I and 4N4W).
The resolution of each structure was reported as 3.2 Å, 3.3 Å and 2.8 Å, respectively.
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The unpublished X-ray structure was prepared in order to identify the Fo-Fc density present
within the ECL and TM7 domains of the receptor. Docked molecular probes were used both
to narrow the range of possibilities of chemical moieties within sections of the CURED and
’map’ the binding pocket into regions favourable for these moieties. These sections were
grouped according to which moieties were favourable.
The aim of working with the 5L7I X-ray structure was to prioritise retrieval of poses from
a drug-bound structure, that being Vismodegib. Vismodegib displays few polar interactions
(D384), its position primarily stabilised by apolar interactions. So priority was given to
docked poses that were predicted to display more polar interactions connecting ECL1 (N219),
ECL3 (D384, Y394, R400) and TM6 (E518) whilst avoiding other residues in ECL3 (D473)
and some in TM6 (Q477, E481) where mutations have been demonstrated to affect binding
in many Hh-driven cancers [199]
An alternative structure (PDB:4N4W) was chosen to find more ’deep’ binders in the region
occupied by SANT-1. It has two polar interactions with residues in ECL3 (Y394) and TM6
(H470) and two apolar moieties than penetrate deeper into the binding pocket. Poses were
therefore prioritised if their positions were predicted to be below the position of H470 whether
they were directly interacting with H470 or not.
Missing atoms or residues for all structures were repaired and minimised with Wit!P [132],
hydrogens added and their positions minimised with CHARMM v31b2 [78]. Protonation
states of histidine residues in all structures were determined via visual inspection. Each
histidine was allocated a status of HID, HIE and HIP for docking dependent upon whether
the ε, δ or both nitrogens in the imidazole side-chain were considered likely to be protonated.
A complete list of protonation states for histidines in all prepared SMO structures can be
found in Appendix Table 7.15
The unpublished receptor structure was prepared for docking with two program suites: Sol-
vation Energy for Exhausive Docking (SEED) version 3.3.5 [60] and DOCK 3.6 [68]/3.7 [24].
Receptors downloaded from the PDB (5L7I and 4N4W) were also prepared for docking with
DOCK. In all cases, the X-ray ligand was removed prior to docking.
For SEED, defaults regarding departures from ideal hydrogen bonding geometry, clashes,
etc. were used and residues comprising the binding site of the protein were determined via
manual inspection. Pre-defined rules regarding bond-length, angle and direction of H-bond
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donors and acceptors allow the construction and distribution of vectors of unitary length on
all hydrogen bonding groups of ideal geometry. To reduce computations of unlikely polar-
bond geometries, coordinates of known ligands were used to restrict the number of force
vectors evaluated to those not exceeding a set geometry criterion (10-70◦).
The Fo-Fc density in the unpublished structure (Figure 4.4) was located primarily in extra-
cellular regions of the SMO binding pocket but also extending deep into transmembrane
regions of the receptor. The top of the electron density was located just below F484 and
extended between other residues in TM6, including the hydrogen-bond network connecting
it to ECL3 (D473, E518, R400), finally extending to lower residues in TM6 (H470).
Figure 4.4: A region of Fo-Fc density (dark grey, mesh representation) from an unpublished X-ray structure is depicted
here with the aligned crystal structure of Vismodegib (green carbons, stick representation) for reference. Key residues
(light grey, stick representation) are labelled and 2D structure (inset) of Vismodegib is displayed. This demonstrates
the binding position and orientation of the CURED with respect to the binding position of a known ligand.
In total, vectors around 29 residues were determined to provide adequate coverage of the
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binding pocket around the electron density. An image of the prepared binding pocket can
be found in Appendix Figure 7.8
For docking with DOCK, receptors were prepared via the generation of a set of spheres
representing the invagination of the binding pocket. The geometric positions of these spheres
were generated using sphgen [133]. The default number and positions of spheres was deemed
inadequate for coverage of SMO ’s binding pocket so more spheres were added and their
positions set within the binding pocket to ensure coverage. This also increased the number
of matching points around key residues for scoring and evaluation of poses.
After generation of vdW and electrostatic grids for the entire protein, a box was generated
from the cluster centre of all spheres so that it enclosed them plus some margin. Within
the boundaries of this box, scoring grids [65] describing protein energy potential functions
were pre-computed for later docking and scoring. The default box size is 5 Å3 but this was
generally increased.
This decision was made as, often, poses were placed partially outside of the boundaries of
the default box. The effect of this was that some atoms were not considered in scoring. As
the eventual score is a delicate balance involving atomic pair-wise calculations of multiple
quantities, components of the overall score for affected molecules were inaccurate, as was the
overall score.
Images of the prepared binding pockets can be found in Appendix Figures 7.9, 7.10 and 7.11.
A receptor was also prepared from 5L7I with an alternative conformation. All residues within
8 Å RMSD of a known ligand against SMO, Vismodegib, were identified and minimised using
CHARMM and, for comparison, MOE [150].
Minimisation was completed with CHARMM using the CHARMM force field, steepest de-
scent and conjugate gradient optimisation with Modified Partial Equalization of Orbital
Electronegativity (MPEOE [204]) atomic partial charges calculated.
Minimisation with MOE was completed with the Amber10 [205]: Extended Huckel Theory
(EHT) [206] force field as implemented in MOE, a method that combines Amber10 and EHT
bonded parameters for large-scale energy minimization. Optimisation was completed with
the Truncated Newton [207] method and atoms were parameterised with AM1-BCC [139]
partial charges.
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Certain residues in the 4N4W binding pocket were subject to a process known as ‘tarting’, the
purpose being to increase ligand preference for specific parts of the protein binding pocket.
Applying this idea, the partial charges of specific atoms in a protein are redefined and the
net effect is an overall increase in the polarity of certain bonds. This increased polarisation
is generally performed on backbone atoms, their partial charges increased by 0.4e prior to
calculating electrostatic potential grids for docking. To encourage retrieval of poses as deep
in the binding pocket as SANT-1 residues 4 Å from its position and below the position of
H470 were tarted.
4.2.2 Ligand preparation
An initial benchmarking campaign was performed to assess the performance of chosen SMO
structures. This campaign took a list of molecules found active against SMO from CHEMBL
[12] and used these to generate a set of challenging ‘decoys’ from the DUD-E website [208].
Using 3D similarity fingerprints, DUD-E decoys are similar in terms of chemical properties
(e.g. molecular weight, number rotatable bonds) to known actives but are unlikely to bind
to the target. This provides a useful metric of scoring ranks vs known activity, otherwise
known as enrichment. All known actives and generated decoys were docked to both of the
5L7I and 4N4W X-ray structures.
In order to identify the CURED, an internal library of 141 molecular ’probes’ that includes
small molecules such as benzene, water and cyclopentane was used in initial docking studies.
A full list of these probes can be found in Appendix Table 7.16.
Additionally, the ZINC12 [131], ZINC15 [14], The Human Metabolome DataBase (HMDB
3.0 [209]), and the Kyoto Encyclopedia of Genes and Genomes (KEGG [210]) and a small
Pharmacognosy library of natural products from the University of Vienna were used. Both
ZINC12 and ZINC15 are freely-available databases of biologically-relevant and purchasable
compounds with additional web-based resources such as similarity searches, activity predic-
tion, etc. The database also focusses on chemical novelty and offers several ’tranches’ for
download such as ’fragment’, lead-like’, ’drug-like’, etc.
The aim of docking HMDB, KEGG and other molecules was to determine whether there
are cell metabolites or biologically relevant molecules that could fit within the region of
electron density. Additionally, checks were made of the various kits and reagents from prior
studies [201] in order to rule out contamination from commercial kit/molecule providers as
108
listed in the paper. Other molecules were docked, even those already ruled out, as negative
controls (Monoolein, Hemisuccinate, Glycerol Monooleate, LKM, THPTA).
For docking with SEED, the probe library was prepared from SMILES using OpenEye’s
QUACPAC [137] suite for appropriate protomer and tautomer generation. Multiple 3D
conformers for each protomer were generated with OMEGA [138] and, as there are few
molecules in the database with rotatable bonds, no restrictions were placed on conformer
generation. AM1-BCC [139] partial atomic charges were calculated for each conformer.
Generation of HMDB and KEGG libraries for use with DOCK was completed using the
internal ligand generation pipeline implemented within the DOCK 3.7 suite to generate
the .db2 files required. The pipeline takes SMILES as input and uses Chem Axon [140]
programs for protomer generation, CORINA 4.1 [141] for initial 3D conformer generation,
AMSOL 7.1 [142] to compute atomic partial charges and ligand desolvation terms and finally
OMEGA to generate multiple conformers.
For this work, the ‘lead-like’ databases were downloaded directly from the ZINC12 and
ZINC15 websites.
4.2.3 Docking and pose minimisation
For SEED, both polar and apolar docking algorithms were selected and all poses to an energy
of +5.0 kcal·mol−1 were retrieved. Otherwise, program defaults regarding certain parameters
(e.g. protein clashes, charge cut-offs) were used. Poses were assessed in terms of fragment
and receptor desolvation energies as well as total interaction energies.
For DOCK, parameters governing van der Waals clashes were increased from defaults (20
kcal·mol−1 → 500 kcal·mol−1) i.e. poses where the vdW score exceeds this were discarded.
The matchgoal parameter was also set higher (1000→ 5000) to increase sampling of molecular
orientations. Simplex minimisation was used. Sphere colouring was not used. Only the
highest scoring pose was retrieved. Regarding all other parameters, program defaults were
used.
For ZINC screens, the positions of all pose structures within the SMO active site were
optimised using SZYBKI [156]. Optimisation parameters were set to minimise torsional
strain of molecular poses using the Merck Molecular Force Field (MMFF94 [157]) with the
Poisson-Boltzmann solvation model [158]. All protein residues within 3 Å of a given pose
were also minimised. Program defaults regarding the optimisation method (e.g. BFGS [159]
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algorithm) were used. Estimates of various energies (e.g. overall interaction, desolvation
cost) were obtained from optimised protein-ligand structures.
Chem Axon’s [140] MarvinSketch v14.12.8.0 for Linux was used for drawing and display-
ing chemical structures and calculating pKa curves used to evaluate docked molecules. The
Cambridge Structural Database’s program, Mogul [211], was used in the evaluation of molec-
ular torsion angles. Receiver Operator Curve (ROC) plots to evaluate docking performance
were generated with Python scripts in the DOCK pipeline. Molecular Tanimoto similarity
(Tc) was calculated with Open Babel [96] using the ECFP4 [94] fingerprint.
4.2.4 qPCR assay
Real-time quantitative reverse-transcription PCR reactions were performed using Power
SYBR Green PCR Master Mix from Thermo Fisher/Life Technologies. Relative Gli1 mRNA
levels were calculated using the comparative ΔCt method, reported in arbitrary units and
normalized with respect to Gapdh mRNA levels.
Primers used were custom with respect to Gli1 (forward primer: 5′-CCAAGCCAACTT
TATGTCAGGG-3′ and reverse primer: 5′-AGCCCGCTTCTTTGTTAATTTGA-3′) and
Gapdh (forward primer: 5′-AGTGGCAAAGTGGAGATT-3′ and reverse primer: 5′-GTGGAG
TCATACTGGAACA-3′). All experiments were repeated with two mechanical replicates and
at least three biological replicates.
4.3 Results
4.3.1 Identifying the region of Fo-Fc density and mapping SMO’s al-
losteric pocket
Docking to the unpublished structure was completed using UCSF DOCK. Spheres were
added primarily to ensure coverage of the area of electron density in the middle of the
binding pocket. In all, 55 matching spheres were used.
During preparation of HMDB and KEGG datasets, some molecules (∼4%), often those with
unusual atomic combinations or unclear protonation states, failed checks within the ligand
generation pipeline. Generally, these were highly-charged molecules or had a large number
(<4) of chiral centres that one would not expect to interact with SMO or be resident in any
system where SMO is present so were omitted from consideration.
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Upon omission of failed protomers, the finalised datasets contained 1001 protomers with
respect to HMDB and 15 245 with respect to KEGG.
All poses were evaluated in terms of whether they fit within the boundaries of the CURED in
terms of its complete volume. Candidate molecules that met this criteria were subsequently
evaluated in terms of unsatisfied hydrogen bond donors and acceptors and shape comple-
mentarity. None of the poses retrieved by docking either HMDB nor KEGG satisfied both
criteria.
The region of electron density within the TM7 bundle of the unpublished structure was
divided into multiple sections (Figure 4.5). These sections reflected differences in predictions
of what probes molecules were favourable and in which section they were favourable.
The entire region was divided into three major segments (Upper, Middle, Lower) and two
points between then (Transition points One and Two).
Figure 4.5: A region of Fo-Fc density (dark grey, mesh representation) from an unpublished X-ray structure is
depicted, key residues (light grey, stick representation) are labelled. Indicative sections of the CURED were categorised
by apparent size and shape.
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Generally, highly polar molecules (e.g. methyl sulfone, proprionic acid) retrieved poses
with unfavourable energies. Both small polar and apolar molecules (e.g. ethanol, tert-
butane) tended to result in poses with higher energies and fewer poses in general, as did
non-aromatic rings. Rings found fewer favourable poses in the Upper region and those that
had large receptor desolvation costs and species 6-ring sized or larger had increasing receptor
desolvation costs the lower into the pocket they were placed.
As expected, highly-scored poses tended to be driven by apolar binding. Some probes (e.g.
phenol, mesoinisotol) scored higher due to polar substituents interacting with polar residues.
Although these substituents were generally placed outside of the CURED, their apolar in-
teraction energies inside it were similar to non-substituted analogues (e.g. benzene).
In the Upper region, few poses addressed the upper portion of this section explicitly or fit
it perfectly. However, in general, probes with large apolar sections had high-scoring poses
placed here and were often unfavourable any deeper in the CURED region. This was generally
driven by lower apolar interaction energies and poses placed closer to or inside the CURED
tended to have lower receptor desolvation costs. Fused-ring systems tended to score higher
in this section and, in some cases, were placed almost within the contour of the CURED
region (Figure 4.6). The aforementioned trend of more favourable receptor desolvation also
held true with poses placed closer to or within the CURED.
Figure 4.6: Example A-carboline docking pose (black carbons, stick representation) within the CURED (dark grey,
mesh representation) in the SMO binding pocket (TM7 bundle). Key residues (light grey, stick representation) are
labelled. Poses placed here tended to have lower protein desolvation and large fused-ring systems tended to score
higher, indicative of greater shape complementarity with the receptor pocket.
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A corner of the upper region was within hydrogen-bonding distance of E481 (Figure 4.7).
Although no docking pose was directly placed here, distance measurements between this
corner of the CURED and the positions of E481 and Q477 suggest a hydrogen-bond donor
at this position would fit, possibly interacting with both.
Figure 4.7: Distances (Å) between E481 and Q477 and the CURED (dark grey, mesh representation). Key residues
(light grey, stick representation) are labelled. Distances (Å) are represented by dasged yellow lines and measured
between polar atoms on residues and a sphere (straw colour) placed within the boundary of the CURED.
For the Middle region, at Transition point 1, the majority of probe poses within the CURED
were unfavourable, particularly any ring-sized moieties. This is suggestive of chains link-
ing the upper and middle sections. SEED was generally unable to place poses in the top
part of this segment, particularly ring-sized probes. The main portion of this section is al-
ready very close (1.8 Å) to D384 so favourable poses with most probe molecules, considering
neighbouring residues, were unlikely (Figure 4.8).
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Figure 4.8: Distance (Å) between D384 and the CURED (dark grey, mesh representation). Key residues (light grey,
stick representation) are labelled. Distances (Å) are measured between polar atoms on residues and a sphere (straw
colour) placed within the boundary of the CURED.
An exception was methanol as several poses were found with favourable polar interaction
energies between methanol and D384 (Figure 4.9). The closer poses were placed to D384,
whether inside or slightly outside the CURED’s boundaries, the greater the interaction
energy with little increase in desolvation cost.
Figure 4.9: Docked methanol (black carbons, stick representation) poses within the CURED (dark grey, mesh
representation) in the SMO binding pocket (TM7 bundle). Key residues (light grey, stick representation) are labelled.
Predicted polar interactions are represented by yellow dashed lines and distances in Angstroms (Å). Methanol’s docked
positions were indicative of a hydrogen-bond donor interaction with D384 as interaction energies between poses and
this residue improved the closer they were placed to D384 with little increase in desolvation cost.
Poses in the lower part of the the Middle region were retrieved with high receptor desolvation
penalties and consequently unfavourable energies for any molecules that were 6-member
ring-sized (e.g. benzene) or bigger (Figure 4.10). A proximal bump in the CURED was not
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directly addressed by any probes but it is within range of polar residues (e.g. Y394, S287)
so moieties could form polar interactions. Substituted rings (e.g. phenol) were generally
unfavourable but some 5-member ring species (e.g. N-methylpyrrole) found poses that were
favourable near this position.
Figure 4.10: Favourable N-methylpyrrole (light grey carbons, stick representation) vs unfavourable benzene (black
carbons, stick representation) in similar positions within the CURED (dark grey, mesh representation) with the distance
to a proximal bump in the CURED represented by a sphere (straw colour). Distances (Å) are represented by yellow
dashed lines. This is suggestive that moieties the size of smaller endocyclic systems (or smaller) are more likely to be
favouble in lower CURED regions.
Larger molecules with poses that crossed between the lower segment through Transition
Point 2 and into the lower CURED region (e.g. indole) tended to be highly unfavourable
and possess high receptor desolvation costs (Figure 4.11).
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Figure 4.11: Unfavourable indole poses (black carbons, stick representation) within the CURED (dark grey, mesh
representation) in the SMO binding pocket (TM7 bundle). Key residues (light grey, stick representation) are labelled.
Endocyclic systems larger than benzene tended to score highly unfavourably, suggestive that moieties must fit within
the CURED’s density. This is as opposed to a large moiety being placed in this position where calculated atomic
density is missing.
Poses from any probe that penetrated toward R400 resulted in very high receptor desolvation
costs and unfavourable energies. This and the position of R400 (Figure 4.12) supports no
direct interaction between residues in this area with the CURED molecule.
Figure 4.12: Position of R400 (magenta carbons, stick representation) in the CURED (dark grey, mesh representa-
tion) X-ray structure vs the same residue’s position with respect to bound ligand Vismodegib (green carbons, stick
repreentation). Key residues (light grey, stick representation) are labelled and distance (Å) are represented by dashed
yellow lines. The distance between the crystal position of Vismodegib’s amide Oxygen and R400 is indicative of no or
a weak interaction. The position and orientation of R400 is further away with respect to the boundary of the CURED
thus an interaction between R400 and a moiety within the CURED is unlikely.
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Finally, for the Lower region, moieties placed within transition Point 2 generally had very
large receptor desolvation costs and unfavourable interaction energies. Any ring-sized molecules
tended to be unfavourable in this region. However, receptor desolvation costs tended to de-
crease for poses closer to or within the CURED.
Although a molecule could not be conclusively identified, a schema for favourable moieties
from docked probes can be proposed (Figure 4.13).
Figure 4.13: Example 2D structure of a molecule indicative of moieties favourable within the CURED (green area)
in the SMO binding pocket (TM7 bundle). Key residues (light grey, stick representation) are labelled.
A complete list of all probes used and calculated interaction energies can be found in the
Appendix Table 7.18
4.3.2 ZINC virtual screen - Round 1
Several constraints were applied to both the ZINC12 and ZINC15 datasets downloaded for
docking. Molecules needed to be purchasable, their molecular weight between 250 and 350Da,
logP ≤ 3.5 and contain protomers within a pH range of 6-8. Applying these constraints led
to database sizes of 4 601 296 and 3 841 554 respectively.
For the structures prepared from 5L7I, spheres were added around the position of the bound
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Vismodegib ligand atoms. Several were added within hydrogen bonding range of key residues
such as the hydrogen bonding network between R400, H470, D473 and E518 and others that
have been shown in other studies to interact with SMO ligands (N219, D384, Q477). In all,
50 matching spheres were used (Appendix Figure 7.10).
Spheres were placed near the same residues for the 4N4W X-ray structure. However, ad-
ditional spheres were placed deeper in its binding pocket. This was to ensure sampling of
poses placed in similar positions to the SANT1 ligand, some spheres placed as deep as L325
and M326. In all, 80 matching spheres were used (Appendix Figure 7.11).
Known actives against SMO were downloaded from the CHEMBL website. After removing
duplicates, this resulted in a dataset of 676 molecules. These were used to generate 51 075
DUD-E decoys for docking against SMO.
Docking of actives and decoys with DOCK defaults initially produced worse than chance
performance with the Vismodegib structure, particularly with respect to ‘early enrichment’.
Early enrichment describes the situation where the correct predictions of known actives are
also amongst highest ranked molecules. In general, few poses (142/676 = 21%) of known
actives were retrieved and increasing the size of the box around the binding site (5 Å3 →
15 Å3) did not improve early enrichment of docked molecules.
It was determined that default DOCK 3.7 parameters regarding conformational sampling
and surface clashes are set more strictly than in previous versions. The default values mean
that far fewer orientations are sampled prior to energy minimisation, where poses clashing
with the molecular surface are finally rejected. It was therefore considered likely that many
viable poses are likely rejected at the minimisation stage. Prior work [24] has determined
that increasing sampling tolerances, coupled with energy minimisation, results in monotonic
improvement of ligand enrichment over decoys for most DUD-E targets.
Subsequent increases in conformational sampling and vdW score tolerances retrieved more
known actives (78%) and improved both early enrichment of actives and performance in
terms of logAUC (Appendix Figure 7.12, Plot A).
Docking with the ZINC12 lead-like dataset led to an initial list of 83 molecules after checks for
availability, torsional strain and likely protonation states. Of these, 44 were selected after an
initial visual inspection, common in high-throughput and virtual screening [166,167]. These
molecules were assessed and graded by lab members experienced in docking and the grades
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analysed. Subsequently, 11 were selected for purchase after checking for similarity with a
prior virtual screen using the ZINC12 dataset [212]. Molecules chosen for purchase were
found to be generally dissimilar to the ligands in that study (Tc: x̄ = 0.22, σx̄ = 0.07) and
known actives (Tc: x̄ = 0.32, σx̄ = 0.10).
Many of the poses retrieved did reproduce the interaction between Vismodegib and D384
from its crystal structure but also tended to place apolar moieties into pockets between N219
and F484 below Y394. Polar interactions with D384 tended to be between charged amino
groups rather than amide groups as per the Vismodegib X-ray structure. Some molecules
(Figure 4.14) also had additional predicted interactions with residues in ECL3 (Y394) and
TM6 (E518) and these were prioritised higher for testing.
Figure 4.14: Predicted binding mode of K5 (black carbons, stick representation) in the SMO binding pocket (TM7
bundle). Key residues (light grey, stick representation) are labelled, predicted polar interactions are represented by
yellow dashed lines. Depicted here is a salt-bridge interaction between its pyrrolidine and D384 in ECL3, amide oxygen
and pyridine interacting with Y394 in ECL3 and amide nitrogen predicted to interact with E518 in TM6.
The remainder of predictions came from docking to the SANT-1 structure (PDB: 4N4W).
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Most compounds were predicted to recreate the binding mode displayed by SANT-1 i.e. with
residues in ECL3 (Y394) and TM6 (H470) (Figure 4.15). Molecules displaying predicted
interactions with residues in ECL3 (D384) and TM6 (E518) were subsequently prioritised.
Amide and urea linkers were typically predicted to interact with residues in these loops and,
as in common in SMO ligands, apolar moieties were placed both above and below these
linkers.
Figure 4.15: Predicted binding mode of K4 (black carbons, stick representation) in the SMO binding pocket (TM7
bundle). Key residues (light grey, stick representation) are labelled, predicted polar interactions are represented by
yellow dashed lines. Depicted here is a salt-bridge interaction between its piperidine and D384 in ECL3, urea oxygen
interacting with Y394 in ECL3, urea nitrogens interacting with E518 in TM6 and triazole interacting with H470 also
in TM6,





































































































































































































































































































4.3.3 Assay results - Round 1
Repression of Hh signalling for all 11 compounds was tested via qPCR. Gli mRNA is a com-
mon metric for Hh signalling activity as it is a target gene of the Hh pathway. Measurements
of relative Gli1 mRNA transcription levels were taken and normalised with respect to Gapdh
mRNA levels. Ligands of known concentration were introduced into the assay and residual
signal thus quantified a given ligand’s ability to repress Hh signalling.
Assays were initially conducted at two ligand concentrations (10µM and 100µM). Measured
residual transcription levels with ligand present were compared to two controls, residual
transcription with no ligand present and with a potent inhibitor, SANT-1. Three compounds,
K5, K6 and K9, displayed significant concentration dependence with respect to residual
transcription levels when compared to controls (Figure 4.16).
Figure 4.16: Normalised Gli mRNA levels for K1 - K11 at 10µM and 100µM. All compounds were tested with
positive (SANT-1) and negative (no ligand) controls and reflect the constitutive activity of SMO. Statistical analysis
of Gli1 mRNA levels across samples was performed via one-way ANOVA with Holm–Sidak post-hoc tests for multiple
comparisons. Ligands K5, K6 and K9 displayed significant (p<0.01) concentration dependence with respect to residual
mRNA transcription levels.
4.3.4 Minimisation of the binding pocket found more SMO poses
Relatively few poses were found in the first round of docking to the Vismodegib X-ray
structure (PDB: 5L7I) than would be expected for a drug-bound structure. It was apparent
from visual inspection of poses retrieved from docking that the dominant chemotype retrieved
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was pyrimidines with unlikely protonation states (∼26% of the top-2000 poses). These poses
were generally placed near the hydrogen-bonding network (R400/H470/D473/E518) and no
lower.
There was also some degree of excessive intramolecular strain in poses that was unable to
be resolved by ligand minimisation, even when minimising nearby (≤3 Å) residues as well.
Primary amides in particular displayed significant torsional strain, pushing the carbonyl
oxygen and amine hydrogen out-of-plane (Figure 4.17). Both phenomena were likely caused
by large van der Waals forces imposed upon the ligand by apolar residues in the binding
pocket and gave rise to the notion that perhaps residues in the binding pocket itself were
not fully relaxed.
Figure 4.17: Example molecular poses from docking with unlikely pyramidine protonation state (left, black carbons,
stick representation) and primary amide with torsional strain (right, black carbons, stick representation) in the SMO
binding pocket (TM7 bundle). Key residues (light grey, stick representation) are labelled, predicted polar interactions
are represented by yellow dashed lines, distances (Å) and angles were measured. It was considered that the placement
of poses in this manner, even after energy minimisation of both the ligand and surrounding residues was conducted,
was suggestive of large vdW forces being applied to the molecules being docked. Additionally, the degree of deviance
from 180◦ of some amides, although within the boundaries of previously published X-ray structures, was considered
excessive. This was considered prima facie evidence that the pocket should be relaxed via energy minimisation to a
lower energy conformation in order to find more likely docking poses.
To find more poses and minimise intramolecular strain, all residues within 8 Å of Vismod-
egib’s position in the binding pocket were minimised - 66 in total (Figure 4.18). Most
residues within this distance were in TM6 and the rest spread evenly between Extra-Cellular
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Loops 1 and 3. Residues were minimised using CHARMM and MOE and the differences
between these results compared to the X-ray structure and to each other.
Figure 4.18: Depiction of residues (banana yellow, cartoon representation) within 8 Å of the binding position of Vis-
modegib (green carbons, stick representation) in ECL1, 3 and 4 and TM6 (pink, cartoon representation) depicting those
that were were relaxed by minimisation with both CHARMM and MOE. Key residues (yellow, stick representation)
are labelled, distances (Å) are represented by yellow dashed lines.
A complete list of minimised residues can be found in Appendix Table 7.19
Overall, there was little movement of binding pocket residues. Movement of atomic positions
in terms of RMSD for each residue was compared to the original X-ray structure. There were
lower RMSDs from the X-ray structure for the CHARMM-minimised structure (RMSD: x̄ =
0.40, σx̄ = 0.21) when compared to the MOE-minimised structure (RMSD from X-ray struc-
ture: x̄ = 0.54, σx̄ = 0.36). Movements in the latter were, however, more ‘inward’ resulting
in a more constricted binding pocket (Figure 4.19). There was, accordingly, a lower overall
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energy for the structure minimised by CHARMM (-18 341.69 kcal·mol−1) when compared to
that obtained from MOE (-18 197.09 kcal·mol−1). Consequently, the CHARMM-minimised
structure was chosen for further docking.
Figure 4.19: Selected minimised binding pocket residues comparing the crystal structure and after minimisation with
CHARMM (light blue, cartoon representation) and MOE (pink, cartoon representation) with the binding position of
Vismodegib (green, stick representation) for reference. Key residues (stick representation) are labelled. Minimisation
with CHARMM resulted in a lower energy structure when compared to MOE and more outward movement of residues.
The resultant structure was a more ‘open’ binding pocket and was used for further docking.
Descriptive statistics for the RMSDs and complete CHARMM output of the energy calcula-
tion can be found in Appendix Tables 7.20 and 7.21 respectively
As in Round 1, known actives against SMO and decoys were redocked to the relaxed structure
to assess its performance. More poses (98% of known actives) were retrieved than the
unrelaxed structures and there were mild improvements both in AUC and early enrichment
of actives (Appendix Figure 7.12, Plot B).
The ZINC12 dataset was also redocked to the CHARMM-minimised structure and the top-
2000 scored poses were retained for analysis. Docking to the CHARMM-minimised structure
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resulted in a very different top-2000 when compared to that from docking to the X-ray
structure. Only 440 (22%) molecules were common to the top-2000 of both docks. Of those,
there were relatively small changes in score but the same molecules displayed very large
changes in ranking (Table 4.2).
min Q1 x̄ Q3 max Pearson r/MCC
rank -1814.0 -669.5 -141.0 315.0 1895.0 0.08/0.08
score -21.420 -7.305 -5.645 -3.790 3.910 0.56
Table 4.2: Five-number summary statistics (min, Q1, median, Q3, max) of differences in ranking and score for the
440 molecules common between ZINC12 dockings. Pearson correlation and Matthews Correlation Coefficient (MCC)
also shown. The data confirm large differences in docking rank and extremely weak correlation (0.08) when comparing
molecules docked to unrelaxed and relaxed structures. A similar but more mild effect was observed for docking score
(MCC=0.56).
Additionally, the proportion of pyrimidines with unlikely protonation states decreased (∼26%
→ ∼7% of the top-2000 poses) and more poses were retrieved interacting with residues in
ECL1 (N219) found in previous ligands against SMO.
Though more poses were retrieved in Round 1 docking to the SANT-1 structure, it was
apparent that none of them were ‘deep’ binding ligands. Tarting of residues was therefore
applied to the already-prepared deep binding X-ray structure (Figure 4.20).
In all, 9 residues were tarted, primarily by increasing the polarity of the backbone carbonyl
groups in apolar residues. A complete list of tarted residues and affected atoms and can be
found in Appendix Table 7.22.
As with the Vismodegib structure, increasing pose sampling improved early enrichment.
However, docking actives and decoys to the tarted structure resulted in worse than chance
prediction for high ranked compounds and a late enrichment of known actives to SMO
(Appendix Figure 7.12, Plot D). This is likely due to a large increase in electrostatic potential
caused by tarting >5 residues in the same binding pocket, even apolar residues such as T466
and F462. Primarily, this meant that more polar decoys that scored poorly when docked to
the untarted receptor were scored far more favourably in the tarted receptor.
Six of the known actives to SMO, also more polar molecules, scored highly when docked to
the tarted receptor after being scored as unfavourable against the untarted receptor. When
omitted from analysis, scores for the remaining actives that retrieved docked positions (463 )
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Figure 4.20: Residues (magenta, stick representation), generally apolar in nature, that were ‘tarted’ below H470
(green carbons, stick representation) in the SMO binding pocket (dark green, cartoon presentation) with the position
of ligand SANT-1 (green carbons, stick representation) for reference with 2D structure (inset) displayed. In all, 9
residues were ‘tarted’ prior to redocking the ZINC12 dataset but the effect on docking score and rank was mild.
in tarted and untarted receptors were broadly correlated (Pearson r = 0.76). 2D structures
and scores for these molecules can be found in the Appendix (Table 7.23)
Upon redocking the ZINC12 dataset, most poses retrieved (1699/85%) were common to the
top-2000 poses of both tarted and untarted receptors and both ranking and scores did not
change significantly (Table 4.3).
Energy minimisation of molecules docked to the Vismodegib structure revealed that using
the relaxed receptor pocket did result in molecules with more favourable protein-ligand
vdW energies as well as slightly more favourable protein and ligand desolvation energies.
However, the mean estimated interaction energies of both rounds of molecules were very
similar for those docked to the X-ray structure (-17.45 kcal·mol−1) when compared to the
relaxed structure (-17.35 kcal·mol−1).
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min Q1 x̃ Q3 max Pearson r/MCC
rank -1506.0 -96.0 -3.0 103.5 1366.0 0.87/0.79
score -7.55 -0.17 0.14 0.46 7.95 0.94
Table 4.3: Five-number summary statistics (min, Q1, median, Q3, max) of differences in ranking and score for the
1699 molecules common between ZINC12 dockings. Pearson correlation and Matthews Correlation Coefficient (MCC)
also shown. Although some docked poses displayed dramatic differences in ranking and score, generally the effect of
tarting residues on docking results was mild as there were strong associations between docking to untarted and tarted
receptors for rank (MCC=0.79) and score (MCC=0.94) respectively.
The effect of the tarted receptor was less pronounced. As expected, Coulomb energies
were more favourable but mean overall protein-ligand interaction energies were similar for
molecules docked to the X-ray structure (-12.15 kcal·mol−1) as compared to the tarted (-12.51
kcal·mol−1) receptor.
Generally, estimated interaction energies were higher for molecules docked to the 4N4W
structure when compared to the Vismodegib structure. This is likely to be due to the higher
(∼10 kcal·mol−1) cost of protein desolvation for poses placed deeper in the 7TM bundle.
A summary of energies as estimated during minimisation can be found in Appendix Table
7.26
4.3.5 ZINC virtual screen - round 2
Docking of the ZINC12 and ZINC15 lead-like datasets as well as a Pharmacognosy library
led to an initial list of 115 molecules after checks for availability, torsional strain and likely
protonation states. Of these, 70 were again subjected to visual inspection and analysis and
submitted for evaluation and grading by lab members prior to the collation of a final list.
Finally, 16 were selected for purchase after again checking for similarity with La Croix et
al and molecules from Round 1. Molecules chosen for purchase were found to be generally
dissimilar to the ligands in that study, broadly dissimilar to Round 1 molecules and all known
actives against SMO (Appendix Table 7.24).
When compared to compounds from Round 1, docking to the Vismodegib relaxed struc-
ture resulted in molecules with larger, ring-sized moieties addressing residues near the
hydrogen-bond network and linking ECL3 (Y394, R400), TM6 (E518, H470) and ECL1
(N219). Again, residues in ECL3 and TM6 prone to mutations in BCCs (D473, E481) were
avoided. Molecules from the ZINC15 dataset, broadly, were more likely to be comprised of
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both aromatic and non-aromatic endocyclic amines so whilst several predictions included
the amide/urea linker as seen in Round 1 poses, several poses were retrieved with the added
benefit of rigidity and shape complementarity (Figure 4.21).
Figure 4.21: Predicted binding mode of compound K2.10 (black carbons, stick representation) in the SMO binding
pocket (TM7 bundle). Key residues (light grey, stick representation) are labelled, predicted polar interactions are
represented by yellow dashed lines. Depicted are interactions between the imidazole of K2.10 and N219 in ECL1, a
salt-bridge between a primary amine and D384 in ECL3 and an interaction between its amide nitrogen and E518 in
TM6.
Predictions from the tarted SANT-1 structure recreated the two polar interactions from the
SANT-1 X-ray structure in ECL3 (Y394) and TM6 (H470). Additional interactions were
predicted with other residues in TM6 (E518 and N521). More poses were retrieved with
improved shape complementarity and more poses penetrated deep into the binding pocket
when compared to poses from Round 1 (Figure 4.22).
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A complete list and 2D structures of molecules K2.1 to K2.20 can be found in the Table
4.4
Figure 4.22: Predicted binding mode of compound K2.19 (black carbons, stick representation) in the SMO binding
pocket (TM7 bundle). Key residues (light grey, stick representation) are labelled, predicted polar interactions are
represented by yellow dashed lines. Depicted is a salt-bridge interaction between the charged primary amine as well as
urea nitrogens of K2.19 with E518 in TM6, an interaction between its urea carbonyl and Y394 as well as interactions
between its pyrazole and N521 and its thiazole and H470 in TM6. This was considered an ideal pose as interactions




























































































































































































































































































































































































































4.3.6 Assay results - Round 2
Repression of Hh signalling for all 16 compounds was again tested via qPCR (Figure 4.23).
Assays were again conducted at two ligand concentrations (10µM and 100µM). Of these,
compounds K2.2, K2.4, K2.7, K2.10-K2.14 and K2.18-K2.20 displayed significant con-
centration dependence with respect to residual mRNA transcription levels when compared
to controls (Figure 4.23)
Figure 4.23: Normalised Gli mRNA levels for K2.1 - K2.20 at 10µM and 100µM. All compounds were tested
with positive (SANT-1) and negative (no ligand) controls and reflect the constitutive activity of SMO. Statistical
analysis of Gli1 mRNA levels across samples was performed via one-way ANOVA with Holm–Sidak post-hoc tests for
multiple comparisons. Ligands K2.2, K2.4, K2.7, K2.10-K2.14 and K2.18-K2.20 displayed significant (p<0.01)
concentration dependence with respect to residual mRNA transcription levels.
4.4 Discussion and conclusions
Although molecular diversity was the goal with this work, it is prudent to consider which
parts of a given compound should be prioritised for novelty. Common to ligands in this work
was a short chain with small functional groups (e.g. aliphatic amide, urea) interacting via
a hydrogen-bonding network in the middle of the binding pocket, linking and potentially
stabilising its conformation. Above and below this central stability were a diverse array of
aromatic groups with no clear molecular trend in terms of size, chemotype or binding mode.
Though the molecule in the CURED structure was unable to be formally identified, the
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role and binding positions of endogenous regulators of SMO activity may be related and
similar. Initial probe docking provided a framework for which moieties were unfavourable
and where in the binding pocket and also provided useful data to inform molecule selection for
subsequent screening efforts. However, docked positions of probes where interaction energies
were favourable allowed the suggestion of a representative 2D structure. Essentially, a bulky
endocyclic system binding near the opening to the binding pocket with possibly an aliphatic
or at least less bulky tail penetrating deeper into the binding pocket. The crystallographic
positions of D384, Q477 and E481 support at least one polar interaction with the ligand.
Molecules in the class of oxysterols could therefore be candidate molecules for further anal-
ysis. At present, the only endogenous regulator of SMO activity known is cholesterol [213].
And, as reported, it was crystallised in the CRD [201], not in the heptahelical bundle where
the CURED is positioned. However, it remains an unresolved question whether other proteins
that interact indirectly with SMO (e.g. PTC1) via cholesterol or cholesterol-like molecules
regulate access to the CRD, the TM7 bundle or, indeed, both of these regions of SMO [214].
Although cholesterol itself was ruled out as a possibility for the CURED, long, cyclic en-
dogenous ligands to SMO were known some time ago [215] and ligands with bulky fused-ring
systems, such as Cyclopamine, have been crystallised with SMO in the TM7 [216] (Figure
4.24, A and B).
More recently, a class of cilia-associated oxysterols were reported to directly activate SMO
and promote accumulation in the primary cilia, allowing SMO to participate in downstream
signalling [217] (Figure 4.24, C-F). Although this study isolated oxysterols in cilia from non-
human SMO, the authors were able to demonstrate that oxysterols were not only able to
activate SMO but that they were able to activate SMO via binding in the TMD bundle
and that enzymes involved in cilia-associated oxysterol biosynthesis would be enriched in
domains of active Hh signaling. Which oxysterols or even other lipidic inhibitors SMO
encounters before or after entering the primary cilia remain open questions. However, the
broad molecular shape of oxysterols when compared to the shape of the CURED demands
that subsequent computational campaigns add all known Hh oxysterols as well as similar
molecules to any analysis.
With regards the virtual screens carried out using molecules from the ZINC dataset, the
hydrogen-bonding network in the middle pocket (R400, H470, D473, E518) provided, prima
facie, several tempting polar residues that have been targeted by ligands with larger moieties
in this position and, by itself, is believed to stabilise SMO’s inactive conformation [218].
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Figure 4.24: Other work involving oxysterol inhibition of smoothened. (A) The cystallographic binding position of
Cyclopamine (green, stick representation surrounded by mesh) is displayed at the top of the heptahelical bundle near
the entrance to the binding pocket, an example of an potent oxysterol-like ligand perhaps too bulky to bind deeper in
the TM7 bundle of SMO (from Weierstall, et al, 2014). (B) 2D structure of Cyclopamine showing its largely apolar
structure (C) 2D structures of various oxysterols from Raleigh, et al, 2018, depicting a bulky fused-ring segment with
short aliphatic tail sections. (C) Depiction of SMO crystal structure with its CRD (red cartoon), C-Terminal Domain
(CTD, grey cartoon) and Cytoplasmic Binding Pocket (CBP, aqua cartoon) as defined by the authors of Raleigh, et
al, 2018. (E-F) CBP for SMO showing key CBP residues (aqua cartoon) and predicted binding mode of two oxysterols
(grey stick representation) from Rayleigh. et al, 2018.
However, the search for chemical novelty was not the only goal as some parameters for
useful SMO ligands needed to be met. In accord with one of the stated goals of both
virtual screens, all tested compounds were predicted to avoid D473, a common mutation in
SMO. Structural rearrangements of the SMO binding pocket from mutations such a D473G,
D473N and D473H have been demonstrated to abolish binding of Vismodegib entirely [199]
and significantly reduce the affinity of other inhibitors such as AntaXV [198]. Other residues
prone to mutation (e.g. E481) were avoided.
Even with these restrictions, cellular assays confirmed hits in both rounds of ZINC docking
with hit rates of 25% and 75% respectively, hit rates somewhat higher than other SMO
campaigns but within the usual range of many GPCR virtual screens (17% - 58% [212]).
This was achieved whilst specifically avoiding similarity with previous ligands, residues prone
to mutation and also despite a well known bias in commercial compound libraries toward
well-studied targets [219] [220] (e.g. β2 Adrenergic Receptor). Both of these factors severely
limit the pool of inhibitors that may bind similarly to known SMO ligands.
Whilst previously known ligands and their binding modes provided a guide for choosing
possible inhibitors, the focus was most certainly on finding novel binding modes. That is,
candidate inhibitors predicted to interact in a similar manner to known SMO ligands were
134
only prioritised if they displayed interactions in addition to those demonstrated by known
SMO ligands. This is simply because SMO ligands tend to be driven by apolar binding (e.g.
Cyclopamine) and then only one or two polar interactions within the same loop or helix.
For example, Vismodegib only displays polar interactions with residues in ECL3 (D384 and
Y394) and otherwise exhibits apolar binding. A more potent ligand, SANT-1, again we
see only two polar interactions but with residues in both ECL3 (Y394) and TM6 (H470).
Accordingly, candidate inhibitors displaying more electrostatic interactions were naturally
prioritised. As were those where molecules were predicted to interact with multiple loops
and helices.
Specific attempts to discover new ’deep’ binding ligands appear to have borne fruit. As
SANT-1 is the only known ligand to bind in this way, and is so affine it was used as the
benchmark inhibitor in all cellular assays conducted for this work, it was considered impor-
tant to find more molecules that bind as deep as SANT-1 and again prioritise novelty. All
molecules tested that were predicted to be deep binders showed concentration-dependent
decreases of constitutive signal activity in the cellular assay. All were predicted to interact
with similar residues (Y394) and penetrate deep into the pocket below H470 but priority
was also given to molecules predicted to interact with residues higher in the pocket such as
those in the hydrogen-bonding network. Those also interacting with H470, as in SANT-1
displayed a greater decrease in residual Hh signal on the cellular assay. That the hit rate
significantly increased in the second screening for the relaxed Vismodegib docking structure
also confirms the importance of shape in docking.
With this in mind, two emerging Structure-Activity Relationships can therefore be elucidated
from assay results. In Round 1, similar Hh signal reductions were observed for K5 and
K6 at 100μM with K5 significantly better at 10μM. Both molecules possess charged cyclic
amines predicted to form a salt-bridge with the carboxylate sidechain of D384 in ECL1 and
amide nitrogen predicted to interact with E518 in TM6. However, K5 also had an additional
predicted interaction between Y394 in ECL3 and its pyridine, also observed with Vismodegib
(Figure 4.25). Whether the additional interactions with E518 result in a more affine ligand
is to be determined in a binding assay.
A second trend was observed in K2.7, K2.11 and K2.12. All three molecules possess a
β-hydroxy moiety predicted to interact with various middle-pocket residues (Figure 4.26).
However, assay results showed greater Hh signal reduction for K2.7 and K2.12, both of
which are predicted to link trans-membrane helices and extra-cellular loops via salt-bridge
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Figure 4.25: Predicted binding modes of K5 (left, black carbons, stick representation) and K6 (right, black carbons,
stick representation) in the SMO binding pocket (TM7 bundle). Key residues (light grey, stick representation) are
labelled, predicted polar interactions are represented by yellow dashed lines. In each case, predicted salt-bridge inter-
actions with ECL3 residues (D384) are complemented with a polar interaction between an amide/urea Nitrogen and
a residue in TM6 (E518). As per assay results, K5’s greater ability to impede Hh signalling at a lower concentration
(10μM vs 100μM) is suggestive of the additional interaction with Y394 being more important in terms of Hh signal
reduction than H470.
interactions with E518 in TM7, Y394 in ECL3 with respect to K2.7 and D384 in ECL1 with
respect K2.12.
It is noteworthy that K2.7 reduces Hh signalling to the level of SANT-1. This is despite
no optimisation ligands from either ZINC screen. Despite uncovering some ligands active
against SMO that were predicted to bind deeper in the binding pocket, none appeared to
reduce Hh signalling as much as SANT-1. Binding assays will be required to confirm whether
K2.7 is as affine as SANT-1 and efforts should be made to test for colloidal aggregation [164],
a common but difficult to predict problem for any inhibitor development campaign.
However, more molecules were found to be active against SMO in the second round of testing
that were also predicted to interact with similar residues to K2.7. This suggests that these
residues (Y394, E518) are likely more accessible and opens possibilities for optimisation of
both interactions and chemotypes without the need to bind deeper and to compete with
SANT-1 on affinity.
More generally, what structural features make a good SMO ligand? In terms of the binding
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Figure 4.26: Predicted binding mode of K2.7 (left, black carbons, stick representation), K2.11 (middle, black
carbons, stick representation) and K2.12 (right, black carbons, stick representation) in the SMO binding pocket (TM7
bundle). Key residues (light grey, stick representation) are labelled, predicted polar interactions are represented by
yellow dashed lines. As per assay results, ligand K2.7 displayed greater Hh signal reduction at 100μM than both
K2.11 and K2.12, comparable to the positive control (SANT-1). K2.12 displayed greater Hh signal reduction than
K2.11 at the lower concentration (10μM) and, like K2.7, was also predicted to link residues in transmembrane (E518)
and extra-cellular helices (D384). These predictions underscore the likely importance of Y394 in SMO ligand binding
and supports the strategy to select for molecules that link transmembrane and extra-cellular helices.
pocket, Y394 in ECL3, in isolation, appears to be a crucial residue for ligands binding
to SMO’s inactive conformation. The pyridine nitrogen of Vismodegib interacts with the
hydroxy sidechain of Y394 and its binding within the TM7 bundle is associated with a
conformational change of ECL3 that occludes the sterol binding groove in the CRD occupied
by active-state SMO [201]. Similarly, a pyrazole in the SANT-1 X-ray structure also interacts
with Y394 [198]. Results from signalling assays performed support this, molecules possessing
predicted interactions with Y394, regardless of the chemotype, generally result in a decreased
Hh signal activity (Figure 4.27).
Secondarily, molecules displaying predicted interactions bridging Y394 and residues in TM6
such as E518 were associated with greater decreases in Hh signalling. A very recent structure
optimisation campaign of a single virtual screening hit combining competitive binding assays
and free-energy methods (MM/GBSA) confirmed the primacy of the binding free-energy
contribution of Y394 but there were large gains in affinity from also targeting E518, whose
energy contribution was only slightly less [221]. Structurally, amide or urea moieties appear
ideal to exploit this linking of ECL3 and TM6 as the rigidity and geometry of these functional
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groups are easily within reach of the hydroxy sidechain of Y394 and the carboxylate of E518,
particularly in the case of compounds such as K5, K11 and K2.19 (Figure 4.27).
Additionally, molecules displaying predicted interactions with another residue in TM6 (H470)
in concert with either or both of Y394 and E518 were also associated with large decreases
in Hh signalling, particularly K6 and K2.19 (Figure 4.27). This effect was not consistent,
however, and of the three residues discussed here, despite as potent a ligand as SANT-1 also
displaying this interaction with SMO, it may be the least important of the three residues
discussed here.
Figure 4.27: Interaction matrix of all compounds tested in Rounds 1 and 2. Colours represent different interacting
moieties in line with traditional colours of atoms in chemistry (red=Oxygen, blue=Nitrogen). Generally, compounds
predicted to interact with Y394 displayed a greater propensity to reduce Hh signalling, followed by those predicted to
link residues in ECL loops and TM helices (e.g. Y394 and E518, respectively). Compounds interacting with H470 also
displayed a greater propensity to reduce Hh signalling but the effect was not consistent, hence Y394 and the strategy
of linking ECL loops and transmembrane helices (e.g. Y394/D384 and E518) appear to be more important for binding
to SMO’s TM7 bundle.
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Tarting of residues in the SMO binding pocket to encourage ‘deep’ binding was less effective
than pocket minimisation in retrieving hits. In principle, tarting a lot of residues should
dramatically increase overall electrostatic potential surrounding affected residues and highly
polar molecules should therefore score higher. This was borne out as more highly polar
decoys outscored actives in the tarted receptor in initial tests. However, docking scores for
less polar actives against SMO were largely unaffected by tarting. Several known actives,
poorly scored in the untarted receptor, did however score highly in the tarted receptor.
It was therefore possible that more molecules active against SMO, polar but not too polar,
could be retrieved. The increased risk of retrieving molecules from ZINC that score high
purely because they are more polar was mitigated as molecules in the ZINC dataset tend
not to be as apparently polar as generated decoys. This was confirmed as docked ZINC12
molecules tended to be scored and ranked similarly in both tarted and untarted receptors.
A few known active molecules were nonetheless retrieved against the tarted receptor after
being missed in docking to the untarted receptor (e.g. K2.19).
A few facets of the SMO binding pocket allow for a greater chance for success in any structure-
based screen of this nature. As with other GPCRs, SMO has a deep and narrow cavity in
its transmembrane domain and is generally not accessible by solvent. It is larger than the
orthosteric binding pocket of aminergic receptors such as the β2AR but significantly smaller
than that of peptide receptors and shape-complementarity is important for docking. The
library bias of commercially-available libraries such as ZINC toward GPCRs increases the
probability of retrieving molecules that meet well with the shape-complementarity desired in
SMO ligands, reflected in the higher than usual hit-rate. Underscoring this, as mentioned,
K2.7, K2.11 and K2.12, posess a β-hydroxy moiety that has been proven important for
binding to specific residues in the β2AR.
Thus, from a structure-based screen of libraries biased toward availability, 15 ligands with
little commonality between their structures were retrieved and their antagonism to SMO
conformed via cellular assay. The importance of a structure-based perspective was demon-
strated when relaxation of the binding pocket prior to docking found that small changes in
the positions of residues around the binding position of Vismodegib resulted in the retrieval
of more antagonists. The importance of key extra-cellular and transmembrane residues was
highlighted in addition to the enhanced activity of compounds that target multiple residues
across domains.
The compounds themselves were demonstrated to be active with predicted binding modes
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that avoid residues prone to mutation and consequent clinical resistance and at least one was
potentially as potent as the most affine Hh pathway inhibitor known. Additionally, without
optimisation, several drug-like compounds displayed significant activity against SMO with
chemotypes that are, in principle, easily synthesisable and amenable to optimisation. All of
this contributes to structural knowledge of SMO and provides excellent starting points for








The greatest costs of any fragment-based campaign are those resulting from an in-depth
analysis of false positives whereas false negatives are a total loss of important information.
Using computational methods on concert with experimental validation, a campaign of ligand
discovery can reduce the probability of such losses. The previous chapters describe specific
attempts to find small molecule inhibitors against two prima facie straightforward molecular
targets, Pim-1 and SMO. As with anything in life and research, the devil was in the tiny but
significant details.
Chapter 4 focussed on the development of both synthetically feasible and optimisable ligands
against Pim-1. Along the way, insights regarding the dynamics and structure of the Pim-1
binding pocket were gained via MD simulation and a docking comparison that informed sub-
sequent structure-based virtual screening campaigns. Although synthetic feasibility remains
a difficult problem, some success was observed in synthesising inhibitors that were active
against Pim-1 as well as some amenable to further optimisation from a later screen using
the ZINC dataset. Some surprising results involving a stabilising peptide are suggestive
of future development of less-explored sections of the Pim-1 binding pocket and, with some
modifications, a crystallised fragment offers attractive extensions for future Pim-1 inhibitors.
Ligands discovered in chapter 4 were both chemically novel and active against SMO. These
ligands were predicted to make interactions distinct from previous SMO ligands within the
allosteric pocket of SMO in the 7TM bundle and were chosen specifically to avoid known
undesirable effects (e.g. interactions with D473, known to be prone to mis-sense mutation).
Minimisation of the SMO binding pocket generally retrieved more ligands and emerging
structure-activity relationships gave additional insight into important residues for future
ligand discovery campaigns.
In light of the above, it bears examining in detail what was learned, both positive and
negative, from the multifaceted investigations of these two targets and how these lessons can
be applied to future work involving these two targets.
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5.2 What was learned from this thesis
5.2.1 Chemically diverse synthetically feasible ligands were found against
Pim-1
A campaign was described in chapter 3 that focussed on the discovery of novelty and syn-
thetic feasibility in ligands for the Pim-1 kinase. A number of small (< 250Da) molecules
from a diverse in-house library were predicted and confirmed to bind via a docking and
crystallographic screen. These fragments, in and of themselves, are unsuitable as a drug
due to the nature of their unspecific binding and generally have low affinity for any target.
However, as demonstrated, fragments with reliable binding modes make an ideal starting
point for extensions into other sections of the Pim-1 binding pocket.
Although not novel per se, the diverse nature of fragments from the in-house library and
their known binding modes enabled consideration of productive extensions. A focus on
synthetic feasibility led to enumeration of points on fragments amenable to extension and
the use of a published set of ‘safe’ synthetic reactions. An additional criterion of availability
determined that these molecules would be extended via purchasable ‘building blocks’ from
the ChemBridge library.
Although the focus on synthesisability and availability potentially compromised the degree
of chemical space exploration in this project, there was some level of compensation for loss
of novelty as specific sections of the Pim-1 binding pocket could be targeted by molecules
synthesised to do so. Coupled with a reliable fragment binding mode, this enabled some
risks to be taken. There are few ligands targeting those near Pim-1’s Specificity Surface
(e.g. D128, D131, E171) and molecular choices during evaluation of docking results guided
us toward making these residues a priority. This is despite the risks inherent in targeting
residues that are both somewhat divergent from ideal shape complementarity and solvent-
exposed.
The result of this campaign was some ligands with good enough affinity to form the basis for
optimisation, traditional in screening campaigns against kinases. These were predicted to
address seldom targeted parts of Pim-1 and were inactive against a selectivity target, Protein
Kinase A. It was found that molecules showing activity were generally more rigid than other
known Pim-1 inhibitors, suggestive of an important facet of any molecule targeting residues
near the Specificity Surface.
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An additional factor appears to have been the nature of the electrostatic interaction with
those residues. Measured activity was highest with ligands that had uncharged moieties
interacting with solvent-exposed charged residues. This is suggestive that solvent screening
‘dampening’ effects were less of a problem than with charged moieties. This was certainly
the case with the most potent compound, a hydroxy benzofuran-benzoic acid, where its
hydroy group was predicted to interact with D128 and its carboxylate predicted to interact
with Pim-1’s catalytic lysine (K67). Compounds possessing a benzoic acid but coupled to a
charged moiety (e.g. piperidine) were inactive in assays. The effect seems to be ameliorated
somewhat by substitution of the charged species with, for example, a short aliphatic chain.
However, the activity of one compound with an additional group of this nature was still
relatively weak with a three-digit Ki.
5.2.2 Novel ligands were also found in focussed libraries for diverse targets
Project 3 in chapter 3 and two ZINC screens in chapter 4 also unearthed chemical novelty
for both Pim-1 and SMO. This is perhaps a slightly surprising result as the ZINC dataset
is perhaps less likely to retrieve kinase ligands. However, several potent hits were observed
against SMO with room for further development and optimisation.
With regards Pim-1, proposed inhibitors were tested via orthogonal assays, some were crys-
tallised and X-ray structures obtained. Those showing activity were predicted to interact
with Pim-1 via canonical binding modes with the hinge and/or catalytic lysine (K67). How-
ever, chemically they were novel when compared to other Pim-1 ligands, generally comprised
of more flexible linkers rather than the large apolar moieties traditionally associated with
Pim-1 inhibitors. The most potent, however, was also the most rigid, a triazolo-thiadiazole
coupled to an indole on one side and a pyridine on the other.
Two rounds of a ZINC screen were also successful in finding ligands for SMO. In some ways
this is not a surprise as the commercial compound libraries it is based on have a well-known
bias toward GPCRs. However, hit rates in both rounds were above expectations and results
showcased the best of a structure-based virtual screen. Molecules showing reasonable activity
were generally dissimilar to previously published ligands and patterns of activity in ligands
with a degree of similarity to each other suggested at least one emerging Structure-Activity
Relationship (SAR). Additionally, ligands were found in assays that lowered signalling ac-
tivities to within range of the most potent inhibitor known against SMO.
So for both targets, chemically diverse hits have been the result of screens of the ZINC library.
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None of the ligands appeared potent in drug terms but the nature of the subset used, drug-like
and filtered for availability, has left some ‘headroom’ for a productive optimisation campaign.
This is the case in terms of the ligands themselves as well as for similar compounds.
5.2.3 Structural information matters
In Project 1 (chapter 3), the importance of binding pocket shape in proteins was highlighted.
The project was designed to address a problem with any virtual screening campaign, that
of making the choice of a starting structure for docking. Related, as fragments often find
multiple poses in a binding pocket, the problem of finding a reliable binding mode to extend in
fragment-based approaches as well as choosing an appropriate docking program was analysed.
Starting structure choice often requires expert input, particularly as subtle differences in
conformation can affect the chemotypes predicted to bind in an active site as well as the
quality of those predictions. A work flow including MD simulation of a bound ligand-
structure coupled with docking using multiple software codes was demonstrated to improve
performance across the board in ‘cognate’ docking, or, the ability of a docking program to
retrieve a ligand pose close to the known X-ray crystal structure. This is presumably as the
simulations were able to explore conformational states that reflect a ‘typical’ bound ligand.
A conformation was found for subsequent docking that allowed for the retrieval of a more
diverse array of ligands than is reflected in the structure of the original bound ligand. It may
in fact be the case that the particular bound ligand matters less than simulation with any
given ligand. By way of contrast, in the absence of a bound ligand, simulation from a bound
ligand state generally worsened docking performance as conformational states reflecting the
unbound state of the protein were sampled. The overall improvement in docking performance
of ligand-bound simulated structures, therefore, both obviates the need for expert choice and
reliance upon the choice of software.
Minimisation of the SMO binding pocket also demonstrated the importance of conformation
for rigid docking as, despite docking to a drug-bound structure, initial results were less than
satisfactory. Even after ligand minimisation, in some cases poses displayed extreme torsional
strain. There was also an unusual frequency of very unlikely protomers placed within the
pocket that scored highly - indicative of a sampling problem. This led to the conclusion that
the binding pocket itself may not be in a conformation likely to retrieve more novel ligands
and with reasonable poses. Minimisation of residues around the position of the ligand in the
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drug-bound structure quite simply led to more ligands that were reflective of a reasonable
binding position.
The provision of exhaustive ligand conformations mattered less than protein structure in all
projects. The shape of the molecular pose is crucial in prediction of the most likely binding
mode in biomolecular studies. However, particularly with the fragment study of Pim-1 in
Project 1 of chapter 3, only a few conformers (5-15) in energetically likely conformations were
necessary to retrieve poses close (< 2Å) to the crystal binding mode for some fragments.
Only a few more conformers per molecule (15-20) were generated in libraries of extended
molecules in Project 2 and Project 3 and for both ZINC screens against SMO in chapter 4.
The number of rotatable bonds in molecules generated by the DOCK pipeline also affects the
number of conformers generated. An ‘energy window’ parameter in conformation generation
dictates accept/reject criteria for conformers. If the difference in molecular strain energy
between a conformer and the global minimum conformer is above a certain threshold, the
conformer is omitted from preparation. This parameter is set progressively much more
strictly for molecules with a higher numbers of rotatable bonds, limiting the number of
conformers generated and, ostensibly, reducing computational time per molecule. This, of
course, has the effect of limiting the amount of chemical space explored by rigid fragments
supplied for docking.
However, it would appear that the lack of conformational space explored by fewer conformers
is compensated for the fact that all docking codes used have a minimisation step after initial
docking of the rigid molecule. This essentially kicks retrieval of the most likely conformation
for each pose down the road. Energy minimisation will not resolve large clashes with the
protein surface or eject the molecule from the binding pocket. However, it can certainly
change pose geometry enough to make and break interactions or fatally affect shape com-
plementarity in correcting the geometry of, for example, amines to reflect sp2-hybridisation
rather than their putative sp3 geometry. The implicit assumption is therefore that it is more
important that an initial docked position of a rigid molecule be converted to a favourable
pose after minimisation than the generation of more conformers prior to docking.
5.2.4 One should always be prepared for surprises
Two unexpected results were observed in this thesis. Firstly, in Project 3 of chapter 3, two
ligands were crystallised in complex with Pim-1 and a consensus peptide, Pimtide. Pimtide
is a consensus peptide that was designed to mimic the binding of the Pim-1 co-substrate and
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is also used to stabilise the protein-ligand complex for crystallography. Secondly, in Project
4 of chapter 3, a fragment from the internal fragment library, f200, was crystallised with only
its quinoxaline moiety, missing entirely a thiophene and unsaturated linker. As the original
structure for this fragment had these functional groups present, this fragment was initially
missed when docking the internal fragment library from where it had originated.
Both ligands in Project 3 of chapter 3 crystallised and displaying water-mediated interactions
with Pimtide. Both of these results are the first examples of direct interactions between a
ligand and Pimtide on the PDB, albeit in only one ligand is this directly observed in the
X-ray crystal structure. As the initial docking was completed without Pimtide in the model,
the predicted pose was very different to the eventual binding mode. In fact, the only way to
retrieve the crystal binding mode was to dock the ligand in a protein prepared with Pimtide
and all crystallographic waters present. Shape complementarity was, again, demonstrated
as being the key influence determining ideal binding positions in protein-ligand complexes.
Residues near the Pim-1 Specificity Surface are presumably difficult to target due to their
degree of solvent exposure. The position of both crystallised ligands means they are in
complex with a crystallographic water, D128 and R6 on Pimtide. A goal for the development
of various peptide substrates has been to analyse protein kinase phosphorylation specificity
but residues nearby to Pimtide’s usual binding position, less conserved in kinases, offer the
possibility other peptide inhibitors. This should be aggressively pursued as the lack of DFG-
loop dynamics means active-state Pim-1 has been extensively targeted so finding chemical
novelty in the small-molecule space will be progressively more difficult. Targeting of these
conserved residues, of course, offers the possibility of more selective Pim-1 ligands too.
The truncated form of the fragment ligand in Project 4 of chapter 3 was initially missed as the
full fragment was that which was used in docking. Attempts to find a docked position for the
full fragment from the position of the X-ray structure inevitably resulted in clashes with the
protein surface and attempts by in-house specialists to model the full fragment into measured
electron density were not able to supplant evidence in favour of the truncated fragment. The
X-ray crystallographic structure of the truncated ligand was, however, suggestive of an ideal
starting structure for a fragment extension project. Apparent interactions between the amide
carbonyl of its quinoxaline core and Pim-1 ’s catalytic Lysine (K67) as well as the amide
nitrogen with a buried water suggested a stable binding mode. The position of the apolar
part of the fragment in within Pim-1 ’s hydrophobic pocket should only have strengthened
its position.
149
Sadly, it was found that neither the quinoxaline core nor several extensions tested were
active against Pim-1 in a FRET-based assay. The most likely explanation seems to be
that, although extended molecules were chosen with polar interactions in mind, none of the
extensions approached the hinge. Many Pim-1 inhibitors have large apolar moeities within
range of the hinge, naturally more apolar in Pim-1. A remedy along these lines would be to
target the hinge by extending the quinoxaline fragment at a different position, for example
7 instead of 6. This has the benefit of concomitantly optimising for shape complementarity
of the Pim-1 binding pocket.
5.2.5 Some aspects didn’t work as well as we would like
Some projects were left with somewhat unsatisfactory results. Specifically, that there were
few ligands found in Project 2 of chapter 3 against Pim-1, that the goal of synthetic feasibility
remains a difficult one and that the CURED found in the SMO allosteric binding pocket in
chapter 4 was unable to be identified.
Lack of affinity caused by the possibility of solvent screening effects between charged ligands
and solvent-exposed charged residues in Project 2 was probably exacerbated by the flexibility
of molecules that were found inactive against Pim-1. Most potential inhibitors had relatively
flexible linkers between moieties within the binding pocket and those predicted to interact
with residues such as D128.
Docking, particularly rigid docking, typically does not attempt to quantify configurational
entropy changes upon ligand binding [222]. Some attempts using rigid multiple poses have
been reported [223]. But, in and of themselves, docking scoring functions are unable to
quantify the degree to which these effects, that oppose the attractive forces involved in
binding [224], will impact on docking predictions.
Appropriate sampling of conformational space via molecular simulation coupled with free
energy methods (e.g. Free Energy Perturbation) are designed specifically to estimate and
decompose the various free energy changes upon ligand binding. These methods do not often
achieve so-called ‘chemical accuracy’ (< 1 kcal·mol−1), ostensibly for reasons related to inad-
equate sampling, leading to Mean Absolute Deviations (MAD) from experimental estimates
more of the order of 4-6 kcal·mol−1 [225]. However, they can be useful for qualitative ranking
of molecules in a series of similar ligands, for example. Addressing the problem of solvent
polarisation effects is more tricky. Again, for qualitative ranking, free energy methods using
polarisable force fields (e.g. AMOEBA [226]) or even hybrid methods (e.g. QM/MM) should
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be useful in congeneric ligand series’. As these are computationally-expensive methods at
present, the aim as hardware speeds increase will be to scale up their use to broader sets of
ligands.
Synthetic feasibility was the goal in the development of ligands in Project 2 of chapter 3 and
results were quite mixed. In almost all cases, compounds were synthesised with methods that
differed to that proposed by our software. In many cases, molecules proposed were required
to be altered slightly to make them synthesisable either at all or not without significant effort
and development expended by synthesis collaborators.
There is no easy automated solution for this. Whilst some syntheses do prove to be relatively
straightforward, in silico reactions should remain more as idea generators than a blueprint
for automated synthetic success. It therefore remains that even apparently straightforward
organic molecule synthesis requires expert intervention for all synthesis methods.
Identification of the molecule(s) within the electron density in chapter 4 also proved elusive.
The endogenous ligand of SMO is, at present, not known and many compounds used in
SMO’s crystallisation in addition to assay kit ingredients were ruled out of consideration
during X-ray model refinement. Docking of databases including compounds known to be
present in cell process such as membrane transport and signal transduction as well as cell
metabolites failed to find a candidate ligand. Docking of small molecular probes provided
valuable insight into the energetics of various segments of the SMO binding pocket and did
allow us to narrow the list of moieties likely to be favourable in these segments. However,
in terms of raw combinatorics, a library of molecules including all possibilities of interacting
moities and appropriate linkers would be huge.
A proposed approach is to build a library of molecules based on filtering rules for specific
segments of the CURED then docking them. From there, the application of, for example,
a scoring function based on spatial criteria [227] could be applied to score and rank the
possibilities. One imagines that would at least further narrow molecular possibilities but a
run-on effect is the possibility of identifying other molecules that could plausibly fit within
the binding pocket to discover new ligands for SMO.
5.2.6 What is a ‘hit’?
Results from both major targets in this thesis prompt the question of what constitutes a
real ‘hit’ in ligand discovery campaigns. Does it have pM affinity for the target? Or merely
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those that show enough to be interesting for further development? Are these criteria target-
dependent? If a compound shows activity but crystallises in an entirely different position
than that predicted, does this no longer count as a hit? And does the limited nature of
biophysical methods mean that we cannot be sure of a molecule’s status as a ‘hit’ until we
obtain an X-ray structure?
In terms of raw affinity, the answer to this question is a resounding no for all ligands tested.
None achieved even nM affinity so in kinase terms, the best ligands at two-digit µM affinity
would be considered relatively weak ligands. However, as stated, most kinase campaigns
begin with ligands inhibiting at this level of affinity. This is closely followed by an intensifying
of effort in the service of optimisation that can take some months or even years prior to testing
(e.g. in vivo assays) and publication.
Sometimes, despite the success of a crystal hit, it may not be considered a real hit. As
reported in Project 3 of chapter 3, two molecules displayed completely different binding
modes to that predicted by docking, due to the unforeseen intervention of Pim-1’s consensus
peptide Pimtide. Unfortunately, one of those crystallised did not show activity in an assay.
A third ligand was shown to be active in assays and was crystallised but, although a dataset
was obtained, it did not survive structural model refinement as the ligand could not be
accurately placed within the electron density measured.
It would be tempting to view those interacting with Pimtide as not real hits. However,
although not reflective of the exact sequence of Pim-1’s co-substrate, one of the aims of
Pimtide is to mimic substrate binding. Additionally, the positions of both ligands should
inhibit ATP binding. It is therefore possible that the binding mode observed with these
ligands reflects a bound state where ATP is replaced but allow for co-substrate binding.
This was not the case where one ligand was crystallised with Pimtide but inactive in assays.
However, it does not preclude others from this possibility.
One of the ligands crystallised with Pimtide showed activity in assays. Assuming it was not
a hydrolysis product that crystallised, this is suggestive of more than one binding mode. The
binding mode elucidated from its X-ray structure still counts as a X-ray crystallographic hit
and the information gained from its binding position will be useful in targeting less conserved
Pim-1 residues.
A third example, whilst it did not progress to a fully refined structure, was active both against
Pim-1 but also showed signs of pan-PIM inhibition. Primarily, the limitations in ligand
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detection using biophysical methods concern false negatives so despite no X-ray structure
and a relatively weak affinity, its status as a hit should be assured.
To summarise, the determination of a molecular ‘hit’ depends upon the criteria used. Some
compounds discovered that make a reasonable starting point for optimisation or show signs
of other useful properties would be disregarded as hits by others. What can be gleaned
from this thesis, however, is that although there are costs associated with pursuing leads
that perhaps end less than satisfactorily, the costs of false negatives are known to be much
greater. So care should be taken before outright rejecting compounds that show reasonable
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7.1 Novel ligands against the kinase Proviral Integration site
for MuLV (Pim-1)
7.1.1 Project 1: Docking software comparisons vs structures from MD
simulation
Figure 7.1: Prepared Pim-1 docking binding site polar (light blue, small spheres) and apolar (light pink, small spheres)
vectors for SEED with crystal ligand (green carbons, stick representation) overlay (PDB:3BGP). Key residues (light
grey, stick representation) are labelled.
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Figure 7.2: Prepared Pim-1 docking binding sites for FRED with binding site contours (dark blue, mesh representa-
tion) with crystal ligand (grey carbons, ball-and-stick representation) overlay (PDB:3BGP). Key residues (light grey,
stick representation) are labelled.
Figure 7.3: Prepared Pim-1 docking binding site for DOCK with matching spheres (green, sphere representation)
with crystal ligand overlay (PDB:3BGP). Key residues (light grey, stick representation) are labelled.
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Figure 7.4: Pim-1 Thermal Shift Assay (TSA) results of 31 fragments that displayed a positive temperature shift of
≥ 4◦C (those with lower temperature shifts not shown) - fragment screen against internal fragment library
Section of protein Residues RMSD x̄ (σx̄)





Catalytic lysine K67 0.61 (0.18)
DFG loop D186-F188 1.63 (0.20)
P-loop G45-V52 0.99 (0.24)
Table 7.1: Mean RMSDs (Å) of Pim-1 apo structure from MD similations - Project 1
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Predict binding mode? (Y/N) RMSD to best pose (Å)
Frag FRED HYBRID SEED DOCK PDB
1 N (>5Å) N (>5Å) Y (1.316) N (>5Å) 5N4Z
2 N (4.858) N (>5Å) Y (1.350) N (>5Å) 5N4N
3 Y (4.118) N (4.616) N (>5Å) N (>5Å) 5N50
4 Y (2.038) Y (2.243) Y (1.453) N (>5Å) 5N4O
5 Y (1.376) Y (1.277) Y (1.309) N (>5Å) -
6 N (>5Å) Y 3.087 Y (2.091) Y (4.161Å) 5N4U
7 Y (1.514) Y 1.436 Y (1.566) N (>5Å) 5N4V
8 Y (1.410) N (>5Å) Y (2.882) N (>5Å) 5MZL
9 Y (2.558) Y 3.129 Y (2.153) N (>5Å) 5N4X
10 N (3.789) N (3.505) Y (1.424) N (>5Å) 5N51
11 N (>5Å) N (>5Å) Y (1.301) N (>5Å) 5N4Y
12 Y (1.593Å) Y 1.607 Y (1.613Å) N (>5Å) 5N52
Table 7.2: RMSD (Å) from the crystal structure of fragments from the internal fragment library as compared to the
docked position for the 3BGP crystal structure for all docking codes used. 2D structure is also displayed - Project 1
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Predict binding mode? (Y/N) RMSD to best pose (Å)
Frag FRED HYBRID SEED DOCK PDB
1 N (>5Å) N (>5Å) Y (1.889) Y (1.889) 5N4Z
2 Y (2.606) Y (2.700) Y (1.791) Y (3.784) 5N4N
3 Y (4.203) Y (3.281) Y (1.929) Y (4.206) 5N50
4 N (>5Å) Y (2.966) N (3.953) N (4.750) 5N4O
5 N (>5Å) N (4.777) Y (2.635) N (>5Å) -
6 Y (2.664) N (>5Å) Y (2.706) N (>5Å) 5N4U
7 N (>5Å) N (>5Å) N (4.249) N (>5Å) 5N4V
8 N (4.787) N (3.005) Y (2.304) N (>5Å) 5MZL
9 N (>5Å) N (3.791) Y (2.244) N (4.808) 5N4X
10 Y (2.216) Y (2.891) Y (2.079) N (4.446) 5N51
11 Y (1.937) Y (1.954) Y (1.594) - 5N4Y
12 N (>5Å) N (4.914) N (4.086) N (>5Å) 5N52
Table 7.3: RMSD (Å) from the crystal structure of fragments from the internal fragment library as compared to the
docked position for the apo MD structure for all docking codes used. 2D structure is also displayed - Project 1
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Predict binding mode? (Y/N) RMSD to best pose (Å)
Frag FRED HYBRID SEED DOCK PDB
1 N (>5Å) N (>5Å) Y (2.559) N (3.475) 5N4Z
2 N (4.144) N (>5Å) Y (0.579) N (>5Å) 5N4N
3 N (>5Å) N (>5Å) N (3.987) N (3.759) 5N50
4 Y (1.586) Y (1.057) Y (2.602) N (>5Å) 5N4O
5 Y (2.492) Y (2.527) Y (1.343) N (>5Å) -
6 N (>5Å) N (>5Å) Y (1.509) N (>5Å) 5N4U
7 Y (4.436) Y (4.479) Y (3.003) Y (3.191) 5N4V
8 N (>5Å) N (>5Å) Y (2.411) N (>5Å) 5MZL
9 N (4.414) Y (3.048) Y (1.834) Y (4.414) 5N4X
10 N (>5Å) N (3.513) Y (1.474) N (4.708) 5N51
11 N (3.594) Y (0.666) Y (0.528) N (>5Å) 5N4Y
12 Y (3.499) Y (3.519) Y (3.976) N (>5Å) 5N52
Table 7.4: RMSD (Å) from the crystal structure of fragments from the internal fragment library as compared to the
docked position for the 3BGP MD structure for all docking codes. 2D structure is also displayed - Project 1
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7.1.2 Project 2: synthetically-feasible extensions of an internal fragment
library
Reaction Number of protomers
1,2,4-triazole acetohydrazide 70









Grignard alcohol 12 379
Grignard carbonyl 5612
Heck non-terminal vinyl 14
heteroaromatic nuc sub 719





Mitsunobu tetrazole 1 35
Mitsunobu tetrazole 2 45
Mitsunobu tetrazole 3 3
Mitsunobu tetrazole 4 3
Negishi 14793
nucl sub aromatic ortho nitro 7
nucl sub aromatic para nitro 4
oxadiazole 9211
reductive amination 8198





tetrazole connect regioisomere 1 875






Table 7.5: Number of derivatives from fragments in Project 1 created in silico using PINGUI and reactions from
Hartenfeller et al by reaction used - Project 2
Number KolbLabID Ki (µM) 2D Structure








































47 K002CT035 191.76 μM
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48 K002CT036 250.44 μM
49 K002CT037
Table 7.6: Complete list of predicted Pim-1 inhibitors, Ki of all that were tested and 2D structure - Project 2
26 27 29
Overall MMFF energy terms
MMFF VdW 173.10853 174.99911 211.79359
MMFF Coulomb -773.74868 -1054.68906 -1010.24262
MMFF Torsion 73.51171 92.36242 86.00307
Protein shell MMFF terms:
MMFF VdW 163.55022 155.04904 179.39431
MMFF Coulomb -634.13971 -834.09671 -847.24709
MMFF Torsion 69.88636 73.76472 89.46652
Protein shell - ligand MMFF terms
MMFF VdW -11.24085 -7.97985 -4.64507
MMFF Coulomb -143.96872 -172.25685 -140.44702
Ligand MMFF Intramol. Terms
MMFF VdW 20.79916 27.92992 37.04436
MMFF Coulomb 4.35975 -48.33549 -22.54851
MMFF Bond 0.0000 0.0000 0.0000
MMFF Bend 0.0000 0.0000 0.0000
MMFF StretchBend 0.0000 0.0000 0.0000
MMFF Torsion 3.62536 18.5977 -3.46346




Overall Ligand-Protein Interaction terms
VdW -15.24877 -13.79325 -8.79115
Coulomb diel=1.0 157.15608 -163.84875 -135.23599
Protein desolv (PB) 11.87588 18.05575 16.61079
Ligand desolv (PB) 18.79844 19.47878 17.90345




Total energy 24.12647 kcal/mol -12.24072 kcal/mol 6.49418 kcal/mol
Table 7.7: Selected Szybki minimisation output for synthesised inhibitors 26, 27 and 29 - Project 2
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30 39 40
Overall MMFF energy terms
MMFF VdW 178.32713 173.22691 178.75834
MMFF Coulomb -994.08532 -849.55585 -953.7639
MMFF Torsion 74.43372 75.55722 77.25445
Protein shell MMFF terms:
MMFF VdW 152.00414 149.60911 158.84842
MMFF Coulomb -793.83878 -633.62987 -776.76304
MMFF Torsion 75.79929 66.65698 70.88795
Protein shell - ligand MMFF terms
MMFF VdW -12.5733 1.3277 -4.06612
MMFF Coulomb -183.92707 -171.73928 -132.58372
Ligand MMFF Intramol. Terms
MMFF VdW 38.89629 22.2901 23.97603
MMFF Coulomb -16.31947 -44.1867 -44.41714
MMFF Bond 0.0000 0.0000 0.0000
MMFF Bend 0.0000 0.0000 0.0000
MMFF StretchBend 0.0000 0.0000 0.0000
MMFF Torsion -1.3656 8.9002 6.3665




Overall Ligand-Protein Interaction terms
VdW -16.18952 -3.71935 -8.58616
Coulomb diel=1.0 -162.83585 -222.80383 -194.34521
Protein desolv (PB) 20.79349 17.2907 19.59708
Ligand desolv (PB) 19.83262 24.08791 18.44216




Total energy 5.69909 kcal/mol -27.89331 kcal/mol -27.88393 kcal/mol
Table 7.8: Selected Szybki minimisation output for synthesised inhibitors 30, 39 and 40 - Project 2
42 47 48
Overall MMFF energy terms
MMFF VdW 196.33979 199.14136 194.1482
MMFF Coulomb -1131.72547 -942.02649 -866.95849
MMFF Torsion 119.45029 86.9706 83.10517
Protein shell MMFF terms:
MMFF VdW 184.86334 175.19889 169.06271
MMFF Coulomb -905.12258 -925.08184 -743.19743
MMFF Torsion 101.90064 76.78063 73.05085
Protein shell - ligand MMFF terms
MMFF VdW -7.2298 -4.80154 -11.25881
MMFF Coulomb -195.32913 -86.67719 -131.8179
Ligand MMFF Intramol. Terms
MMFF VdW 18.70625 28.74401 36.3443
MMFF Coulomb -31.27376 69.73254 8.05684
MMFF Bond 0.0000 0.0000 0.0000
MMFF Bend 0.0000 0.0000 0.0000
MMFF StretchBend 0.0000 0.0000 0.0000
MMFF Torsion 17.54965 10.18997 10.0543




Overall Ligand-Protein Interaction terms
VdW -10.34907 -10.1994 -15.50657
Coulomb diel=1.0 -184.8342 125.85612 136.16232
Protein desolv (PB) 19.76263 16.49491 13.70759
Ligand desolv (PB) 20.32186 19.62251 19.44108




Total energy -4.23345 kcal/mol 107.54893 kcal/mol 49.06539 kcal/mol
Table 7.9: Selected Szybki minimisation output for synthesised inhibitors 42, 47 and 48 - Project 2
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Table 7.10: Predicted Pim-1 inhibitors, aniline triazole series - Project 3
7.1.3 Project 3: novel inhibitors from the ZINC dataset
ID Kinase tested
Compound Abl ASK1 B-Raf Lyn MAPK2 mTOR Pim-1 Pim-2 Plk4 Rsk2 TTBK2
56 111 100 100 102 97 99 98 118 104 104 103
57 82 94 105 86 92 100 77 95 98 96 104
58 88 100 94 96 101 72 44 57 96 97 105
59 105 105 92 100 111 102 83 105 112 96 107
60 104 110 101 95 101 101 94 92 107 87 99
61 96 99 110 96 98 101 99 109 106 84 99
Table 7.11: Mean % residual activity at 10µM of Pim-1 inhibitors as determined by third-party vendor (Eurofins)
using method in [97] - Project 3
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Compound In-house IC50 (µM) Eurofins IC50 (µM)
57 308.02 56.5
58 13.2 4.2
59 NOT TESTED > 100µM
61 1843 > 100µM
Table 7.12: Calculated IC50’s of Pim-1 inhibitors as determined by third-party vendor (Eurofins) using method in [97]
- Project 3
Figure 7.5: IC50 curves for compounds 57 and 58 as determined by third-party vendor (Eurofins) using method
in [97] (Eurofins)
7.1.4 Project 4: extensions of truncated fragment f200
Figure 7.6: Mean distances (Å) between simulated amide (left) and iminol (right) tautomers with W62 (black trace)
and K67 (red trace) against Pim-1for first 10ns of simulations
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Figure 7.7: Mean RMSD (Å) between simulated amide (red trace) and iminol (black trace) tautomers against Pim-1
for first 20ns of simulations
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Table 7.13: Predicted quinoxaline dervative inhibitors, unique IDs and 2D structures - Project 4
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7.2 Novel inhibitors against the Smoothened receptor
Compounds Assay kit ingredients
Vitamin K Pierce BCA assay kit (Thermo-Fisher)
Vitamin E Power SYBR Green Cells-To-CT (Thermo-Fisher)




Table 7.14: Exhaustive list of molecules ruled out by collaborators as fitting within the CURED
PDB code
Residue number Unpublished structure 5L7I 4N4W
H63 HIP HIE HIE
H103 HID - -
H227 HID HID HIE
H231 HIE HIE HIP
H340 HID HIP HIE
H361 HIE HIE HIE
H433 - HIP HIP
H470 HIE HIE HIE
H1078 HIP -
Table 7.15: Protonation states of Histidines in all Smoothened structures used for docking where HID=only the
δ Nitrogen on imidazole sidechains were protonated, HIE=ε Nitrogen is protonated and HIP=both Nitrogens are
protonated.
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Figure 7.8: Prepared SMO docking binding site polar (light blue, small spheres) and apolar (light pink, small spheres)
vectors for SEED with CURED Fo-Fc density for reference, key residues (light grey, stick representation) are labelled
- unpublished X-ray structure
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Figure 7.9: Prepared SMO docking binding site for DOCK with matching spheres (green, sphere representation) with
CURED Fo-Fc density for reference, key residues (light grey, stick representation) are labelled - unpublished X-ray
structure
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Figure 7.10: Prepared SMO docking binding site for DOCK with matching spheres (green, sphere representation)
with Vismodegib (green, stick representation) for reference, key residues (light grey, stick representation) are labelled
- PDB: 5L7I
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Figure 7.11: Prepared SMO docking binding site for DOCK with matching spheres (green, sphere representation)
with SANT-1 (green, stick representation) for reference, key residues (light grey, stick representation) are labelled -
PDB: 4N4W
194












2,2-Dimethylpropane Diphenyl Ether Phenylurea

















5-phenyl-1,4-benzodiazepine-2-one Imidazole – less polar Quinoline












Benzene Methyl benzoate Trifluoroethane
Benzodioxolane Methyl guanidine Trifluoromethane















Table 7.16: All molecular ’probes’ used in docking to the unpublished structure to identify the molecule in the
CURED.
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Fragment Interaction energy: Max(µ± σ) Notes
Highly polar molecules
Benzoic acid No favorable poses Apolar but acid moiety
Methyl sulfone No favorable poses Small strongly polar molecule
Imidazole – more polar No favorable poses Small ring, few seeded positions
Proprionic acid No favorable poses Small acid
Phosphate anion No favorable poses
Small, polar molecules
Acetate -0.8 One pose
Acetone -8.25 (-3.99 ± 1.43)
Aminomethane -7.22 (-3.62 ± 1.22)
D-Proline -5.69 (-1.98 ± 1.64)
L-Proline -13.39 (-2.50 ± 2.60)
Methanol -6.83 (-2.46 ± 1.30)
Trifluoroethane -5.13 (-1.88 ± 1.14)
Thiophene -6.39 (-2.77 ± 1.22)
Dimethylammonium -14.26 (-4.32 ± 2.85) Polar interactions outside blob,
large receptor desolvation costs
Dimethylether -8.06 (-3.29 ± 1.38) No convincing poses, outside blob
Ethylammonium -14.18 (-4.21 ± 3.56) Polar interactions outside blob,
large receptor desolvation costs
Ethanol -8.13 (-3.32 ± 1.68) Polar interactions outside blob,
large receptor desolvation costs
Methylamidine -18.85 (-5.75 ± 3.55)
Methylammonium -14.43 (-3.04 ± 3.09) Polar interactions outside blob,
large receptor desolvation costs
Methyl guanidine -17.79 (-6.26 ± 3.44) Polar interactions outside blob,
large receptor desolvation costs
N-Methyl-methylsulfonamide -17.79 (-2.69 ± 1.77) Polar interactions outside blob,
large receptor desolvation costs
N-Methyl Methylamide -10.34 (-3.48 ± 1.99)
N-Methylacetamide -10.33 (-4.04 ± 2.00)
Pyrrole -6.57 (-3.15 ± 1.45)
Tetrahydropyrrole -16.41 (-5.83 ± 4.24) Scores inflated by polar interac-
tions that are outside blob.
Tetrahydrofuran -9.52 (-5.06 ± 1.81)
Thiazole -5.84 (-2.62 ± 0.97)
Thiazolidinone -9.93 (-3.47 ± 1.45) Polar interactions outside blob,
large receptor desolvation costs
Trifluoromethane -5.13 (-1.88 ± 1.14)
Trimethylammonium -8.69 (-3.44 ± 1.83)
Water -2.97 (-1.49 ± 0.72)
Small, apolar molecules
Ethane -7.32 (-2.61 ± 1.36)
Ethene -5.41 (-2.14 ± 1.04)
Methane -4.30 (-2.49 ± 0.91)
Propane -8.36 (-3.71 ± 1.40)
Propene -7.45 (-3.14 ± 1.12)
Tert-butane -8.03 (-3.90 ± 1.70)
2,2-Dimethylpropane -8.04 (-4.67 ± 1.81)
Table 7.17: Calculated interaction energies in kcal·mol−1, (maximum, mean and standard deviation) of molecular






Dibenzocyclohexane -9.14 (-4.34 ± 2.60) Hag 5 -12.24 (-5.51 ± 3.41)
Quinoline-4,5,
dihydroxyl-1-amine
-13.33 (-4.62 ± 3.27) Indane -10.54 (-5.04 ± 2.88)
alpha-Carboline -12.48 (-4.94 ± 3.24) Indole -9.45 (-4.25 ± 2.45)
Acetphenone -11.83 (-4.76 ± 2.66) Isopropanol -9.09 (-4.53 ± 1.70)
Adamantane -11.83 (-10.33 ± 0.515) Isoquinoline -9.50 (-4.28 ± 2.47)
Adenine -9.5 (-3.62 ± 2.00) Isoquinazoline -9.68 (-4.05 ± 2.64)
5-amidine indole -25.43 (-6.67 ± 5.35) 2-methyl-2-butene -8.90 (-4.43 ± 1.87)
2-aminopyradine -7.95 (-3.29 ± 1.72) Methyl benzoate -11.72 (-4.64 ± 2.93)
2-aminopyramidine-4-
one
-10.58 (-4.19 ± 1.88) Methylcyclopropane -7.98 (-4.59 ± 1.21)
Aniline -10.37 (-5.20 ± 2.08) 1,3-dimethylbenzene -9.87 (-4.58 ± 2.48)
Anisol -10.33 (-4.19 ± 2.36) N(3)-methyl-2-
aminopyrimidinone
-11.58 (-4.64 ± 2.41)
Imidazole – less polar
version
-8.22 (-3.45 ± 1.44) 3-methylanisole -11.40 (-4.46 ± 2.89)
Beta-carboline -8.22 (-4.41 ± 3.08) N-methylbenzoimidazole -11.27 (-4.64 ± 2.62)
Benzamidine -22.43 (-5.57 ± 4.46) 5-methylisooxazole -9.86 (-3.89 ± 1.85)
Benzene -6.50 (-2.76 ± 1.76) 2-methyl-2-
phenylpropane
-11.43 (-5.56 ± 3.17)
Bromobenzene -10.23 (-4.73 ± 2.58) Methylphenylsulfide -9.40 (-3.69 ± 2.37)
Butene -8.07 (-4.56 ± 1.05) Methylphenylsulfone -11.32 (-3.31 ± 2.36)
Benzamide -11.38 (-4.17 ± 2.47) Methylphenylsulfoxide -10.00 (-3.85 ± 2.39)
Benzodioxolane -9.56 (-3.76 ± 2.47) 2-methylthiophene -7.87 (-3.46 ± 1.65)
Benzonitrile -8.34 (-3.01 ± 1.92) Methylphenol -9.29 (-4.17 ± 2.29)
Benzothiophene -8.69 (-3.68 ± 2.32) 3-methoxyanisole -12.74 (-4.86 ± 3.14)
Cis-
Dihydroxycyclohexane
-13.03 (-5.20 ± 3.04) Meso-Inositol -13.65 (-5.19 ± 3.03)
Cyclohexoguanidine -21.30 (-6..48 ± 4.39) Napthalene -10.14 (-4.39 ± 2.87)
Chlorobenzene -9.51 (-4.16 ± 2.67) Nitrobenzene -10.30 (-4.28 ± 2.45)
Cyclohexane -8.78 (-4.09 ± 2.65) N-Methylindole -10.53 (-4.22 ± 2.52)
Cyclopentanone -8.22 (-4.66 ± 1.53) N-Methylpyrrole -8.09 (-3.83 ± 1.74)
Cyclopropane -6.57 (-2.92 ± 1.40) 1,2-dimethylbenzene -9.51 (-4.41 ± 2.64)
Cytosine -9.81 (-4.25 ± 1.99) 5-phenyl-1,4-
benzodiazepine-2-one
-16.43 (-5.51 ± 4.18)
Decahydroquinoline -13.52 (-6.41 ± 3.67) 5-phenyl-1,4-
benzodiazepine
-13.27 (-4.62 ± 2.53)
Decaline -12.90 (-5.78 ± 3.56) 1, 4-dimethylbenzene -10.48 (-4.48 ± 2.76)
Delta-valerolactam -10.22 (-5.54 ± 1.96) Phenole -9.65 (-3.92 ± 2.08)
2,3-Dihydroxy-
tetrahydrofurane
-12.48 (-5.45 ± 2.35) Phenylethane -10.45 (-4.15 ± 2.55)
Dihydroxy-benzene -8.36 (-4.23 ± 2.04) 2-phenylethanol -10.70 (-3.75 ± 2.53)
Dihydroxy-cyclohexane -13.03 (-7.24 ± 2.64) Phenylsulfonamide -11.65 (-3.25 ± 2.44)
2,4-diaminopyrimidine -8.90 (-3.80 ± 1.90) Phenylurea -12.50 (-4.29 ± 2.81)
2,4-dichlorotoluene -12.24 (-5.00 ± 3.21) Piperazine -16.07 (-6.75 ± 4.99)
1,2-difluorobenzene -8.75 (-3.68 ± 2.10) Piperadine -18.01 (-5.83 ± 4.62)
N, N, Dimethylaniline -11.58 (-4.15 ± 2.78) Proline -13.87 (-2.51 ± 2.48)
Dinitrobenzene -12.38 (-4.85 ± 3.09) Purine -10.51 (-3.45 ± 2.04)
Diphenyl Ether -10.87 (-3.39 ± 2.52) N-pyrrolidinaldehyde-2-
carboxylic acid
-15.62 (-6.66 ± 2.68)
cis-(D-Ala,D-Ala)-2,5-
Diketopiperazine
-12.58 (-4.33 ± 2.84) Pyridine -8.98 (-3.10 ± 1.82)
2,5-Diketopiperazine -12.49 (-4.10 ± 2.69) 2-Pyrrolidinone -9.22 (-4.63 ± 1.54)
3,6-dimethyl-2,5-diketo-
1,4-piperazine
-12.59 (-4.87 ± 2.85) Quinazoline -10.49 (-4.00 ± 2.62)
N-ethylpyrrolidinone -14.54 (-6.55 ± 2.50) Quinoline -10.72 (-4.01 ± 2.81)
N-ethylimidazole -9.12 (-3.88 ± 2.01) Trans-Dihydroxy-
cyclohexane (anti)
-12.17 (-4.89 ± 2.77)
Fluorobenzene -7.73 (-3.62 ± 1.81) Tetraline -11.29 (-5.25 ± 3.16)
2,3,4-furantricarboxylic-
acid
-11.50 (-5.63 ± 2.67) Tetrahydro-2-
pyrimidinone
-11.35 (-5.07 ± 1.91)
Guanine -12.75 (-4.40 ± 2.70) Tetrahydro-quinoline -12.21 (-4.94 ± 3.01)
Quinoline-4,7-diamine -11.79 (-4.62 ± 3.21) Toluene -8.61 (-4.33 ± 2.17)
Quinoline-3,10-diamine -10.84 (-3.98 ± 2.80) Trifluoromethylbenzene -12.35 (-4.54 ± 2.77)
Quinoline-3-E-
methylamide-10-amine
-11.63 (-4.76 ± 2.93) Uracil -9.56 (-3.55 ± 1.67)
Table 7.18: Calculated interaction energies in kcal·mol−1 (maximum, mean and standard deviation) of molecular
probes found inside CURED.
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Figure 7.12: ROC plots of molecular enrichment of known actives for prepared SMO Vismodegib (plots A and B) and
SANT-1 receptors (plots C and D). In each case, it is demonstrated that increasing the box margin and orientational
sampling from defaults enhanced the model’s ability to dock and score molecules known to be active against SMO.
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TM1 TM2 TM3 TM4 TM5 TM6 TM7 ECL1 ECL2 ECL3
I234 W281 V321 V404 T466 M525 Y207 Q284 D382
L325 I408 C469 F526 I215 M301 G383





























Table 7.19: Smoothened residues within 8Å of the Vismodegib binding position by helix/loop that were energy
minimised by both MOE and CHARMM
n min max range x̃ x̄ (σx̄)
CHARMM 66 0.091 1.019 0.928 0.21 0.40 (0.21)
MOE 66 0.331 1.685 1.685 0.46 0.54 (0.36)
Table 7.20: Descriptive statistics for distance in RMSD of selected residues from X-ray structure of PDB:5L7I
of CHARMM-minimised and MOE-minimised receptor structures demonstrating that overall movement of atomic
positions in SMO pocket residues was mild when using CHARMM (x̃=0.40) or MOE(x̃=0.54).
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ENER ENR: Eval# ENERgy Delta-E GRMS
ENER INTERN: BONDs ANGLes UREY-b DIHEdrals IMPRopers
ENER EXTERN: VDWaals ELEC HBONds ASP USER
CHARMM
ENER> 0 -18341.68878 0.00000 8.92134
ENER INTERN> 298.29580 1476.16693 0.00000 1259.32198 27.59509
ENER EXTERN> -4615.67876 -16787.38982 0.00000 0.00000 0.00000
MOE
ENER> 0 -18197.08623 0.00000 9.39867
ENER INTERN> 342.27848 1621.19000 0.00000 1286.86442 44.01162
ENER EXTERN> -4565.37810 -16926.05265 0.00000 0.00000 0.00000
Table 7.21: Calculated receptor energies of receptors after minimisation with CHARMM and MOE of SMO receptors.
Despite more overall movement of atom positions in the MOE structure, the CHARMM-minimised structure was overall
lower in energy.
Residue code Atoms affected (AMBER atom types)
VAL270 (VAM) O (-0.500 → -0.900), H (-0.248 → -0.648)
LEU325 (LEV) O (-0.500 → -0.900), H (-0.248 → -0.648)
GLY328 (GLZ) O (-0.500 → -0.900), H (-0.248 → -0.648)
GLY456 (GLZ) O (-0.500 → -0.900), H (-0.248 → -0.648)
PHE462 (PHF) O (-0.500 → -0.900), H (-0.248 → -0.648)
THR466 (THS) O (-0.500 → -0.900), H (-0.248 → -0.648), HOG (-0.310 → -0.710)
ALA524 (ALB) O (-0.500 → -0.900), HN (-0.248 → -0.648)
MET525 (MEU) O (-0.500 → -0.900), HN (-0.248 → -0.648)
THR528 (THS) O (-0.500 → -0.900), H (-0.248 → -0.648), HOG (-0.310 → -0.710)
Table 7.22: Tarted Smoothened residues with atomic partial before and after tarting residues in PDB: 4N4W
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Number ZINCID 2D Structure Tarted score Untarted
score
1 CHEMBL497218 -153.07 -4.23
2 CHEMBL523431 -124.25 -1.61
3 CHEMBL1823838 -109.37 -28.42
4 CHEMBL3126707 -90.91 -5.75
5 CHEMBL3604610 -71.71 1.47
6 CHEMBL3604612 -69.16 3.57
Table 7.23: Molecules known to be active against SMO that scored high when docked to the tarted receptor but poorly
against the untarted receptor and their interaction energies in both docks. This is to demonstrate that the interaction
energies of some very polar molecules were scored highly simply due to the increase in electrostatic potential around
tarted residues.
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x̄ ± σx̄ min Q1 x̃ Q3 max
Lacroix, et al 0.29 ± 0.08 0.12 0.23 0.29 0.35 0.55
Round 1 0.52 ± 0.12 0.23 0.44 0.51 0.61 0.85
All actives 0.29 ± 0.10 0.04 0.51 0.71
Table 7.24: Descriptive statistics of ECFP4 Tanimoto similarity of Round 2 molecules with Lacroix et al and Round
1 molecules showing overall low similarity between Round 2 molecules with Round 1 molecules, a prior study using the
ZINC12 dataset and all known actives against SMO
5L7I 4N4W
R1 (X-ray) R2 (relaxed) R1 (X-ray) R2 (tarted)
Total Energy 19.54 19.63 17.31 -2.58
Overall: MMFF VdW 144.5 168.77 177.45 185.06
Overall: MMFF Coulomb -1101.92 -1057.74 -1205.42 -1269.97
Overall: MMFF Torsion 98.55 107.34 90.32 96.68
Prot vdw 120.83 144.93 155.12 163.50
Prot: MMFF Torsion 90.01 99.54 83.18 91.71
Lig: MMFF VdW 31.38 34.56 27.62 28.19
Lig: MMFF Torsion 8.54 7.81 7.14 4.97
Prot-Lig: MMFF VdW -7.72 -10.73 -5.29 -6.63
Prot-Lig: MMFF Coulomb -28.53 -28.63 -52.63 -33.42
Prot-Lig: VdW -14.75 -17.9 -12.45 -13.86
Prot-Lig: Coulomb diel=1.0 -165.1 -135.02 -185.17 -178.37
Prot-Lig Protein desolv:(PB) 26.42 25.44 34.50 34.97
Prot-Lig Ligand desolv: (PB) 24.93 22.53 22.20 21.26
Overall Prot-Lig Interaction -17.45 -17.35 -12.15 -12.51
Table 7.25: Mean estimated energies from SZYBKI (kcal.mol−1) for ZINC12 Round 1 vs Round 2 molecules - X-ray
vs altered receptor structures
5L7I 4N4W
ZINC12 ZINC15 ZINC12 ZINC15
Total Energy 19.63 -0.16 -2.58 35.81
Overall: MMFF VdW 168.77 165.61 185.06 143.13
Overall: MMFF Coulomb -1057.74 -1095.80 -1269.97 -855.63
Overall: MMFF Torsion 107.34 100.37 96.68 76.60
Prot vdw 144.93 146.05 163.50 140.22
Prot: MMFF Torsion 99.54 95.42 91.71 70.58
Lig: MMFF VdW 34.56 28.67 28.19 18.12
Lig: MMFF Torsion 7.81 4.96 4.97 6.02
Prot-Lig: MMFF VdW -10.73 -9.12 -6.63 -15.22
Prot-Lig: MMFF Coulomb -28.63 -52.37 -33.42 -12.48
Prot-Lig: VdW -17.90 -16.92 -13.86 -25.11
Prot-Lig: Coulomb diel=1.0 -135.02 -138.42 -178.37 -10.26
Prot-Lig Protein desolv:(PB) 25.44 25.75 34.97 22.79
Prot-Lig Ligand desolv: (PB) 22.53 21.12 21.26 7.23
Overall Prot-Lig Int -17.35 -16.46 -12.51 -0.88
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